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 Calcitonin gene-related peptide (CGRP) and adrenomedullin (ADM) 
receptors are heterodimeric complexes composed of the calcitonin receptor-like 
receptor (CLR) and a receptor activity-modifying protein (RAMP). Association with 
RAMP1 gives a high affinity CGRP receptor, whereas association with RAMP2 or 
RAMP3 gives high affinity ADM receptors. CGRP and ADM are widely distributed 
throughout the body and play important roles and are implicated in many diseases 
including migraine, heart failure and sepsis. 
 Recently, CGRP has been shown to promote nitric oxide (NO) production 
and inducible NO synthase (iNOS) expression in trigeminal ganglion glial cells via 
ERK activation. CGRP is known to induce iNOS/NO production in thoracic artery 
smooth muscle cells (TA-SMC) pretreated with interleukin-1b. However, the 
molecular mechanism of CGRP-induced iNOS/NO production in TA-SMC is 
unknown. Therefore, in order to determine if CGRP induces iNOS/NO production 
via ERK activation, I first investigated the exact mechanisms through which CGRP 
activates ERK1-2 in HEK cells. By using different inhibitors I showed that CGRP-
induced ERK activation is mainly activated through two major pathways. I showed 
for the first time that CGRP induces ERK activation through transactivation of 
ErbB1 and as expected through the cAMP/PKA pathway. Then, in order to 
characterise a suitable model to study CGRP-induced iNOS expression, I used 
primary TA-SMC and I showed that CGRP induces iNOS upregulation, which is 
reduced when cells are incubated with U0126, a MEK inhibitor. Thus, these results 
suggest that CGRP induces iNOS expression via ERK activation in TA-SMC. 
However, further experimentation is required to determine the exact ERK pathway 
responsible for iNOS induction. 
 Compared to CLR•RAMP1 and CLR•RAMP3, little is known about the post-
endocytic sorting of CLR•RAMP2. Using HEK cells stably expressing 
CLR•RAMP2, I investigated the molecular mechanisms regulating the ADM 
receptor. I first showed that, unlike CLR•RAMP1, even transient stimulation of 
CLR•RAMP2 with ADM promotes degradation of both CLR and RAMP2, indicating 
that this ADM receptor does not recycle to the cell-surface. Moreover, I showed 
that CLR, not RAMP2, is constitutively ubiquitinated, which was further enhanced 
upon ADM stimulation. In order to elucidate the role of ADM-mediated 
ubiquitination of CLR, I made a lysine-less mutant of CLR, named CLRD9KR. I 
showed that ubiquitination of CLR did not affect ADM-induced trafficking of 
CLR•RAMP2 to lysosomes, nor did it affect the degradation or the ERK signalling 
of CLR•RAMP2. However, I showed that ubiquitination of CLR regulated the rate 
of degradation of the receptor. Together, these results indicate that CLR•RAMP2 
does not recycle and is degraded via a molecular mechanism that is accelerated 
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AC adenylate cyclase 
ACE angiotensin-I-converting enzyme 
ADAM a disintegrin and metalloprotease 
ADM adrenomedullin 
ADM2 adrenomedullin-2 
Akt protein kinase B 
ALIX apoptosis-linked gene-2-interacting protein X 
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cAMP cyclic adenosine monophosphate 
ang II angiotensin II 
AP adaptor protein family 
AT1R AT1 receptor (angiotensin receptor family) 
AT2R AT2 receptor (angiotensin receptor family) 





B2 receptor bradykinin receptor family 
BSA bovine serum albumin 
CalDAG-GEFI Ca2+- and diacylglycerol-regulated guanine nucleotide 
exchange factor I 





CLR calcitonin receptor-like receptor 
CNS central nervous system 
CSBP cytokinin Specific Binding Protein 
CT calcitonin 
CTR CT receptor 
CXCR2 chemokine receptor family 
CXCR4 chemokine receptor family 
DAG diacylglycerol 
DMEM Dulbecco’s Modified Eagles medium 
DMSO dimethyl sulphoxide 
DNA deoxyribonucleic acid 
cDNA complementary DNA 
δOR  δ receptor (opioid receptor family) 
κOR  κ receptor (opioid receptor family) 
µOR  µ receptor (opioid receptor family) 
DUB de-ubiquitinating enzymes 
ECE-1 endothelin-converting enzyme-1 
E. coli Escherichia coli 
EP2 receptor prostanoid receptor family 
ER endoplasmic reticulum 
ErbB1 epidermal growth factor receptor 
ERK extracellular signal-regulated kinase 
pERK phosphorylated ERK 
ES embryonic stem 




Hrs hepatocyte growth factor-regulated tyrosine kinase substrate 
GDP guanosine diphosphate 
GEF guanine nucleotide exchange factor 
cGMP cyclic guanosine monophosphate 
GnRH receptor gonadotrophin-releasing hormone receptor family 
GPCR G protein-coupled receptor 
GTP guanosine triphosphate 
GRK GPCR kinase 
IAPP islet amyloid polypeptide 
ILV intralumenal vesicles 
IP3 inositol 1,4,5-triphosphate 
JNK c-Jun N-terminal kinase 
LH luteinizing hormone 
LMP lysosomal membrane protein 
LPA lysophosphatic acid 
M1 receptor acetylcholine receptor (muscarinic) family 
M3 receptor acetylcholine receptor (muscarinic) family 
MAPK mitogen-activated protein kinase 
MEK MAP kinase kinase 
MHC major histocompatibility complex 
MVB multivesicular bodies 
NK1R NK1 receptor (tachykinin receptors family) 
NO nitric oxide 
e/iNOS endothelial/inducible NO synthase 
NSF N-ethylmaleimide-sensitive fusion protein 




P2Y12 receptor P2Y receptor family 
PAMP ProADM N-terminal 20 peptide 
PDGF platelet-derived growth factor 
PDZ postsynaptic density 95/disc large/zonula occludens-1 
PI3K phosphatidylinositol 3-kinase 
PKA protein kinase A 
PKC protein kinase C 
aPKC atypical PKC 
cPKC conventional PKC 
nPKC novel PKC 
PLC phospholipase C 
pM picomole 
PP2A protein phosphatase type 2A 
proADM pro-adrenomedullin 
proCT pro-caclitonin 
PTH parathyroid hormone 
PTH1 receptor parathyroid hormone receptor family 
PTH2 receptor parathyroid hormone receptor family 
PTX pertussis toxin 
PVDF polyvinylidene difluoride 
PYK2 proline-rich tyrosine kinase 2 
RAMP receptor activity-modifying protein 
RCP receptor component protein 
RIPA radioimmunoprecipitation assay 
RK reactivating kinase 




RNA ribonucleic acid 
RT room temperature 
RTK receptor tyrosine kinase 
S.E. standard error 
SMC smooth muscle cells 
SNX1 sorting nexin-1 
SP substance P 
TA-SMC thoracic aorta SMC 
TfR transferrin receptor 
TPA 12-o-tetradecanoylphorbol-13-acetate 
Tsg101 tumour susceptibility gene 101 
UIM ubiquitin-interacting motif 
V2R V2 receptor (vasopressin and oxytocin receptor family) 
VPAC1 receptor VIP and PACAP receptor family 
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Vps4 vacuolar protein sorting 4 
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Chapter 1. Introduction 
  




1.1 Calcitonin Peptide Family 
 The calcitonin peptide family includes calcitonin (CT), islet amyloid polypeptide 
(IAPP), calcitonin gene-related peptide (CGRP), adrenomedullin (ADM) and 
adrenomedullin-2 (ADM2). The mature peptides exhibit a high degree of sequence 
homology, particularly a highly conserved disulphide bond (Fig. 1.1). They exhibit 
similar biological properties on a wide range of tissues. All these peptides have 
been listed in order of discovery, although CGRP and ADM, subject of this study, 
are described in more detail. 
 
1.1.1 Calcitonin 
 CT is a 32 amino acid peptide, discovered and purified in 1962 by Copp et al. 
(Copp et al., 1962; Copp and Cheney, 1962). Calcitonin is produced from the 
calcitonin-related polypeptide alpha gene CALCA, located on the short arm of 
chromosome 11 (Hoppener et al., 1984; Przepiorka et al., 1984). Alternative 
splicing of CALCA gene transcripts results in the production of two different 
mRNAs encoding either for proCT or for CGRP (Amara et al., 1982) (Fig. 1.2). 
ProCT is then cleaved to form CT and another 21 amino acid peptide named 
katacalcin (Hillyard et al., 1983). Katacalcin (also known as PDN-21) does not 
possess similar structure to CT or other members of the calcitonin peptide family. 
The biological activities of katacalcin are poorly defined, however they are 
believed to be similar to CT (Hillyard et al., 1983). The CALCA gene consists of 6 
exons (reviewed in (Breimer et al., 1988)). The first three exons are common to 
both mRNAs. Exon IV codes for proCT, followed by a polyadenylation signal, 
whereas exons V and VI code for CGRP, followed by the polyadenylation signal. 
 CT was initially shown to be secreted by the thyroid gland (Hirsch et al., 1963) 
and was later more precisely identified as the secretion product of thyroidal 
parafollicular cells (later termed C cells) (McMillan et al., 1974; Meyer and Abdel-
Bari, 1968; Wolfe et al., 1973). The name CT was given because of its 
hypocalcemic effect on blood Ca2+ (Copp and Cheney, 1962), countering the 
action of parathyroid hormone (PTH). CT contributes to Ca2+ homeostasis by 
direct inhibition of osteoclast-mediated bone resorption and by enhancing Ca2+ 
excretion by the kidney (Friedman and Raisz, 1965; Raisz and Niemann, 1967; 
Warshawsky et al., 1980). Salmon CT is currently used as therapeutic to treat 
osteoporosis and Paget’s disease ((Overgaard et al., 1992) and is reviewed in 
(Hamdy and Daley, 2012; Lee and Sinko, 2000; Patel et al., 1993)). 
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 CT has also been found in brain (Cooper et al., 1980; Fischer et al., 1981; Flynn 
et al., 1981), suggesting a role in the central nervous system (CNS). Indeed, CT 
has been found to inhibit food intake in rats when given by intracerebral and 
subcutaneous injection (Freed et al., 1979; Levine and Morley, 1981; Perlow et al., 
1980). Moreover, administration of CT in humans reduces gastric emptying 
(Jonderko et al., 1988) and inhibits glucose-induce insulin secretion (Passariello et 
al., 1981).  
 
1.1.2 Calcitonin Gene-Related Peptide 
1.1.2.1 Structure and Synthesis of CGRP 
 CGRP is a 37 amino acid neuropeptide that was identified in 1982 (Amara et 
al., 1982). It was discovered from the alternative tissue-specific processing of 
mRNA transcripts from the CALCA gene. This alternative splicing results in the 
production of a distinct mRNA that encodes CGRP (Amara et al., 1982). CGRP 
exists in two forms, denoted α and β (or I and II), which differ by only three amino 
acids, but share similar biological activities. αCGRP is encoded by the calcitonin 
gene CALCA located on chromosome 11 (Fig. 1.2). The expression of mRNA 
splicing for CT or αCGRP is tissue-specific (Amara et al., 1982; Rosenfeld et al., 
1983). For example, the expression of CT mRNA predominates in the thyroid 
whereas αCGRP-specific mRNA appears to predominate in the nervous system. 
βCGRP isoform is coded by a separate gene CALCB, also located on 
chromosome 11 and is thought to have arisen by gene duplication (Amara et al., 
1985; Steenbergh et al., 1985). It is the effects of αCGRP that are discussed in 
this study and hereafter will be denoted CGRP. 
 The tertiary structure of CGRP has not been fully determined. However, in 
common with other members of the calcitonin family, CGRP has a disulphide 
bridge (Cys2-Cys7) in the N-terminal region. This ring structure is followed by an α-
helix initially thought to exist between residues Val8 and Arg18 (Breeze et al., 1991; 
Lynch and Kaiser, 1988), and then later confirmed between residues Val8 and 
Leu16 (Boulanger et al., 1995), followed by a γ-turn between residues Ser19 and 
Gly21 (Boulanger et al., 1995).  
 
  









Figure 1.2 Schematic representation of the transcription/translation of CALCA gene. 
CALCA is located on the short arm of chromosome 11. Alternative splicing of the 
transcript of CALCA leads to the formation of two different mRNAs. Splicing of the exon IV 
yield a proCT mRNA (hightlighted in red), which is translated into the CT/KC precursor. 
Splicing of the exon V and VI produce a CGRP mRNA, leading to the CGRP precursor 
(hightlighted in blue). Exons hightlighted in green represent non-translated and precursor 
sequences. 
  




1.1.2.2 Distribution of CGRP 
 CGRP has been shown to be concentrated in distinct areas of the peripheral 
and central nervous systems (Rosenfeld et al., 1983) and it has been detected in 
both autonomic and motor neurons. In many tissues, CGRP-containing nerves are 
closely associated with blood vessels (Brain and Cambridge, 1996), which alluded 
to its function as a vasoactive mediator. Indeed, CGRP-containing nerves 
innervate smaller arteries in the vascular smooth muscle layer. This allows CGRP 
to be released where it can act on smooth muscle cells (SMC) layer to promote 
arteriolar dilatation (reviewed in (Brain and Grant, 2004)). The distribution of 
CGRP-containing nerves has been studied in most tissues, but it most extensively 
been reviewed with respect to the pathophysiological function in the cerebral 
circulation (reviewed in (Edvinsson, 2001)). CGRP-containing nerves have a 
perivascular distribution and as a consequence plasma levels of CGRP in human 
are generally low, normally in the picomole (pM) range (Girgis et al., 1985). It is 
generally considered that the levels of CGRP in plasma are likely to be due to 
leakage after localised release rather than for a specific systemic function. 
However, CGRP has the ability to decrease blood pressure and increase heart 
rate when given by intravenous administration in human volunteers, indicating that 
if sufficiently high plasma levels of CGRP are reached, systemic vasoactive effects 
can be triggered (Gennari and Fischer, 1985). Moreover, this observation 
suggests that CGRP can act on endothelial cells, confirmed by the fact that certain 
endothelial cells express CGRP receptors (Nikitenko et al., 2006). 
 
1.1.2.3 Biological Effects of CGRP and its Role in Disease 
 CGRP is distributed throughout the central and peripheral nervous systems, 
which suggests its involvement in various brain activities associated with 
gastrointestinal, sensory and cardiovascular functions (reviewed in (Maggi, 1995; 
van Rossum et al., 1997)). 
 When CGRP is given by intracerebroventricularly, it reduces food intake (Krahn 
et al., 1984). This observation was supported by the fact that lesions of the lateral 
part of the dorsal parabrachial nucleus, a region rich in CGRP-containing cell 
bodies (Shimada et al., 1985), induce hyperphagia (Nagai et al., 1987). Moreover, 
CGRP inhibits gastric acid secretion (Kraenzlin et al., 1985; Tache et al., 1984) 
and gastric emptying (Raybould et al., 1988). 
 CGRP is widely studied for its effects on the cardiovascular system, which are 
the subject of this study. CGRP is the most potent microvascular vasodilator 
identified to date. This effect was first demonstrated in skin, where femtomole-pM 
amounts of injected CGRP induced reddening, due to local microvascular dilation 
(Brain et al., 1985). In addition to its great potency, CGRP also differs from other 




vasodilatory substances in that it has a particularly long duration of action. A dose 
of 15 pM injected into human skin produces an erythema that lasts for 5–6 h (Brain 
et al., 1985). 
 It has been identified that CGRP can promote vascular relaxation through 
activation of a number of different signalling pathways. These mechanisms include 
either nitric oxide (NO)/endothelium-dependent mechanisms or cyclic adenosine 
monophosphate (cAMP)-mediated/endothelium-independent pathways. The most 
common pathway is cAMP/endothelium-independent. CGRP acts on SMC to 
stimulate adenylate cyclase (AC) activity producing an increase in cAMP 
production. This mechanism has been shown in cultured SMC (Crossman et al., 
1990), endothelium denuded arteries in cat brain vessels (Edvinsson et al., 2001) 
and in human intracranial arteries (Edvinsson et al., 1998). The increase in cAMP 
promotes activation of protein kinase A (PKA), which in turn phosphorylates and 
opens ATP-sensitive K+-channels, leading to relaxation. In fact, the ATP-sensitive 
K+-channel blocker, glibenclamide prevents CGRP-induced responses and 
hyperpolarises arterial SMC (Nelson et al., 1990; Smillie and Brain, 2011). 
Endothelium-dependent relaxation to CGRP occurs by a significant increase in 
both cAMP and cyclic guanosine monophosphate (cGMP) (Gray and Marshall, 
1992). This implicates the release of NO from the endothelium, which relaxes the 
SMC through activation of guanylate cyclase and accumulation of cGMP. The 
importance of the increase in cAMP in the vascular endothelial cells remains to be 
determined, but it has been demonstrated that cAMP is able to stimulate 
endothelial NO synthase (eNOS) activity, leading to increased synthesis and 
release of NO (Ferro et al., 1999). The activation of eNOS via cAMP is probably 
mediated via PKA and protein kinase B (Akt), as a study demonstrated that PKA 
and Akt can phosphorylate and activate eNOS (Harris et al., 2004). CGRP also 
induces the production of NO via inducible NOS (iNOS) (Schini-Kerth et al., 1994; 
Vause and Durham, 2009). iNOS is known to produce large quantities of NO 
(Nathan and Xie, 1994) which is implicated in inflammatory processes. For 
example, in sepsis bacterial components such as lipopolysaccharide are known to 
induce expression of iNOS (Okamoto et al., 1998), which may lead to severe 
hypotension observed in sepsis (reviewed in (Hauser et al., 2005)). NO production 
is also implicated in the pathophysiology of migraine (Goadsby et al., 1990; 
Iversen and Olesen, 1996; Olesen and Jansen-Olesen, 2000) and in 
atherosclerosis, where it seems to be beneficial by inhibiting SMC proliferation 
(reviewed in (Ginnan et al., 2008)). 
 Since its discovery, CGRP has been implicated in the pathogenesis of migraine. 
Goadsby et al. showed that during migraine, plasma levels of CGRP but not of 
other neuropeptides, such as neuropeptide Y, vasoactive intestinal polypeptide 
and substance P (SP) were increased (Goadsby et al., 1990). For this reason, 
pharmaceutical companies initiated development of CGRP receptor antagonists to 
treat migraine. Current treatments for migraine include the selective 5-




hydroxytryptamine (5-HT, also known as serotonin) receptor 1B/1D agonists called 
triptans, which work by constricting cranial blood vessels and by reducing the 
release of CGRP and SP (Tepper et al., 2002). However, triptans can have side 
effects and are not effective for all patients. For example some patients may suffer 
from severe rebound attacks and triptans are not suitable for patients with 
cardiovascular disorders such as angina (Dahlof, 2002). Clinical trials have shown 
that some CGRP receptor antagonists have a comparable efficacy to other 
treatments, but with higher safety and tolerability profiles (reviewed in (Villalon and 
Olesen, 2009)). One of them, the non-peptide BIBN4096BS, later called 
olcegepant, developed by Boehringer Ingelheim (Doods, 2001) showed promising 
results and was delivered in phase II clinical trials (Olesen et al., 2004). However, 
further trials were not pursued as the drug could be delivered only intravenously. 
Merck Research Laboratories developed an orally bioavailable agent MK-0974, 
called telcagepant, which reached phase III clinical trials (Ho, 2009; Ho et al., 
2008a; Ho et al., 2008b). However, the trials have been stopped as some patients 
showed elevated liver transaminases (Tepper and Cleves, 2009). Boehringer has 
developed another antagonist, BI 44370 TA that has completed the phase II trial 
(Diener et al., 2011). The potent antagonist BMS-846372, is orally active but show 
limited aqueous solubility (Luo et al., 2012b). Subsequently, a derivative was 
made, the BMS-927711, which is currently in phase II clinical trials (Luo et al., 
2012a). The role of CGRP in migraine is yet to be more clearly defined and 
understanding the mechanisms that regulate CGRP receptor trafficking and 
signalling may help to discover new therapies to treat this and other diseases. 
 
1.1.3 Islet Amyloid Polypeptide 
 Islet amyloid polypeptide (IAPP), also named amylin, is a 37 amino acid peptide 
purified from amyloids in pancreatic islets, characteristic of type-2 diabetes 
(Cooper et al., 1987; Westermark et al., 1987). The IAPP gene consists of 3 exons 
located on the short arm of chromosome 12 (Roberts et al., 1989). 
 IAPP is co-secreted with insulin from β-cells of the pancreatic islet of 
Langerhans in response to increased glucose levels (Moore and Cooper, 1991). 
IAPP possesses a vasodilatory activity (Brain et al., 1990), which is 100 times less 
potent than CGRP and is not thought to be involved in the regulation of the blood 
pressure. On the other hand, IAPP together with insulin plays an important role in 
glycaemic control. However, whereas insulin promotes storage of glucose from the 
blood to different tissues, IAPP prevents absorption of nutrients. Notably, IAPP 
acts by slowing gastric emptying (Kong et al., 1997; Young et al., 1995) and by 
inhibiting food intake (Chance et al., 1993; Lutz et al., 1994; Morley et al., 1994). 
IAPP has also been reported to inhibit glucagon secretion (glucagon counters 
insulin action by forcing tissue to release glucose in the blood flow), which has 




been found to be beneficial in patients suffering from type-1 and 2 diabetes 
(Fineman et al., 2002a; Fineman et al., 2002b; Gedulin et al., 1997). Moreover, 
IAPP has also been shown to be increased in obese people not suffering from 
diabetes, reduced in the type-2 diabetes population (Enoki et al., 1992), and 
elevated in pancreatic cancer (Permert et al., 1994). Due to its action on the food 
metabolism, the IAPP receptor antagonist pramlimtinde (Kolterman et al., 1995), 
has been approved by the Food and Drug Administration in 2005 for the treatment 
of type-1 and 2 diabetes (reviewed in (Jones, 2007)). 
 IAPP is the main component of amyloid deposits that form in the islets of 
Langerhans in patients with type-2 diabetes (Cooper et al., 1987; Westermark et 
al., 1987), where it has been shown that those amyloid deposits are toxic for the β-
cells (Lorenzo et al., 1994), which suggests that they may be the cause of the 
insulin-related dysfunction in type-2 diabetes. 
 
1.1.4 Adrenomedullin 
1.1.4.1 Structure and Synthesis of Adrenomedullin 
 Human ADM is a 52-amino acid peptide with a single disulphide bridge between 
cysteine residues 16 and 21 and with an amidated tyrosine at the carboxy 
terminus. ADM is a potent hypotensive peptide originally isolated from human 
pheochromocytoma cells and was identified by its ability to stimulate cAMP 
production in platelets (Kitamura et al., 1993a). ADM shares homology with CGRP 
and was therefore added to the calcitonin peptide family (Kitamura et al., 1993a). 
Rat ADM has 50 amino acids, with 2 deletions and 6 substitutions compared with 
the human peptide (Sakata et al., 1993).  
 ADM is first synthesised as a large precursor molecule, termed 
proadrenomedullin (proADM). In both rat and human this precursor consists of 185 
amino acids. ProADM is cleaved between Lys43 and Arg44 to produce a 20-amino 
acid amidated peptide, designated proADM N-terminal 20 peptide (PAMP). ADM is 
produced by cleavage of the Lys93-Arg94 and Arg148-Arg149 bonds (Kitamura et al., 
1993b; Sakata et al., 1993). The proteolytic enzymes responsible for this 
processing are currently unknown. PAMP is not discussed in this report but for 
more detail see (Samson, 1998). The gene encoding proADM has been mapped 
and localised to a single locus of chromosome 11. The human ADM gene 
comprises 4 exons and 3 introns, with TATA, CAAT and GC boxes in the 59-
flanking region (Ishimitsu et al., 1994). 
 




1.1.4.2 Circulating Adrenomedullin in Health and Disease 
 The ADM gene is expressed in a wide range of tissues. The initial report on the 
distribution of ADM mRNA, suggested that the highest levels of expression were in 
the adrenal medulla, ventricle, kidney, and lung (Kitamura et al., 1993b). However, 
it is now known that ADM is more highly expressed in endothelial cells (Sugo et 
al., 1994) and vascular SMC (Sugo et al., 1995) than in the adrenal medulla and 
that ADM has come to be regarded as a major secretory product of the vascular 
endothelium, together with NO and endothelin-1. An initial study reported that 
circulating levels of ADM in plasma were in the pM range (Kitamura et al., 1994). 
This was confirmed by several research groups, with a normal plasma 
concentration of ADM of 1-10 pM, with most values between 2-3.5 pM (reviewed in 
(Hinson et al., 2000)). ADM levels have been measured in a wide range of disease 
states (reviewed in (Hinson et al., 2000)). In many cardiovascular disorders, 
plasma levels of ADM are reported to be elevated, possibly released to 
compensate for elevated blood pressure. In general, it appears that elevated ADM 
is a consequence, rather than a cause of the pathology. It is unclear whether the 
increases in plasma ADM are due to a required hormonal function or whether it 
represents leakage due to excess production (reviewed in (Hinson et al., 2000)). 
Of all the conditions investigated, the greatest increase in plasma ADM has been 
observed during sepsis and septic shock (Ehlenz et al., 1997; Hirata et al., 1996). 
ADM plays a key role in the pathophysiology of septic shock (see below). 
 
1.1.4.3 Biological Actions of Adrenomedullin 
 ADM and its receptors are expressed in several tissues and organs, including 
the heart, blood vessels, kidneys, lungs, gastrointestinal tract, endocrine glands 
and brain (reviewed in (Hinson et al., 2000)). This wide distribution suggests that 
ADM is involved in the regulation of several biological functions. Although the first 
paper on ADM described only the cardiovascular effects of this peptide (Kitamura 
et al., 1993a), it is now known that ADM is rather more than simply a vasodilator. 
ADM has been shown to have a remarkable range of actions, from regulating 
cellular growth and differentiation, through modulating hormone secretion, to 
antimicrobial effects (reviewed in (Hinson et al., 2000)). Similar to the other 
members of the calcitonin family, ADM has been found to reduce food intake in 
rats (Murphy and Samson, 1995; Taylor et al., 1996), as well as inhibiting insulin 
secretion (Martinez et al., 1996) and gastric emptying (Martinez et al., 1997). 
However, only the effects on the cardiovascular system are discussed in this 
report. 
 The mechanisms via which ADM can elicit vascular relaxation are 
heterogeneous with respect to both species and vascular bed. The mechanisms 
are incompletely understood, but relaxation predominantly occurs by the 




eNOS/NO pathway and K+-channel-dependent mechanisms (Hirata et al., 1995; 
Lang et al., 1997; Terata et al., 2000). Nishimastu et al. examined the NO-
dependent relaxation to ADM in the rat aorta and identified the involvement of a 
phosphatidylinositol 3-kinase (PI3K)/Akt-dependent pathway in the stimulation of 
eNOS (Nishimatsu et al., 2001). The results showed that ADM stimulated Akt 
activation in aortic endothelium via a Ca2+/calmodulin-dependent mechanism 
(Nishimatsu et al., 2001). There are therefore a variety of mechanisms by which 
ADM may induce vascular relaxation, and further research is required to fully 
understand them. However, it is clear that there is an overall similarity in the 
mechanisms of CGRP and ADM-induced relaxation (reviewed in (Brain and Grant, 
2004)). 
 The vascular endothelium constitutes a cellular barrier that plays a crucial role 
in the maintenance of vessel integrity and controls exchange of small solutes and 
macromolecules between the intravascular and interstitial space. Increased 
endothelial permeability is a hallmark of virtually every acute inflammatory 
reaction. It results in extravasation of fluid and plasma molecules as well as 
inflammatory mediators through the activated endothelium. Two main mechanisms 
are involved: perturbation of adhesion structures resulting in the loss of endothelial 
cell-cell contacts and activation of the actin-myosin based contraction system 
resulting in cell retraction and subsequent intracellular gap formation (reviewed in 
(Temmesfeld-Wollbruck et al., 2007)). Upregulation of ADM is observed in sepsis 
and septic shock. Studies with three separate knockout mouse models affecting 
the ADM system (ADM gene, CALCRL gene (ADM receptor component) and 
peptidylglycine alpha-amidating monooxygenase gene enzyme which catalyses 
the COOH-terminal amidation of peptide hormones) have shown an extreme 
generalised oedema formation suggesting a strong barrier stabilising function for 
the peptide (Caron and Smithies, 2001; Czyzyk et al., 2005; Dackor et al., 2006). 
In vitro studies have shown that ADM concentration-dependently reduced the 
hyperpermeability induced by stimuli as diverse as hydrogen peroxidase, 
thrombin, Escherichia coli (E. coli) hemolysin or Staphylococcus aureus α-toxin 
(Brell et al., 2005; Hippenstiel et al., 2002; Hocke et al., 2006). ADM acts by 
blocking the phosphorylation of endothelial myosin light chain induced by these 
molecules. This, in turn, reduces the formation of F-actin stress fibres, known to be 
vital for force generation during actin-myosin based cell contraction in the 
endothelium (Brell et al., 2005; Hippenstiel et al., 2002). Thus, ADM may act as a 
general microfilament-relaxing peptide in endothelial cells. The tightening effect of 
ADM on endothelial barrier has also shown in an ex vivo model (Hocke et al., 
2006). Overall, ADM stabilises endothelial barrier function in vitro, ex vivo and in 
vivo under several conditions simulating inflammatory reaction in various vascular 
beds (e.g. (Brell et al., 2005; Hippenstiel et al., 2002; Kis et al., 2001)). However, 
the exact mechanism of how ADM acts on endothelial cells to maintain endothelial 
barrier function remains unclear. 





 Adrenomedullin-2 (ADM2, also known as intermedin) was simultaneously 
discovered by two groups using two different approaches. The first approach 
utilised searches of genomes from humans, other mammals and non-vertebrates 
(Roh et al., 2004). The second approach screened mammalian complementary 
DNA (cDNA) libraries for potential mammalian homologues of five orthologues of 
ADM which they had identified in pufferfish (Takei et al., 2004). The ADM2 gene is 
located on the distal arm of the chromosome 22q13 (Roh et al., 2004). It is 
translated as a prepro-peptide of 148 amino acids, which can be cleaved in two 
alternative peptides: short ADM2 (40 amino acids) and long ADM2 (47 amino 
acids) (Roh et al., 2004). Short ADM2 is believed to be the most important one in 
vivo. Similar to ADM, the tissue distribution of ADM2 is quite wide and is reviewed 
in (Hong et al., 2012). The highest peptide content is present in the kidney, 
hypothalamus and stomach (Roh et al., 2004; Takei et al., 2004). 
 ADM2 has similar biological activities to ADM and CGRP. When ADM2 is 
administered by intraperitoneal (Roh et al., 2004) or intravenous injection (Takei et 
al., 2004), it decreases blood pressure through vasodilatation. However, when it is 
given by intracerebroventricularly, it increases blood pressure and heart rate by 
activating the sympathetic nervous system (Hashimoto et al., 2007; Takahashi et 
al., 2011). 
 As ADM2 expression is high in the stomach and kidney it was not surprising to 
find that it regulates energetic metabolism. ADM2 inhibits food and drink intake 
(Roh et al., 2004; Taylor et al., 2005), gastric emptying (Roh et al., 2004) and 
induces anti-diuresis and anti-natriuresis (Takei et al., 2004). Moreover, ADM2 has 
been shown to be involved in the regulation of secretion of other peptides 
including prolactin and growth hormone (Taylor and Samson, 2005). Thus, it 
seems that ADM2 plays an important role in the regulation of the homeostasis of 
growth and metabolism. 
 
  




1.2 G Protein-Coupled Receptors 
 In order to maintain homeostasis in any living organism, it is essential that cells 
are able to sense and respond to the external environment. To do so, cells 
communicate with each other through mediators released into the extracellular 
milieu. Therefore, they also need mechanisms that recognise and integrate these 
mediators. One mechanism, by which cells do this, is through the expression of 
cell-surface receptors. The largest family of cell-surface receptors is the 
superfamily of the GPCRs. This family of cell-surface receptors is characterised by 
its seven transmembrane spanning domains and represents the largest class of 
drug targets. There are more than 800 known GPCRs in the human genome, 
which are involved in virtually every physiological process (Fredriksson et al., 
2003). In the cardiovascular system GPCRs play a pivotal role by regulating 
essential cardiovascular functions such as heart rate and contractility and vascular 
tone. GPCRs can be divided into five subfamilies: the rhodopsin (originally called 
A or I), secretin (B or II), glutamate (C or III), adhesion and frizzled/taste2 
(Fredriksson et al., 2003). All the calcitonin peptide family exert their biological 
actions through activation of GPCRs that belong to the secretin family. 
 
1.2.1 Activation and Termination of GPCR-Induced Signalling 
1.2.1.1 Activation of G Proteins 
 GPCRs can be activated by a wide range of stimuli, such as photons of light, 
odorant molecules, peptides, hormones and lipid molecules (reviewed in 
(Kristiansen, 2004)). GPCRs transfer extracellular signals across the plasma 
membrane to intracellular effectors via G proteins (Fig. 1.3). G proteins belong to 
the GTPase family, enzymes able to hydrolyse guanosine triphosphate (GTP) 
(reviewed in (Kjeldgaard et al., 1996)). G proteins consist of three protein subunits, 
a guanosine diphosphate (GDP)/GTP-binding α-subunit and a β-subunit and a γ-
subunit. The β- and γ-subunits form a stable dimeric complex referred as the βγ-
subunit. The inactive form predominates when GDP is bound to the α-subunit and 
promotes the association with the βγ-subunit complex. The binding of the agonist 
to the receptor induces a conformational change of the GPCR allowing activation 
of heterotrimeric G proteins by interaction with the GPCR. Upon activation, GDP is 
realised from the G protein allowing GTP to bind to the α-subunit, which 
subsequently leads to the dissociation of the GTP-α-subunit from the βγ-subunit 
complex. Both GTP-α-subunit and the βγ-subunit complex are then free to activate 
downstream effectors (reviewed in (Cabrera-Vera et al., 2003; Kjeldgaard et al., 
1996)). Gα-subunits are divided into four families based on similarity of α-subunits: 
Gαs, Gαi/o, Gαq/11 and Gα12/13. The Gαs and Gαi/o activate or inhibit the activity of 
AC resulting in an increase or decrease of cAMP production, respectively. The 




Gαq/11 stimulates phospholipase C (PLC) leading to the formation of inositol 
trisphosphate (IP3) and diacylglycerol (DAG). The Gα12/13 activates small GTPases 
including the Rho family of GTPases e.g., RhoA. These second messengers then 
activate several intracellular pathways to modulate cell function (reviewed in 
(Cabrera-Vera et al., 2003; Hamm, 1998)). 
  









Figure 1.3 GPCRs interact with different G protein families to initiate cell-surface 
signalling. (1) Agonist binding to GPCRs promotes coupling of the receptor and the G 
protein. This coupling induces realised of GDP from the G protein that allows GTP to bind 
to the α-subunit, leading to the dissociation of the α-subunit from the βγ-subunits. (2) 
Once free, the α-subunit induces signalling of the receptor. There are four main Gα-
subunit that can activate different signalling pathways. Gαs promotes activation of AC 
leading to the formation of cAMP. Gαi/o inhibits AC activity resulting in a decrease of 
cAMP. Gαq/11 promotes the activation of PLC which mediates the formation of IP3 and 
DAG. IP3 then induces mobilisation of Ca2+ from intracellular stores. Gα12/13 promotes 
activation of small GTPases such as RhoA. 
  





 Activation of GPCRs triggers not only activation of G proteins, but also cellular 
events that lead to a rapid attenuation of receptor responsiveness, a process 
termed desensitisation. Signalling of activated GPCRs at the cell-surface must be 
rapidly terminated in order to prevent uncontrolled signalling. There are two types 
of desensitisation: homologous and heterologous. Homologous desensitisation is 
the activation of one subtype of GPCR leading to the loss of responsiveness of 
only this subtype. For example, consider a cell that expresses receptors A and B. 
The cell is stimulated with the agonist of receptor A and it induces desensitisation 
of only receptor A, this is considered homologous desensitisation. Whereas, the 
activation of one subtype of GPCR that leads to the desensitisation of multiple 
GPCRs subtypes, independently of their agonist occupation is considered 
heterologous desensitisation. In other words, in our cell with receptors A and B, 
stimulation with the agonist A leads to the desensitisation of both receptors A and 
B. 
 The first step in desensitisation is phosphorylation of the receptor (reviewed in 
(Claing et al., 2002; Ferguson, 2001)), either by second messenger activated 
kinases, such as PKA (Benovic et al., 1985; Stadel et al., 1983) and protein kinase 
C (PKC) (Cho et al., 2007; Hardy et al., 2005); or by another kinase family named 
GPCR kinase (GRK) (Benovic et al., 1986b; Strasser et al., 1986) (Fig. 1.4). The 
second messenger-dependent phosphorylation can both act as homologous and 
heterologous desensitisation and was originally believed to be the principal 
mechanism of desensitisation. The exact mechanism of desensitisation remains 
poorly understood. However, it is believed that the GPCR is phosphorylated within 
the site required for association with G proteins and thus prevents their interaction 
(Benovic et al., 1985). Since their discovery, GRKs have been shown to play a 
central role in the desensitisation of many GPCRs (reviewed in (Premont and 
Gainetdinov, 2007)). This mechanism was first described in the vision system with 
the rhodopsin receptor. Protein kinases called rhodopsin kinases (i.e. GRK1) 
phosphorylate light-activated rhodopsin receptors (Kuhn, 1978), which lowers 
rhodopsin-mediated activity (Miller and Dratz, 1984). Another protein that was 
identified to bind to activated rhodopsin receptor, called 48-kDa protein, was 
shown to be required to promote complete desensitisation of the receptor (Wilden 
et al., 1986). This protein later called S-antigen or arrestin, showed to bind only to 
phosphorylated rhodopsin receptor. Studies with the β2-adrenoceptor (β2-AR, also 
known as β-adrenergic receptor) similarly identified kinases that only 
phosphorylate activated β2-AR and thus named β-adrenergic kinase or βARK 
(Benovic et al., 1986a; Benovic et al., 1986b). βARK (i.e. GRK2) also induces 
desensitisation of β2-AR. However, βARK phosphorylation is by itself insufficient to 
induce desensitisation, which can be restored by adding arrestin (Benovic et al., 
1987). These results suggested that arrestin-like protein could exist in non-visual 




systems. Subsequently, β-arrestin1 and β-arrestin2 were discovered and cloned 
(Attramadal et al., 1992; Lohse et al., 1990). 
 
1.2.1.3 Internalisation 
 Another mechanism, by which uncontrolled/sustained signalling is terminated, is 
by removal of GPCRs from the cell-surface. This process termed endocytosis, 
controls and regulates the entry and exit of small and large molecules. There are 
two broad categories of endocytosis: phagocytosis, which is the uptake of large 
particles and typically restricted to certain mammalian cells; and pinocytosis, which 
is the uptake of fluid, solute and small particles. Four main mechanisms have been 
described for pinocytosis (reviewed in (Conner and Schmid, 2003; Doherty and 
McMahon, 2009)), but the two best-characterised mechanisms for GPCR 
internalisation are clathrin-mediated endocytosis and caveolae-mediated 
endocytosis. 
 The caveolae-mediated endocytosis was observed and described more than 50 
years ago (Yamada, 1955) (Fig. 1.5). Caveolae are essentially composed of 
cholesterol and sphingolipids and are referred to lipid rafts (reviewed in (Harder 
and Simons, 1997)). The main structural member of caveolae is the caveolin 
protein family (Rothberg et al., 1992). They form a curved membrane invagination 
with wide opening and narrow-neck that can be pinch off. The dynamin family 
proteins are large GTPases that have been shown to be involved in endocytosis of 
coated pits and large invaginations (Damke et al., 1994). Notably, they have been 
shown to self-assemble into rings around the neck of membrane invaginations 
(Hinshaw and Schmid, 1995), suggesting a role in the “constriction” of the neck to 
release the caveolae from the plasma membrane ((Henley et al., 1998; Oh et al., 
1998) and reviewed in (Schnitzer et al., 1996)). The activation of dynamin in 
caveolae has been shown to be regulated by the protein kinase Src (Shajahan et 
al., 2004). Moreover, Src has been found to phosphorylate caveolins (Li et al., 
1996), which is believed to trigger internalisation of caveolae (Aoki et al., 1999; Li 
et al., 1996; Mastick et al., 1995; Nomura and Fujimoto, 1999; Schlegel et al., 
2001). 
 Clathrin-mediated endocytosis was first described in 1964 (Roth and Porter, 
1964) and is involved in the constitutive transport of essential nutrients, such as 
iron-laden transferrin that binds to transferrin receptors (TfR) (reviewed in (Mayle 
et al., 2012)) (Fig. 1.5). However, it is clear now that clathrin-mediated endocytosis 
is also involved in internalisation of agonist-activated receptors (reviewed in 
(Brodsky et al., 2001)). Clathrin was first identified in 1975 (Pearse, 1975) and 
later described as a three-legged structure, named triskelion, which can self-
assemble to form closed polygonal “cages” (reviewed in (Brodsky et al., 2001)). 
The other major components of clathrin-mediated endocytosis are the adaptor 




proteins family (AP), identified in 1979 (Keen et al., 1979). There are four isoforms 
of AP (AP1-4), each mediating vesicle formation at distinct subcellular localisations 
(reviewed in (Robinson and Bonifacino, 2001)). Only AP2 regulates the 
endocytosis at the plasma membrane. AP2 plays a central role in clathrin-
mediated endocytosis as they direct the self-assembled clathrin “cage” into curved 
bud (reviewed in (Brodsky et al., 2001)), and also interact with different cargos to 
be internalised (Collins et al., 2002; Ohno et al., 1995). GPCRs cannot bind 
directly to AP2, instead it has been shown that β-arrestins physically link GPCRs 
to AP2 (Laporte et al., 1999) and clathrin (Goodman et al., 1996). These 
interactions are important for an efficient recruitment of the GPCR into clathrin-
coated pits, but not essential, as it has been shown that disabling or deletion of 
either binding site in β-arrestins does not completely prevent receptor 
internalisation (reviewed in (Kim and Benovic, 2002)). 
 After internalisation, the fate of GPCRs depends on both the cell type and on 
the type of receptor. Typically, following agonist-induced internalisation GPCRs 
are efficiently recycled back to the cell-surface. However, many GPCRs are 
trafficked to a degradation pathway and proteolytically degraded in the lysosome, 
a process called down-regulation. This molecular “sorting” of GPCRs can occur at 
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1.2.2 Molecular Mechanisms of GPCR Sorting at the Plasma 
Membrane 
 The first molecular sorting of GPCRs occurs at the plasma membrane, where 
agonist-activated receptors differ in their ability to undergo specific endocytosis 
pathways (i.e. clathrin versus caveolae endocytosis pathways). Moreover, some of 
these receptors are post-translationally modified to direct them through a specific 
molecular pathway. 
 
1.2.2.1 Segregation of GPCRs in Microdomains of the Plasma Membrane 
 Before endocytosis, GPCRs can be directed into different microdomains of the 
membrane, which would then affect their fate. The β2-AR has been shown to be 
internalised via clathrin-dependent mechanism in several cell types such as COS-
1 cells (fibroblast-like cell line) (Goodman et al., 1996) and HEK cells (human 
embryonic kidney cell line) (Orsini and Benovic, 1998). However, other studies 
suggest that in A431 cells (human epidermoid carcinoma cell line), β2-ARs 
undergo clathrin-independent endocytosis (Raposo et al., 1989). Cholecystokinin 1 
receptor internalisation was observed to occur via both clathrin- and caveolae-
mediated endocytosis in CHO cells (Chinese hamster ovary cell line) (Roettger et 
al., 1995). The existence of these two mechanisms may explain the two different 
fates of the receptor: a rapid resensitisation versus a less rapid resensitisation and 
down-regulation. The internalisation of the P2Y1 and P2Y12 receptors (P2Y 
receptor family, also known as purinergic receptors) is clathrin-mediated, however, 
only internalisation of P2Y12 is β-arrestin-dependent (Mundell et al., 2006). P2Y12 
and P2Y1 have been shown to segregate in distinct coated pits, which 
subsequently lead to their different post-endocytic fates (Mundell et al., 2006). 
 
1.2.2.2 Interaction with β-Arrestins 
 β-arrestins have been shown to regulate desensitisation and internalisation of 
GPCRs (reviewed in (Luttrell and Gesty-Palmer, 2010)). GPCRs have different 
affinities for β-arrestin1 or 2, which based on this affinity has led to two classes of 
GPCRs (Oakley et al., 2000). GPCRs such as the β2-AR which preferentially bind 
β-arrestin2, are termed class A receptors. Soon after internalisation, these 
receptors release β-arrestin2 and rapidly recycle to the cell-surface. Whereas 
class B GPCRs such as the V2 receptor (V2R, vasopressin and oxytocin receptor 
family) bind to both β-arrestin isoforms with equal affinity. Class B GPCRs 
receptors internalise with β-arrestins and recycle more slowly to the cell-surface 
(Oakley et al., 1999; Oakley et al., 2000). Moreover, when the C-terminal tails of 
β2-AR and the V2R are “swapped”, the kinetics of trafficking of these receptors is 




completely reversed (Oakley et al., 1999). This result led to the discovery of a 
cluster of serine residues within the C-terminal tail that determines the affinity for 
β-arrestins, and that modification of this cluster is sufficient to alter the kinetics of 
GPCR trafficking (Oakley et al., 2001). Similarly, mutation of serine residues in the 
C-terminal tail of the CXCR4 (chemokine receptor family) showed impairment in 
endocytosis and down-regulation (Marchese and Benovic, 2001; Parent et al., 
1999), suggesting involvement of serine phosphorylation in the pre- and post-
endocytic sorting. 
 
1.2.2.3 Ubiquitination of GPCRs 
 Certain GPCRs are directed to specific endocytic pathways by covalent 
modification of intracellular facing lysine residues by a small regulatory protein 
called ubiquitin. Ubiquitin is best known for its role in targeting proteins to the 
proteasome to be degraded (reviewed in (Glickman and Ciechanover, 2002)), 
including the proteasome-dependent degradation of GPCRs that may occur due to 
misfolding during the biosynthetic pathway (Cook et al., 2003; Petaja-Repo et al., 
2001). Ubiquitin is also involved in the pre- and post-endocytic sorting of GPCRs. 
 The ubiquitin machinery is composed of three enzymes called E1, E2 and E3 
(responsible for conjugating ubiquitin moieties to the protein) and de-ubiquitinating 
enzymes (DUBs) that proteolytically remove ubiquitin molecules from proteins. 
Ubiquitin conjugation to proteins requires three steps. Ubiquitin is first “activated” 
by an E1 enzyme (activating enzyme) in an ATP-dependent reaction by forming a 
thioester bond at its active-cysteine site with the COOH-terminus of ubiquitin. 
Ubiquitin is then transferred to the active site cysteine residue of an E2 enzyme 
(conjugating enzyme). Finally, ubiquitin is transferred to a lysine residue on the 
target protein by forming an isopeptide bond. This action is either mediated directly 
by an E3 enzyme (homologous to the E6-AP carboxyl terminus (HECT)-domain 
containing E3 ligases) or by the E2 enzyme with assistance from the E3 ligase 
(Really Interesting New Gene (RING)-finger containing E3 ligases) (Hershko et al., 
1983). It is known that there is only two E1 (Ciechanover et al., 1982; Pelzer et al., 
2007), several E2 and multiple families of E3, which are therefore able to provide 
reactions with specificity. DUBs are a large family of proteases comprised of about 
90 members and specifically cleave the bond that links ubiquitin and proteins. 
Their main function is to remove the ubiquitin before the protein is degraded in 
order to maintain ubiquitin-homeostasis and recycle ubiquitin pool. This process 
usually occurs at the entry of the proteasome and the lysosome (reviewed in 
(Nijman et al., 2005)). Indeed, DUBs have been shown to also regulate the post-
endocytic sorting of receptors, such as for PAR2 (protease-activated receptor) 
(Hasdemir et al., 2009) and CXCR4 (Berlin et al., 2010), where deubiquitination 
promotes lysosomal targeting and down-regulation of these receptors. 




 The role for ubiquitin in the endocytic sorting of GPCR was first shown for the 
yeast GPCR, Ste2 (Fig. 1.6). Ubiquitination of the C-terminal tail of the receptor is 
required to promote internalisation and trafficking to the vacuole (equivalent to the 
mammalian lysosome) (Hicke and Riezman, 1996). In contrast, PAR1 (protease-
activated receptor) is constitutively ubiquitinated and deubiquitination promotes 
internalisation of the receptor (Wolfe et al., 2007). Studies on β2-AR have shown 
that ubiquitination of β-arrestin was required for the internalisation and subsequent 
down-regulation of the receptor (Shenoy et al., 2001), where the time course of 
ubiquitination/deubiquitination of β-arrestin correlates with the time of 
association/dissociation with the receptor (Shenoy and Lefkowitz, 2003). 
Therefore, ubiquitin indirectly regulates the endocytosis of GPCRs by controlling 
the association of β-arrestin with the receptor. 
 A study of the β2-AR (Shenoy et al., 2001) was the first one to show that 
mammalian GPCRs are regulated by ubiquitination. Ubiquitination of the β2-AR 
promotes its trafficking to lysosomes for degradation (Fig. 1.6). Indeed, a mutant 
lacking all intracellular facing lysine residues, although able to signal and 
internalise normally, but was not ubiquitinated and exhibited reduced degradation 
(Shenoy et al., 2001). Other GPCRs such as PAR2 (Jacob et al., 2005) and the 
CXCR4 (Marchese and Benovic, 2001) are similarly regulated by ubiquitination. 
However, ubiquitination of GPCRs is not always required for downregulation. 
Activation of the δ receptor (δOR, opioid receptor family) promotes ubiquitination 
and trafficking to lysosomes (Tanowitz and Von Zastrow, 2002; Tsao and von 
Zastrow, 2000b). However, lysine-less δOR mutant still efficiently trafficked to 
lysosomes, even in the absence of ubiquitination (Tanowitz and Von Zastrow, 
2002). A subsequent study showed that ubiquitination of δOR regulates the rate at 
which the receptor is degraded (Hislop et al., 2009). 
  










Figure 1.6 Roles of ubiquitination in the regulation of GPCRs. Ubiquitin is a small 
regulatory protein, that can be covalently attached to GPCRs to lysine residues. 
Ubiquitination can perform at least three known functions. (1) Ubiquitin can regulate the 
internalisation of GPCRs, as has been shown for Ste2 (Hicke and Riezman, 1996) or 
PAR1 (Wolfe et al., 2007). (2) Ubiquitin also targets the GPCR to the lysosome, where the 
receptor is degraded, as shown for PAR2 (Jacob et al., 2005). (3) Finaly, ubiquitination 
regulates the rate of degradation, as for the δOR (Hislop et al., 2009). 
  




1.2.3 Endosomal Sorting of GPCRs 
 Once internalised, GPCRs traffic to early endosomes (reviewed in (Mellman, 
1996)), where they are sorted into recycling pathways to return to the cell-surface 
or alternatively, enter the down-regulation pathway to be trafficked to lysosome. 
 
1.2.3.1 Recycling Pathway of GPCRs 
 The recycling pathway was for a long time thought to occur by default. 
However, accumulating evidence showed the recycling pathway as a complex and 
active system. 
 Studies of the β2-AR have shown that dephosphorylation of the receptor was 
required before recycling back to the cell-surface (Krueger et al., 1997; Pippig et 
al., 1995; Sibley et al., 1986). Dephosphorylation was mediated by the protein 
phosphatase type 2A (PP2A) (Pitcher et al., 1995). Similar mechanisms also 
regulate other GPCRs, such as the V2R (Innamorati et al., 1998) and the NK1 
receptor (NK1R, tachykinin receptors family, also known as neurokinin 1 receptor) 
(Garland et al., 1996). Subsequently, it has been shown that dephosphorylation 
reduces binding of β-arrestins to GPCRs (Sohlemann et al., 1995) and that the 
longer they are associated with β-arrestins the longer they are “sequestered” on 
endosomes (Oakley et al., 1999; Oakley et al., 2000). These studies suggest that 
β-arrestins play an important role in the sorting of the receptor by preventing its 
entry into the recycling pathway. 
 PDZ (postsynaptic density 95/disc large/zonula occludens-1) domain-containing 
proteins have been shown to bind to C-terminal tail of GPCRs and affect their 
post-endocytic sorting. A PDZ domain (Kennedy, 1995) is a motif required for 
protein-protein interactions that is found in the C-terminal tails of many GPCRs 
(reviewed in (Marchese et al., 2008)). For example, the Na+/H+ exchanger 
regulatory factor (NHERF), which contains a PDZ domain, has been found to bind 
β2-AR and promote efficient recycling of the receptor (Cao et al., 1999). This PDZ 
domain, when inserted into the C-terminal tail of the δOR, is sufficient to induce 
recycling of this receptor that normally undergoes efficient down-regulation (Gage 
et al., 2001). The N-ethylmaleimide-sensitive fusion (NSF) protein has also been 
shown to bind to the C-terminal tail of the β2-AR, and is also involved in the 
regulation of its recycling (Cong et al., 2001). When the binding domain of NSF 
was mutated, β2-AR failed to recycle normally after agonist stimulation. However, 
studies with the β2-AR showed that PDZ domain was sufficient to induce recycling 
of the receptor independently of NSF binding (Gage et al., 2005). GPCRs unable 
to bind such regulator proteins undergo down-regulation pathways and are 
targeted to lysosomes. 




1.2.3.2 Regulation of GPCRs by the Rab GTPase Family 
 In humans, the GTPase Rab proteins constitute one of the biggest groups of the 
Ras-like protein family (reviewed in (Zerial and McBride, 2001)). They have been 
shown to regulate the trafficking and transportation of intracellular vesicles by 
regulating the budding, transport, tethering, docking and fusion of vesicles 
(reviewed in (Tuvim et al., 2001)). Due to their central role in intracellular traffic, 
Rab proteins have been shown to regulate the trafficking of GPCRs. An important 
aspect of the Rab family is that each member is localised in surfaces of distinct 
membrane-bound vesicles/organelles. For example, Rab5 is mediating the 
transport of vesicles from the plasma membrane to early endosome (Gorvel et al., 
1991) (Fig. 1.7). Many GPCRs have been shown to internalise in Rab5-positive 
vesicles, such as the β2-AR and the NK1R, where the use of the dominant negative 
Rab5-S34N mutant inhibited agonist-induced internalisation of these receptors 
(Schmidlin et al., 2001; Seachrist et al., 2000). Unlike the β2-AR, the AT1 receptor 
(AT1R, angiotensin receptor family) has been found to directly bind to Rab5 and 
internalise into Rab5-containing large hollow core vesicles (Seachrist et al., 2002). 
However, dominant negative of Rab5 did not block its internalisation, but 
prevented the receptor to traffic to those large vesicles. Therefore, AT1R by 
binding to Rab5 seems to regulate its own trafficking into those target vesicles. 
Conversely Rab4 and Rab11 are involved in the recycling of cargo from early and 
recycling endosomes to the cell-surface. Rab4 on its own promotes rapid recycling 
from early endosomes (van der Sluijs et al., 1992), whereas in association with 
Rab11, Rab4 induces later and slower recycling from recycling endosomes to the 
cell-surface (Sonnichsen et al., 2000). For example, the dominant negative Rab4-
N121I mutant blocks the recycling of the β2-AR, without affecting its 
desensitisation and internalisation (Seachrist et al., 2000). Similarly, the dominant 
negative Rab11a-S25N mutant also blocks the slower recycling of CXCR2 (Fan et 
al., 2003).  
 Regarding the down-regulation pathway, Rab7 has been found to localise to 
late endosomes and lysosomes. In fact, Rab7 regulates the traffic of vesicles from 
early to late endosomes (Meresse et al., 1995) and then to lysosome (Bucci et al., 
2000). Indeed, overexpression of the dominant negative Rab7-N125I and Rab7-
T22N mutants prevents the degradation of κ receptor and CXCR2 (Fan et al., 
2003; Li et al., 2000). 
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1.2.3.3 Down-Regulation Pathways of GPCRs: the ESCRT Machinery 
 Persistent activation of GPCRs can promote trafficking to down-regulation 
pathways, an important process for signal termination. However, certain GPCRs 
are always directly targeted to these pathways to be degraded. 
 Studies in yeast (Stack et al., 1995) have revealed a set of proteins, involved in 
the traffic of ubiquitinated cargos from endosomes to lysosomes, that are highly 
conserved between species (reviewed in (Williams and Urbe, 2007)). This 
machinery is called the endosomal sorting complex required for transport (ESCRT) 
and is divided in 4 main complexes. ESCRT-0 is the complex responsible for 
clustering ubiquitinated-cargos, which comprises the hepatocyte growth factor-
regulated tyrosine kinase substrate (Hrs) (Fig. 1.8). Hrs contains an ubiquitin-
interacting motif (UIM) that targets ubiquitinated-cargos to the ESCRT machinery 
(Hofmann and Falquet, 2001; Lloyd et al., 2002). ESCRT-I and ESCRT-II are 
involved in the formation of intralumenal vesicles (ILVs) within the endosome and 
ESCRT-III is involved in the cleavage of the neck of these vesicles. Once 
endosomes are filled with many of these ILVs they are referred to as a 
multivesicular bodies (MVBs), organelles that precede lysosomes (Morales et al., 
1999). The protein tumour susceptibility gene 101 (Tsg101), a component of 
ESCRT-I (Babst et al., 2000), has been shown to directly bind Hrs to mediate 
traffic of ubiquitinated-cargos to lysosome (Lu et al., 2003). The main components 
of ESCRT-III are the charged MVB protein (CHMP) family (Howard et al., 2001) 
that have been found to polymerise around the neck of ILVs and induce their 
scission (Hanson et al., 2008). The AAA-ATPase vacuolar protein sorting 4 (Vps4) 
is another protein essential for ESCRT function that disassembles and recycles 
ESCRT-III components (Azmi et al., 2006; Babst et al., 1998; Scheuring et al., 
2001). 
 Many GPCRs that traffic to lysosomes have been reported to require the 
ESCRT machinery. CXCR4 was the first mammalian GPCR to shown to interact 
with components of ESCRT machinery. Down-regulation of CXCR4 has been 
shown to be dependent on Hrs and Vsp4 (Marchese et al., 2003). The post-
endocytic sorting of PAR2 also has been reported to be Hrs-dependent (Hasdemir 
et al., 2007) unlike PAR1 which traffics to lysosomes independently of Hrs and 
Tsg101 (Gullapalli et al., 2006). However PAR1 requires interaction with CHMP4B 
and C and Vsp4, which is mediated by apoptosis-linked gene-2-interacting protein 
X (ALIX) (Dores et al., 2012). ALIX is protein regulator involved in apoptosis (Vito 
et al., 1999) but also recruits CHMP4/ESCRTIII complexes to facilitate MVB 
formation (Katoh et al., 2003). A more recent study on the ocular albinism type 1 
GPCR has also shown that its degradation is dependent on several components of 
the ESCRT-0, –I and –III (Giordano et al., 2011). Interestingly, some GPCRs that 
traffic to lysosomes in an ubiquitin-independent manner have been shown to 
interact directly with some components of the ESCRT machinery, such as the δOR 




that require Hrs and Vsp4 to traffic to lysosome (Hislop et al., 2004) and the CGRP 
receptor that require Hrs (Hasdemir et al., 2007). 
 
1.2.3.4 Non-ESCRT Protein Implicated in Lysosomal Sorting of GPCRs 
 The GPCR-associated sorting protein (GASP) family were first identified as a 
binding partner of the δOR (Whistler et al., 2002). Overexpression of the last 497 
residues of the C-terminal tail of GASP that act as a dominant-negative or 
mutation of the domain for interaction between the receptor and GASP caused 
recycling of the receptor. Subsequently, GASP was been found to bind to a broad 
spectrum of GPCRs, such as the dopamine 2 (D2) receptor (Bartlett et al., 2005), 
the opioid receptors µOR and κOR, β1-AR and the CT receptor (CTR, calcitonin 
receptor) (Simonin et al., 2004). GASP is widely distributed, but is predominantly 
expressed in the CNS (Simonin et al., 2004). Interestingly, GASP has been found 
to bind β2-AR, a receptor that usually undergoes recycling. This suggests that 
GASP may be involved in the sorting of β2-AR for down-regulation, observed 
during chronic stimulation (Whistler et al., 2002). 
 Sorting nexins (SNX) are another protein family involved in the endosomal 
sorting of GPCRs to lysosomes. These membrane-associated proteins are 
characterised by the presence of a PX domain (named after NADPH oxidase 
domains of p40phox and p47phox) (reviewed in (Ponting, 1996)). They consist of 
approximately 100-130 amino acids and have the ability to bind various 
phosphatidylinositol phosphates (PIPs) (reviewed in (Ponting, 1996)). SNXs were 
first implicated in the sorting of the epidermal growth factor receptor (ErbB1), a 
receptor tyrosine kinase (RTK), where stimulation with epidermal growth factor 
(EGF) promotes binding of SNX-1 to the receptor and induced degradation of 
ErbB1. Degradation was enhanced by overexpression of SNX-1 (Kurten et al., 
1996). SNX-1 was also shown to bind Hrs, promoting the sorting of ErbB1 to 
lysosomes (Chin et al., 2001). PAR1 was the first GPCR identified to associate 
with SNX-1, where overexpression of the C-terminal tail of SNX-1 that function as 
a dominant negative blocked agonist-mediated trafficking of PAR1 to endosomes 
(Wang et al., 2002). Suggesting that SNX-1 is involved in the trafficking of PAR1 to 
lysosomes. This was later confirmed using siRNA to deplete cells of endogenous 
SNX-1 (Gullapalli et al., 2006). Interestingly, as opposed to ErbB1, SNX-1-
mediated PAR1 trafficking to lysosomes is Hrs- and Tsg101-independent 
(Gullapalli et al., 2006). SNX-1 has been shown to bind other GPCRs, including 
the oxytocin receptor and δOR, both of which are known to undergo lysosomal 
sorting (Heydorn et al., 2004). However, similarly to GASP, SNX-1 has been found 
to bind members of the NK1R and acetylcholine (muscarinic) receptor family, 
which are known to recycle back to the cell-surface (Heydorn et al., 2004), which 




again suggests a role for SNX-1 in down-regulation after chronic agonist 
stimulation. 
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1.2.4 Down-Regulation of GPCRs 
1.2.4.1 Proteasome 
 The proteasome is a multi-protein complex found in the cytoplasm and nuclei of 
all eukaryotic cells. The function of the proteasome is the degradation of 
abnormal/misfolded proteins and proteins involved in the regulation of cell viability 
and cell cycle by degrading critical regulatory protein such as cyclins and 
transcription factors. It also has been found to be involved in the processing and 
presentation of major histocompatibility complex (MHC)-class I antigens at the 
cell-surface (Rock et al., 1994).  
 The proteasome is composed of two main particles often referred to their 
Svedberg sedimentation coefficient (denoted S): the core particle 20S (DeMartino 
and Goldberg, 1979; Wilk and Orlowski, 1983) (responsible for the proteolytic 
activity) and the regulatory particle 19S, which is responsible for the recognition of 
ubiquitin-complex protein (Schmid et al., 1984; Schuldt and Kloetzel, 1985). The 
20S and 19S form the complex denoted 26S and named proteasome (Arrigo et al., 
1988). The proteasome is a threonine protease (Fenteany et al., 1995; Seemuller 
et al., 1995) that possesses three main activities: a chymotrypsin-like activity that 
cleaves after large hydrophobic residues; a trypsin-like activity that cleaves after 
basic residues; and a peptidylglutamyl-peptide hydrolysing that cleaves after acidic 
residues (Wilk and Orlowski, 1983). As the proteasome is found in both the 
cytoplasm and nucleus, its main targets are cytoplasmic and nuclear proteins. 
However, proteasome has been found to be involved in the regulation of misfolded 




 Unlike the proteasome, many studies have shown that the degradation of 
GPCRs mainly occurs in lysosomes (Hanyaloglu and von Zastrow, 2008; 
Marchese et al., 2008; Tsao and von Zastrow, 2000a). Lysosomes were first 
described in the mid 1950’s (De Duve et al., 1955) as new cytoplasmic membrane-
enclosed organelles that contain different types of enzymes that requiring an 
acidic pH (~pH 5). Lysosomes constitute the primary degradative compartment of 
the cell and receive their substrates from endocytosis or autophagy. However, 
lysosomes are also involved in the presentation of MHC-class II (Collins et al., 
1991) and in cell death (Trump et al., 1962). 
 Lysosomes are comprised of two main classes of proteins, soluble hydrolytic 
enzymes and lysosomal membrane proteins (LMPs). Lysosomes contain about 50 
different degradative enzymes that can hydrolyse proteins, DNA, RNA, 




polysaccharides and lipids (review in (Weissmann, 1964)). The proteases, which 
are described more precisely below, comprise aspartic, cysteine and serine 
protease families of hydrolytic enzymes, such as the cathepsin family. LMPs are 
generally contained within the lysosomal compartment and have diverse functions, 
including acidification of the lysosomal lumen, protein import from the cytosol, 
membrane fusion and transport of degradation products to the cytoplasm 
(reviewed in (Callahan et al., 2009)). Among them, lysosome-associated 
membrane proteins (LAMPs) are one of the most abundant, however their roles 
remain poorly understood. 
 
1.2.5 Regulation by Proteases 
 Proteases are enzymes that catalyse proteolysis, which consists of the 
hydrolytic breakdown of peptide bond. Proteases are classified into six groups 
according to their active site: serine proteases, cysteine proteases, threonine 
proteases, aspartic proteases, glutamic proteases and metalloproteases (Rawlings 
et al., 2012). Beyond their proteolytic role in digestion in the stomach and the 
down-regulation of protein in lysosomes, proteases have been found to be 
involved in the regulation of GPCRs, by acting on the activation of receptors, 
promoting transactivation of receptor tyrosine kinases or controlling the post-
endocytic sorting of GPCRs. 
 Proteases can control the availability of extracellular bioactive components, 
which mediate GPCRs’ activation. For example, angiotensin I-converting enzyme 
(ACE) is a zinc metalloprotease that cleaves angiotensin I, an inactive precursor, 
into the active angiotensin II (ang II) (Skeggs et al., 1956). Ang II can then promote 
its actions (e.g. vasoconstriction) through the activation of AT1R and AT2R 
receptors (reviewed in (de Gasparo et al., 2000)). Additionally, ACE has been 
found to degrade bradykinin (Grafe et al., 1993; Jaspard et al., 1993) and then 
prevent the vasodilatatory activity of this peptide. Therefore, ACE regulates blood 
pressure by increasing the levels of ang II and degrading bradykinin. Alternatively, 
some proteases such as thrombin and trypsin have been found to directly 
stimulate PAR receptors by cleaving the N-terminus and to expose a new N-
terminus, which acts as a tethered ligand (Nystedt et al., 1994; Vu et al., 1991). 
Conversely, other proteases such as the cathepsin G have been found to prevent 
activation of PARs by proteolytically removing the tethered ligand (Dulon et al., 
2003). 
 The transactivation of ErbB1 by GPCRs was first described by Daub et al. in 
1996 (Daub et al., 1996). The mechanism by which GPCRs induce ErbB1 
transactivation is still unclear and can depend on receptor and cell type. However, 
many mechanisms involve the release of precursor forms of the ErbB1 type 
ligands, such as the heparin binding-EGF, transforming growth factor-α, and 




amphiregulin. These ligands are generated by the activation of zinc-dependent 
metalloproteases from the a disintegrin and metalloprotease (ADAM) family. 
ErbB1 transactivation promotes activation of extracellular signal-regulated kinase 
(ERK) and PI3K/Akt pathways to regulate cell proliferation and migration (Prenzel 
et al., 1999; Schafer et al., 2004a; Schafer et al., 2004b). 
 Finally, proteases are also involved in the sorting of certain GPCRs. For 
example, DUBs cleave ubiquitin-protein bonds allowing GPCRs to be trafficked for 
degradation (see 1.2.2.3). Endosomal proteolysis of GPCR ligands can also 
regulate GPCR signalling, trafficking and resensitisation. Endothelin-converting 
enzyme-1 (ECE-1) is present in early endosomes and regulates many GPCRs. 
Following activation, GPCRs, together with the ligand and β-arrestin internalise to 
early endosomes. β-arrestin must be released for GPCRs to recycle back to the 
cell-surface (Oakley et al., 1999) and until recently the mechanism triggering the 
release of β-arrestins was unknown. Studies on the post-endocytic sorting of NK1R 
and CGRP receptor revealed that ECE-1 degrades SP and CGRP at endosomal 
pH, destabilising the GPCR/ligand/β-arrestin complex and promoting recycling of 
receptors back to the cell-surface (Padilla et al., 2007; Roosterman et al., 2007). 
  




1.3 Receptors of the Calcitonin Peptide Family 
1.3.1 Heterodimeric Receptors 
 Receptors of the calcitonin peptide family are GPCRs belonging to the secretin 
family (class II). Based on their ability to bind both β-arrestin isoforms they are 
sometimes termed class B receptors. The CTR was first cloned in 1991 (Lin et al., 
1991) and consists of 482 amino acids. The calcitonin receptor-like receptor 
(CLR), was cloned shortly after, based on sequence homology with CTR (~55% 
homology between the receptors) and consists of 461 amino acids (Fluhmann et 
al., 1995; Njuki et al., 1993). However, CLR was consider as orphan until Aiyar et 
al. observed evidence of CGRP binding and CGRP-dependent cAMP activation in 
HEK cells transfected with CLR (Aiyar et al., 1996). A major breakthrough was 
achieved two years later when McLatchie et al. (McLatchie et al., 1998) showed 
that a family of single transmembrane proteins called receptor activity-modifying 
proteins (RAMPs) were necessary to confer receptor function to CLR. Unlike CLR, 
CTR possesses receptor function when expressed alone (Lin et al., 1991). The 
RAMP family consists of three proteins named RAMP1-3. When CLR associates 
with RAMP1 (CLR•RAMP1), it forms a high affinity CGRP receptor. Alternatively, 
when CLR associates with RAMP2 or 3 (CLR•RAMP2 and CLR•RAMP3), they 
form high affinity receptor for ADM (McLatchie et al., 1998) (Fig. 1.9). RAMPs not 
only confer specificity of ligand but also are necessary to promote terminal 
glycosylation of CLR and to promote its transit from the ER/Golgi to the cell-
surface (Fraser et al., 1999; Hilairet et al., 2001b; McLatchie et al., 1998). 
 Similarly to CLR, RAMPs have been shown to interact with CTR (Christopoulos 
et al., 1999; Muff et al., 1999), where association with RAMPs forms IAPP 
receptors. A specific receptor for ADM2 has not yet been clearly defined, however, 
ADM2 can activate CGRP and ADM receptors, as well as IAPP receptors. 
Although, the highest affinity receptor observed for ADM2 is CLR•RAMP3 (Roh et 
al., 2004). The redundancy of CTR, CLR and RAMPs combinations has shown a 
certain degree of cross reactivity between the different peptide of the family, which 
could also explain the similarity of biological functions of these peptides 
(Christopoulos et al., 1999). It certainly suggests that these receptors must be 
tightly regulated in order to present the correct cellular phenotype. Moreover, 
RAMPs also bind other members of the secretin GPCR family, such as the PTH1 
and PTH2 receptors (parathyroid hormone receptor family) and the VPAC1 and 
VPAC2 receptors (VIP and PACAP receptor family) (Christopoulos et al., 2003). 
 CTRs are often coupled to Gαs and Gαq mediating accumulation of cAMP and 
activation of PLC, respectively (Chabre et al., 1992; Force et al., 1992). For 
example, CT induces inhibition of bone resorption by rat osteoclasts in a cAMP- 
and PKC-dependent manner (Su et al., 1992). Interestingly, CTR has been found 
to couple to Gαs, Gαi and Gαq in LLC-PK1 (kidney tubule cell line) in a cell cycle 




dependent manner (Chakraborty et al., 1991). Regarding CLR, it is generally 
accepted that receptors predominantly signal via Gαs-mediated activation of AC to 
increase intracellular cAMP and activate PKA (Aiyar et al., 1999; Poyner et al., 
1992; Van Valen et al., 1990; Withers et al., 1996). However, similarly to CTR, 
CLR has been found to also stimulate activation of PLC by coupling with Gαq/11 
(Drissi et al., 1998) and also to be sensitive to pertussis toxin (PTX, a toxin that 
specifically inhibits Gαi) (Main et al., 1998; Mittra and Bourreau, 2006). 
 
1.3.2 Receptor Component Protein 
 There is evidence of another protein that associates with CGRP and ADM 
receptors, the receptor component protein (RCP). RCP was first identified in 1996 
by its ability to promote the CGRP-mediated responses in Xenopus laevis oocytes 
(Luebke et al., 1996). RCP was specific for CLR•RAMP1 and CLR•RAMP2, as it 
had no effect on the signalling of receptors for CT, IAPP, neuropeptide Y, 
vasoactive intestinal peptide and β-endorphin (Luebke et al., 1996; Prado et al., 
2001). RCP was shown to be highly conserved in mice, rabbit and human (~82% 
of homology at the protein level) (Naghashpour et al., 1997; Rosenblatt et al., 
2000). In parallel, the cloning and expression of CLR in HEK cells showed 
evidence of CGRP binding and CGRP-induced cAMP production (Aiyar et al., 
1996), but not in COS-7 cells (fibroblast-like cell line) (Han et al., 1997), 
suggesting the presence of a component in HEK cells that makes CLR a functional 
receptor. However, when CLR was transfected with RAMPs only in COS-7 cells, it 
yields a functional receptor (Buhlmann et al., 1999). Later studies showed that in 
fact RCP was endogenously found in COS-7 cells (Evans et al., 2000). 
Additionally, the distribution of the expressed RCP in the central and peripheral 
nervous system in rat correlates with that of CGRP receptors (Ma et al., 2003). 
The use of an RCP antisense construct transfected in NIH 3T3 cells (mouse 
embryonic fibroblast cell line) has been shown to reduce ADM-induced activation, 
but did not affect ADM binding to the receptor or receptor expression at the cell-
surface (Evans et al., 2000; Prado et al., 2001), suggesting that RCP does not act 
as a chaperone to target CLR to the cell-surface, but rather to facilitates efficient 
coupling of the receptor to the cellular signalling pathways. However, the real 
implication of RCP in a functional complex receptor remain to be determine as a 
study in yeast strongly suggest that RAMP itself is sufficient to confer functional 
activity of CGRP and ADM receptor (Miret et al., 2002). 
 
  











Figure 1.9 CGRP and ADM receptors. The GPCR CLR that belongs to the secretin 
family and bind both β-arrestins (class B), can bind with the different members of the 
RAMPs transmembrane proteins. When CLR associates with RAMP1 (CLR•RAMP1), it 
forms a high affinity CGRP receptor, however when CLR associates with RAMP2 or 3 
(CLR•RAMP2 and CLR•RAMP3), high affinity ADM receptors are formed.  




1.3.3 CGRP and ADM Receptor Regulation 
 Like many of GPCRs, CGRP and ADM receptors internalise after agonist-
induced stimulation (Hilairet et al., 2001a; Kuwasako et al., 2000). Once 
internalised the fate of CLR•RAMP1 depends on the duration of the exposure to 
CGRP (Cottrell et al., 2007). Transient stimulation of CLR•RAMP1 with CGRP 
allows recycling of CLR•RAMP1, whereas continuous stimulation causes 
trafficking of CLR•RAMP1 to lysosomes where it is degraded (Cottrell et al., 2007). 
As mentioned previously, it has been shown that the recycling of CLR•RAMP1 is 
regulated by the metalloprotease, ECE-1 (Padilla et al., 2007). Another study 
looking at the post-endocytic sorting of CLR•RAMP3 has shown that the C-
terminal tail of RAMP3, but not RAMP1 or 2, contains a PDZ type I domain. They 
showed that NSF binds to this PDZ domain and promotes recycling of 
CLR•RAMP3 back to the cell-surface (Bomberger et al., 2005).  Unlike 
CLR•RAMP1 and CLR•RAMP3, very little is known about the trafficking and post-
endocytic sorting of CLR•RAMP2 (Kuwasako et al., 2000). 
 
  




1.4 G Protein-Coupled Receptor Signalling: 
Activation of Mitogenic Signalling Pathways 
 The mitogen-activated protein kinases (MAPK) are enzymes involved in the 
regulation of critical cell functions such as proliferation, gene expression, 
differentiation, mitosis, cell survival and apoptosis. The traditional notion that only 
RTKs are able to mediate activation of MAPK is no longer adequate. It is now well 
established that GPCRs can promote activation of mitogenic pathways in many 
different cell types (reviewed in (Luttrell, 2003; Rozengurt, 2007)). Therefore, the 
elucidation of the intracellular signalling pathways activated by GPCRs is of great 
importance, as these studies could establish new potential targets or strategies for 
the treatment of human disease. This study is focused on GPCR-induced 
pathways that activate ERK1 and 2. These have been separated in four main 
pathways: 1) cAMP/PKA, 2) PLC/PKC/Ca2+, 3) ErbB1 transactivation and 4) β-
arrestin-dependent endosomal signalling. 
 
1.4.1 Overview of the MAPK Pathways 
 The first MAPK to be identified was ERK2, defined by its molecular weight 
around 42 kD. Three independent studies observed this protein, which they named 
p42, to be phosphorylated on tyrosine residues following stimulation with different 
mitogenic agents such as EGF, platelet-derived growth factor (PDGF) and 12-o-
tetradecanoylphorbol-13-acetate (TPA) (Bishop et al., 1983; Gilmore and Martin, 
1983; Nakamura et al., 1983). p42 itself was later found to be a serine/threonine 
protein kinase (Rossomando et al., 1989). The first MAPK to be cloned was p44 
and named ERK1 for extracellular signal-regulated protein kinase 1, because of 
the wide variety of extracellular signals that activate it (Boulton et al., 1990). 
Shortly after, ERK2 and 3 were cloned (Boulton et al., 1991) suggesting the 
existence of an ERK family. ERK1 and 2 have ~85% sequence identity. Other 
MAPKs have since been identified such as the c-Jun N-terminal kinases (JNK) 
(Derijard et al., 1994; Hibi et al., 1993; Kyriakis et al., 1994) and p38 (also known 
as Cytokinin Specific Binding Protein (CSBP) or reactivating kinase (RK)) (Han et 
al., 1994; Lee et al., 1994; Rouse et al., 1994). They show some regulation 
similarities with ERK1 and 2 but are activated by different mitogenic agents. 
 Generally, MAPKs are activated by a cascade of phosphorylation and by other 
protein kinases. The cascade usually consists of at least three distinct kinases, 
from upstream to downstream: MAPK kinase kinase (MAP3K), MAPK kinase 
(MAP2K) and MAPK, which then promote cellular responses (Fig. 1.10) (reviewed 
in (Pearson et al., 2001; Seger and Krebs, 1995)). MAP3K are generally activated 
by small GTPases. For example, the ERK1-2 module generally consists of 




activation of Ras a small GTPase, Raf kinase (MAP3K), MEK1-2 (MAP2K) and 
finally ERK1-2 (MAPK) (reviewed in (Robinson and Cobb, 1997)). 
 There are two important aspects of MAPK pathways. First is the existence of 
cross talk, where intermediates can regulate activation or inhibition of other 
signalling pathways (Corbit et al., 1999; Frost et al., 1997). Second is the 
formation of complexes between scaffolding proteins and the different members of 
signalling cascades that facilitate signal transduction (Choi et al., 1994; Yasuda et 
al., 1999). One such scaffolding protein is β-arrestin (Lefkowitz and Shenoy, 
2005). 
 The functions of ERK1 and 2 are similar and difficult to distinguish from each 
other. A study from Yao et al. showed that genetic deletion of erk2 gene resulted 
in embryonic lethality in mice. The mice exhibited disrupted mesoderm formation 
with an increase in apoptosis and defects in cellular differentiation. The same 
group also created an erk2 null embryonic stem (ES) cell line for in vitro studies. 
Interestingly, although erk2 null cells exhibit a reduction in total ERK activation 
upon stimulation, with an augmentation of ERK1 phosphorylation, there is no 
significant difference in ES cells proliferation. This result suggests that ERK1 is 
able to compensate the loss of ERK2. However, the mutant erk2 embryos 
possessed no ERK1-2 phosphorylation, suggesting that ERK1 activity was not 
present to compensate the loss of ERK2 (Yao et al., 2003). In contrast, erk1 
deficient mice are viable, fertile, and of normal size. However, these mice show a 
deficit in the maturation of thymocytes leading to severe reduction of proliferation 
of T cells (Pages et al., 1999). These results show that ERK2 is able to 
compensate ERK1, even if the findings from the study of thymocytes were 
controversial (Nekrasova et al., 2005). 
 Analysis of zebrafish embryogenesis using expression knockdown techniques 
revealed that ERK1 and 2 can promote expression of both common and distinct 
sets of genes (Krens et al., 2008). ERK1 induced transcription of genes regulating 
dorsal-ventral patterning development and subsequent embryonic cell migration, 
whereas ERK2 induced transcription of genes involved in cell migration, 
mesendoderm differentiation and patterning (Krens et al., 2008). Together, these 
observations suggest that ERK1 and ERK2 are not entirely functionally redundant 
and have similar yet distinct functions. ERK2 seems to play a more critical role 
than ERK1, as loss of the latter can be compensated by ERK2, whereas the 
opposite is not always true. As the effects of ERK1 and 2 are difficult to 
distinguish, this pathway is usually referred to as the ERK1-2 pathway.  











Figure 1.10 Simplified Overview of Mammalian MAPK Cascades. Schematic 
representation of the organisation of MAPK cascades. Extracellular stimulus can promote 
activation of MAP3K that phosphorylate and activate MAP2K, which then phosphorylate 
and activate MAPK and lead to cellular responses. Three main MAPK modules are listed 
with their different cellular outcomes. Image was taken from Wikipedia website file: MAPK-
pathway-mammalian.png http://en.wikipedia.org/wiki/Mitogen-activated_protein_kinase. 
  




1.4.2 The cAMP/PKA Pathway 
 GPCRs coupled to Gαs stimulate the activation of AC to promote the increase of 
intracellular cAMP levels (reviewed in (Gilman, 1984a; Gilman, 1984b)) that 
subsequently activates PKA (Brostrom et al., 1970; Gill and Garren, 1971; Tao et 
al., 1970). The PKA pathway regulates several MAPK pathways, including 
activation of p38 (Zheng et al., 2000) or inhibition of ERK5 (Pearson et al., 2006). 
GPCRs that activate Gαs proteins have also been shown to regulate the ERK1-2 
module (Fig. 1.11). 
 
1.4.2.1 Activation of the ERK1-2 Module 
 The first evidence that the cAMP/PKA pathway can stimulate ERK1-2 came 
from a study where a constitutively active Gαs subunit mutant was shown to 
promote ERK1 phosphorylation in COS-7 cells (Faure et al., 1994). This 
observation was later confirmed by another study examining the β2-AR in wild type 
(WT) or mutant S49 lymphoma cell lines lacking Gαs or PKA. When the β2-AR was 
expressed in WT cells, isoproterenol stimulation induced ERK1-2 activation, 
whereas when β2-AR was expressed in the mutant cell lines, it was unable to 
promote ERK1-2 activation following stimulation (Wan and Huang, 1998). Further 
analyses have shown that the small GTPase, Rap-1 and the protein kinase, B-Raf 
(MAP3K) were also involved in this pathway (Vossler et al., 1997; Wan and 
Huang, 1998). Rap-1 activation is mediated by PKA and promotes association with 
B-Raf, which then triggers B-Raf activation. Additional studies have shown that in 
fact PKA promotes phosphorylation of Src (Obara et al., 2004; Schmitt and Stork, 
2002) which recruits a Rap-1 guanine nucleotide exchange factor (GEF), Crk SH3 
domain-binding guanine nucleotide-releasing factor (C3G) (Schmitt and Stork, 
2000; Schmitt and Stork, 2002). This complex Src-C3G then activates Rap-1 by 
replacing its GDP by GTP and promoting activation of the ERK1-2 module. In 
contrast, studies have also shown that the activation of Rap-1 was mediated in a 
cAMP-dependent but PKA-independent manner (Laroche-Joubert et al., 2002; 
Weissman et al., 2004). This mechanism involves EPAC (exchange protein 
directly activated by cAMP), another Rap-1 GEF that is directly activated by cAMP. 
The activation of EPAC then promotes activation of Rap-1 (Laroche-Joubert et al., 
2002). However, the use of an EPAC-specific analogue that activates EPAC but 
not PKA, has shown that Rap-1 activation failed to promote ERK1-2 
phosphorylation (Enserink et al., 2002), suggesting that Rap-1 and ERK1-2 are 
independently regulated. In fact, it was subsequently shown that it was the 
subcellular localisation of EPAC that was responsible for the lack of activation of 
ERK1-2 (Wang et al., 2006). Indeed, this study showed that EPAC was normally 
localised to the periphery of the nucleus, which lead to activation of Rap-1 but not 




ERK1-2. In contrast, an EPAC mutant that contains a CAAX membrane-targeting 
motif was able to activate Rap-1 and ERK1-2 (Wang et al., 2006). 
 
1.4.2.2 Inhibition of the ERK1-2 Module 
 Activation of Gαs-mediated cAMP/PKA pathway can also lead to inhibition of 
ERK1-2 module (Cook and McCormick, 1993; Graves et al., 1993; Wu et al., 
1993). Activation of cAMP/PKA pathway lead to the inhibition of PDGF- and EGF-
mediated ERK1/2 activation, through inhibition of Raf-1 (also known as C-Raf, 
MAP3K), another member of the Raf family (Cook and McCormick, 1993; Wu et 
al., 1993). Raf-1 is phosphorylated in vitro and in vivo in a cAMP/PKA dependent 
manner (Hafner et al., 1994; Mischak et al., 1996; Wu et al., 1993). The PKA-
mediated phosphorylation of Raf-1 first leads to a reduction in its association with 
Ras (a small GTPase that activates Raf-1) and therefore attenuates the activation 
of Raf-1 by Ras (Dhillon et al., 2002). Additionally, Gαs-mediated inhibition of 
ERK1-2 has also been shown to involve Rap-1 (Schmitt and Stork, 2001). Indeed, 
activation of cAMP/PKA-mediated Rap-1 leads to the sequestration of Raf-1 and 
prevents its activation by Ras. 
 
1.4.3 The PLC/PKC/Ca2+ Pathway 
 Similarly to Gαs, activation of Gαq/11 leads to the activation of ERK1-2, JNK and 
p38 MAPK modules. Gαq/11 activates the activation of PLCβ isoforms (Smrcka et 
al., 1991; Taylor et al., 1991; Taylor et al., 1990), which in turn catalyses the 
hydrolysis of phosphatidylinositol 4,5-biphosphate into two second messengers: 
IP3 and DAG. IP3 induces mobilisation of Ca2+ from endoplasmic reticulum (ER) 
(Putney, 1986). DAG and intracellular Ca2+ then act in synergy or individually to 
promote ERK1-2 activation via PKC-dependent or –independent mechanisms. 
There are many members of the PKC family and they are divided into three main 
groups: the conventional PKC isoforms (cPKC) that are activated by both Ca2+ and 
DAG; novel PKC isoforms (nPKC) that are activated only by DAG; and the atypical 
PKC isoforms (aPKC) that are activated by neither Ca2+ or DAG, but rather by 
other second messengers such as small GTPases (reviewed in (Webb et al., 
2000)). Interestingly, the βγ subunits activated by GPCRs has been found to also 
promote PLCβ isoforms activation (Camps et al., 1992; Della Rocca et al., 1997; 
Katz et al., 1992) leading to the ERK1-2 activation. 
 




1.4.3.1 PKC-Dependent Pathways 
 Early experimentation showed that members of the three groups of PKCs where 
able to promote TPA-mediated ERK1-2 activation (Kolch et al., 1993; 
Schonwasser et al., 1998; Ueda et al., 1996). The cPKC- and nPKC-mediated 
mechanisms require the activation of Raf-1, notably PKCα that has been found to 
directly phosphorylate Raf-1 (Kolch et al., 1993) (Fig. 1.12). For example, this 
mechanism has been observed for the AT1R (Arai and Escobedo, 1996), the B2 
receptor (bradykinin receptor family) (Adomeit et al., 1999) and the 5-HT2 receptor 
(Hershenson et al., 1995). Another mechanism has been described for PKC-
mediated ERK1-2 activation. In unstimulated cells, Raf kinase inhibitor protein 
(RKIP) sequesters Raf-1 and prevents its activation. However, when stimulated 
with TPA or EGF, PKC phosphorylates RIKP which leads to the dissociation of the 
RKIP/Raf-1 complex and Raf-1 is thereby free to be activated and promote 
activation of MEK and ERK1-2 (Corbit et al., 2003). Additionally, RKIP has been 
found to also bind and inhibit GRK-2 when it is released from Raf-1, thus 
preventing desensitisation and sustain ERK1-2 activation of α1B-AR 
(adrenoceptor), PTH receptor and β2-AR (Lorenz et al., 2003). However, more 
experimental evidence is needed to define this mechanism of GPCR regulation. It 
is also interesting to note that, the B2 receptor, the M1 and M3 receptors 
(acetylcholine receptors (muscarinic) family) and the β2-ARs that can activate both 
Gαi and Gαq/11, have been shown to activate ERK1-2 via a cooperation of Gαq/11-
mediated PKC and of Gαi-induced Ras activation (Blaukat et al., 2000). Similar 
observations were seen for the α1B-AR and α2A-AR (Della Rocca et al., 1997). 
 
1.4.3.2 PKC-Independent Pathways 
 An alternative Gαq/11-mediated activation of ERK1-2 involves the protein kinase 
proline-rich tyrosine kinase 2 (PYK2), which belongs to the focal adhesion kinase 
family (Lev et al., 1995) (Fig. 1.12). It has been shown that bradykinin, which 
promotes Gαq/11-mediated increase of intracellular Ca2+, leads to PYK2 
phosphorylation independently of PKC (Lev et al., 1995). In turn, phosphorylated 
PYK2 induces ERK1-2 activation. Furthermore, bradykinin-induced PYK2 
phosphorylation leads to its association with and activation of Src to promote 
ERK1-2 activation in a Ras-dependent manner (Dikic et al., 1996). Another study, 
observed that α1B-AR dependent activation of Gαq/11, promoted activation of Ca2+-
calmodulin, which directly and indirectly regulated PYK2 phosphorylation and thus 
ERK1-2 activation (Della Rocca et al., 1997). A more recent study has revealed 
that activation of WFB cells (rat fibroblast cell line) with vasopressin, endothelin or 
PDGF induced Ca2+-calmodulin to directly bind to PYK2 and leads to its activation 
(Kohno et al., 2008). Additionally, Gαq/11-mediated activation of M1 receptor 
promotes ERK1-2 activation in a Rap-1/B-Raf-dependent manner (Guo et al., 




2001). Similarly to the Gαs-mediated activation of Rap-1, this mechanism requires 
the activation of a Rap-1 GEF, namely Ca2+- and DAG-regulated GEF I (CalDAG-
GEFI) that in turn activates Rap-1 independently of PKC (Guo et al., 2001). 
  








Figure 1.11 The cAMP/PKA-mediated ERK1-2 activation. (1) Stimulation of Gαs leads 
to AC activation and production of cAMP. (2) cAMP promotes activation of PKA that 
induces phosphorylation by Src of C3G, a Rap-1 GEF and lead to activation of Rap-1 and 
in turn to ERK1-2 pathway via B-Raf. (3) Alternatively, cAMP can directly activate another 
Rap-1 GEF, EPAC that also induce Rap-1 activation and ERK1-2 independently of PKA. 
  






Figure 1.12 The PLC/PKC/Ca2+-mediated ERK1-2 activation. (1) Stimulation of Gαq 
leads to activation of PLC that promotes hydrolyse of PIP2 and formation of IP3 and DAG. 
(2) IP3 then induces release of Ca2+ from intracellular storage (e.g. endoplasmic reticulum, 
ER). (3) Ca2+ and DAG promotes activation of PKC that induces phosphorylation of Raf-1 
and in turn lead to ERK1-2 activation. (4) Alternatively, Ca2+ and DAG can directly activate 
the Rap1 GEF CalDAG-GEFI to promotes activation of ERK1-2, independently of PKC. 
(5) Finaly, Ca2+ alone can induce the activation of the complex calmodulin/PYK2 that 
phosphorylates Src and lead to ERK1-2 activation through Ras/Raf-1, independently of 
PKC. 
  




1.4.4 Transactivation of ErbB1 
 As previously mentioned, activation of certain GPCRs can lead to 
transactivation of ErbB1 (Daub et al., 1996). Other members of the RTK family are 
also transactivated by GPCRs including the insulin growth factor receptor (Rao et 
al., 1995) and the PDGF receptor (Linseman et al., 1995). However, ErbB1 
transactivation remains the best characterised, even if the mechanisms are not 
fully understood. ErbB1 transactivation occurs in many different cell types, is 
mediated by many different GPCRs and occurs through many different 
mechanisms. 
 Daub and colleagues first identified ErbB1 transactivation in Rat-1 cells 
(fibroblasts cell line) using endothelin-1, lysophosphatic acid (LPA) and thrombin 
that involve Gαq/11- and Gαi-mediated responses (Daub et al., 1996) and in HaCaT 
(human keratinocytes cell line), primary mouse astrocytes and COS-7 cells, using 
LPA (Daub et al., 1997). In these studies, they described a mechanism that 
required Src in order to induce ERK1-2 activation but downstream of ErbB1 
activation (Fig. 1.13). Whereas ang II-induced ErbB1 transactivation in primary rat 
thoracic aorta SMC (TA-SMC) showed that Src phosphorylation is required to 
activate ErbB1 (Eguchi et al., 1998). Other studies have also identified that 
increases in intracellular Ca2+, most likely through PLC activation, were required to 
induce ErbB1 transactivation, leading to ERK1-2 activation via Ras activation, 
such as the bradykinin receptor (Zwick et al., 1997) and AT1R (Eguchi et al., 1998; 
Murasawa et al., 1998). Moreover, the studies of AT1R showed that ErbB1 
transactivation was mediated through activation of the calmodulin/PYK2 complex 
(Eguchi et al., 1998; Murasawa et al., 1998). 
 All these pathways appear to converge on GPCR-mediated release of soluble 
EGF-like ligand, which then activates ErbB1 receptor (reviewed in (Ohtsu et al., 
2006)) (Fig. 1.13). EGF-like ligands, such as the heparin binding-EGF (Prenzel et 
al., 1999), transforming growth factor-α (Pai et al., 2002) and/or amphiregulin 
(Gschwind et al., 2003), are released by proteolytic cleavage by member of the 
ADAMs metalloprotease family (Gschwind et al., 2003; Prenzel et al., 1999; 
Schafer et al., 2004a; Schafer et al., 2004b). In this mechanism, Src activation is 
required upstream of the metalloprotease to induce ErbB1 activation (Buteau et 
al., 2003), downstream of ErbB1 to mediate ERK1-2 activation (McCole et al., 
2002) or for both (Pierce et al., 2001). 
 It should be noted that these mechanisms are mediated by GPCRs coupled to 
both Gαq/11 and Gαi proteins. Studies have shown that forskolin-induced increases 
cAMP production promote transactivation of ErbB1 and subsequent ERK1-2 
activation (Bertelsen et al., 2004; Piiper et al., 2002; Piiper et al., 2003). This 
mechanism involves activation of PKA that promotes ErbB1 phosphorylation 
directly and/or indirectly (Bertelsen et al., 2004; Piiper et al., 2003). To date, only a 




few Gαs-mediated ErbB1 transactivation events leading to ERK1-2 activation have 
been described. One such event is activation of the EP2 receptor (prostanoid 
receptor family, known as prostaglandin E2 receptor), where cAMP/PKA/Src 
activation mediates ErbB1 transactivation (Sales et al., 2004). The GnRH receptor 
(gonadotrophin-releasing hormone receptor family, also known as luteinizing 
hormone (LH) receptor) (Carbajal et al., 2011; Evaul and Hammes, 2008; 
Panigone et al., 2008) and the MC2 receptor (melanocortin receptor, also known 
as adrenocorticotropic hormone (ACTH) receptor) (Carbajal et al., 2011) also 
induce ErbB1 transactivation in a cAMP/PKA-dependent manner in cells issued 
from the three major steroidogenic tissues: the testes, the ovary, and the adrenal 
gland. However, LH-, but not ACTH-induced transactivation has been shown to be 
both metalloprotease-dependent (Carbajal et al., 2011; Panigone et al., 2008) and 
metalloprotease-independent (Carbajal et al., 2011; Evaul and Hammes, 2008), 
depending on tissue. 
 
1.4.5 The β-Arrestin-Dependent Pathway 
 As previously mentioned, activation of a specific MAPK module feature two 
important aspects, first is the existence of cross talk between these pathways 
(Corbit et al., 1999; Frost et al., 1997) and second is the formation of complexes 
between scaffold proteins and the different member of a MAPK module to facilitate 
signal transduction (Choi et al., 1994; Yasuda et al., 1999). One of this scaffold 
protein identified is β-arrestin (Lefkowitz and Shenoy, 2005). 
 The role of β-arrestins as promoter of GPCR desensitisation and internalisation 
has already been described. However, β-arrestins also facilitate mitogenic 
signalling due to their ability to act as a scaffold for signalling proteins (reviewed in 
(Luttrell and Gesty-Palmer, 2010)). This role was first described for the β2-AR, 
where β2-AR associated with β-arrestin1 binds to activated Src and promotes a G 
protein-independent ERK1-2 activation (Luttrell et al., 1999) (Fig. 1.14). Activation 
of PAR2 (DeFea et al., 2000) and AT1R (Luttrell et al., 2001) induces association 
of the receptors with β-arrestins and internalisation of the receptor/β-arrestins 
complex, where Raf-1, MEK1 and ERK1-2 were found in this complex. The 
formation of this receptor/β-arrestins complex was shown to induce ERK1-2 
activation. Similarly, β-arrestins have been shown to bind members of the JNK 
MAPK module, such as JNK3 and apoptosis signal–regulating kinase 1 (activator 
of JNK), when AT1R was activated (McDonald et al., 2000). Additionally, this β-
arrestin-dependent signalling takes place not only at the plasma membrane, but 
also in the endosomal system, where certain GPCRs can be sequestered for long 
periods. Stimulation of AT1R promotes internalisation of the receptor together with 
β-arrestin2 leading to a subcellular distribution of ERK1-2 activation in endosome 




(Luttrell et al., 2001). This β-arrestin-dependent pathway, also referred as 
endosomal signalling, has been described to have slower and more sustain 
kinetics, compared to the cell-surface G protein-dependent ERK activation (Ahn et 
al., 2004). Moreover, it has been shown that β-arrestin-activation of ERK module 
does not induce translocation of phosphorylated ERK1-2 into the nucleus, which 
fails to elicit a transcriptional response or stimulate cell proliferation (DeFea et al., 
2000; Tohgo et al., 2002). These results suggest that endosomal signalling is 
involved in the cytosolic responses that require slower but persistent activation of 
ERK1-2. Additionally, when a NK1R fused to β-arrestin1 was expressed in HEK 
cells, the receptor was constitutively desensitised, uncoupled from G proteins and 
sequestered in endosomes. This mutant receptor did not respond to neurokinin A 
stimulation, however, it promoted a robust, constitutive activation of ERK1-2. 
Immunoprecipitation of the receptor revealed presence of Raf-1, MEK1 and ERK1-
2. These results suggested that stable association between β-arrestin and the 
receptor formed a stable “signalosome” able to promote MAPK activation (Jafri et 
al., 2006).  
 Similarly, NK1R, which internalises with β-arrestin in endosomes following SP 
stimulation, has been shown to sustain ERK1-2 activation when the complex 
NK1R/β-arrestin is sequestered in endosomes (Cottrell et al., 2009). Indeed, it has 
been previously shown that the dissociation of this complex was promoted by the 
degradation of SP in endosomes by the metalloprotease ECE-1 (Roosterman et 
al., 2007). Inhibition of ECE-1 leads to the retention of the complex NK1R/β-
arrestin. Altogether, all these results show β-arrestins acting as a scaffold protein 
able to bind members from ERK1-2 modules and promoting their activation. This 
G protein-independent signalling takes place from the cell-surface to endosomes 
and lead to more sustain but less robust ERK1-2 activation compare to G protein-
mediated ERK1-2 activation. 
  







Figure 1.13 ErbB1 transactivation-mediated ERK1-2 activation. GPCRs can promote 
RTK transactivation that leads to ERK1-2 activation. Many mechanisms have been 
described depending on the cell type and the GPCR type. (1) The most characterised 
mechanism involve increase of intracellular Ca2+ that lead to activation of Src (2) through 
PKC or calmodulin/PYK2 activation. (3) Src has been shown to either induce activation of 
metalloproteases called ADAM that promote release of extracellular EGF-like ligands 
leading to the activation of ErbB1. (4) Alternatively Src can directly activate ErbB1. (5) 













Figure 1.14 β-arrestin-dependent endosomal signalling. The sequestered 
agonist/GPCR/ β-arrestin complex in endosomes can mediate a second wave of ERK 
signalling distinct from that which is induced at the cell-surface. (1) Specifically, β-arrestins 
acts as molecular scaffolds to recruit many effector proteins such as the ERK1-2 module: 
MEK1-2, Raf-1 and Src. (2) This complex leads to the activation of ERK1-2. The signal is 
terminated by dissociation of the agonist/GPCR/ β-arrestin complex. 
 
  




1.5 Aims of this Project 
 This report is divided in two different parts. The first part describes the 
mechanisms and function of CGRP-induced ERK activation. The second part 
describes mechanisms of the post-endocytic sorting of the GPCR for ADM, 
namely, CLR•RAMP2. 
 It is well documented that CGRP can promote activation of ERK. However, the 
biological functions of CGRP-induced ERK activation remain poorly defined. 
CGRP-induced ERK activation has recently been linked with the induction of iNOS 
in trigeminal ganglion glial cells (Vause and Durham, 2009). The induction of iNOS 
produces large amounts of NO (Nathan and Xie, 1994) and iNOS is upregulated in 
different pathologies including migraine (Olesen and Jansen-Olesen, 2000), 
atherosclerosis (Ginnan et al., 2008) and sepsis (Hauser et al., 2005). CGRP is 
similarly upregulated in migraine and sepsis (Goadsby et al., 1990; Zhou et al., 
2001). In the cardiovascular system, CGRP together with interleukin-1β, has been 
shown to promote upregulation of iNOS and NO release in SMC (Schini-Kerth et 
al., 1994). As both CGRP and NO are important signalling molecules in the 
cardiovascular system, I aimed to determine the exact mechanisms through which 
CGRP activates ERK1-2 as a first step towards deciphering the mechanisms in 
SMC and whether CGRP upregulates iNOS via an ERK-dependent pathway. The 
first part of this project using HEK cells as a model is: 
• To determine whether CGRP induces transactivation of ErbB1. 
 
• To elucidate the role of endosomal signalling and β-arrestin in CGRP-
induced ERK activation. 
 
• To investigate whether CGRP-induced ERK activation is mediated by 
cAMP/PKA pathway or PLC/PKC/Ca2+ pathway. 
 
• Finally to characterise primary rat thoracic artery SMC as a model to study 
the involvement of ERK activation in CGRP-induced iNOS expression. 
 
 It has been shown that both CLR•RAMP1 and CLR•RAMP3 can recycle after 
transient stimulation (Bomberger et al., 2005; Cottrell et al., 2007). Moreover, it 
has been shown that ECE-1 regulates the recycling of CLR•RAMP1 by cleaving 
CGRP (Padilla et al., 2007). However, nothing is known about the regulation of 
CLR•RAMP2. As ADM is also cleaved by ECE-1, only at endosomal pH 
(unpublished data, G. S. Cottrell), then it was hypothesised that ECE-1 would 
similarly regulate CLR•RAMP2. It is important to study such mechanisms, as a 
better understanding of how receptors are trafficked may lead to the development 




of new therapies to treat disease. I first used a HEK cell model in the aim to 
undertake the key findings of this study to a more physiological model such as 
HMEC-1. The second part of this project is: 
• To determine whether ADM induces the recycling or the degradation of 
CLR•RAMP2. 
 
• To investigate the molecular mechanisms involved in the post-endocytic 
sorting of CLR•RAMP2, such as ubiquitination. 
 
• To establish the role of ubiquitination in the ADM-induced degradation of 
CLR•RAMP2. 
 
• Finally, to characterise a more suitable model such as HMEC-1 cells, to 






















 All reagents, chemicals, peptides and inhibitors used in this study are listed in 
Appendix I. The compositions of buffers and growths media are details in 
Appendix II.  
 
2.1.1 Cell Lines 
Cell type Cell line Source Medium 
Human Embryonic 






AdDMEM*, HIFBS* (2% 
(v:v)), L-glu* (2 mM), 
zeocin (100 µg/mL) 
HEK-
CLR•RAMP1 G.S. Cottrell AdDMEM, HIFBS (2% (v:v)), L-glu (2 mM), 
hygromycin B (200 











MCBD, HIFBS (10% 
(v:v)), L-glu. (2 mM), 
EGF* (10 ng/mL), 
HCORT* (1 µg/mL) 




TA-SMC See 2.2.2 
DMEM, HIFBS (10% 
(v:v)), NEAA* (1% (v:v)), 
P/S* (1% (v:v)), 
fungizone (0.1% (v:v)) 
Table 2.1 List of Cell Lines. *AdDMEM = Advanced DMEM, HIFBS = heat inhibited foetal 
bovine serum, L-glu. = L-glutamine, EGF = epidermal growth factor, HCORT = 
hydrocortisone, NEAA = non-essential amino acids, P/S = penicillin/streptomycin. The 
medium DMEM and MCDB are described in Appendix I. 
 
2.1.2 Animals 
 Male Wistar rats (80–100 g) were killed by cervical dislocation following 
institutional guidelines for animal welfare and schedule 1 of the Animals (scientific 
procedures) Act 1986. 
  






Supplier Cat. number WB* ICC* 
α-smooth 
muscle actin Mouse - 1/250 
Sigma-
Aldrich A5228 
β-actin Mouse 1/100,000 - Sigma-Aldrich A1978 
CLR (RK11) Rabbit 1/2,000 1/2,000 (Cottrell et al., 2005) N/A 
EEA1 Mouse - 1/100 BD Bioscience 610457 
Phospho 
ERK1/2 Mouse 1/1,000 - Santa Cruz sc-7383 
ERK2 Rabbit 1/10,000 - Santa Cruz sc-154 
HA Rabbit 1/5,000 1/500 Sigma-Aldrich H6908 
iNOS Rabbit 1/2,500 1/100 Cell signalling 2977S 
LAMP1 Mouse - 1/1,000 Santa Cruz sc-20011 
c-Myc Rabbit 1/10,000 1/500 Sigma-Aldrich C3956 
Transferrin 
receptor Mouse 1/5,000 - Invitrogen 13-6800 
Ubiquitin Mouse 1/5,000 - Santa Cruz sc-8017 
Table 2.2 List of Primary Antibodies. *ICC = immunocytochemistry; *WB = Western 
blot. All stock of antibodies, if not supplied in glycerol, were diluted in glycerol (50% (v:v)) 
and stored at -20°C. The factor of dilution is not included in the table and therefore was 
added during experimentation. 
  





Supplier Cat. number WB ICC 
Mouse 






































Table 2.3 List of Secondary Antibodies. All stock of antibodies, if not supplied in 
glycerol, were diluted in glycerol (50% (v:v)) and stored at -20°C. The factor of dilution is 
not included in the table and therefore was added during experimentation. 
 
2.1.4 Plasmid DNA 
Plasmid Resistance Source/Reference 
pOG44 - Invitrogen (R750-07) 
pcDNA5/FRT Hygromycin B Invitrogen (R750-07) 
pcDNA5/FRT-CLR-HA Hygromycin B G.S. Cottrell, unpublished 
pcDNA3.1/Blasticidin-RAMP1-Myc Blasticidin (Cottrell et al., 2005) 
pcDNA3.1/Blasticidin-RAMP2-Myc Blasticidin G.S. Cottrell, unpublished 
pcDNA5/FRT-CLR•RAMP1 Hygromycin B (Cottrell et al., 2007) 
pcDNA5/FRT-CLR•RAMP2 Hygromycin B G.S. Cottrell, unpublished 
pcDNA5/FRT-CLRΔ9KR•RAMP2 Hygromycin B (see Chap. 5.5) 
pcDNA3-β-arrestin1-FLAG WT - (Luttrell et al., 1999) 
pcDNA3-β-arrestin1-FLAGP91G P121E - (Luttrell et al., 1999) 
Table 2.4 List of Plasmid DNA. All plasmid DNA were stored at -20°C. The CLR, RAMP1 
and RAMP2 vectors were a gift from G. S. Cottrell. The β-arrestin1 vectors were a gift 
from R. J. Lefkowitz. 
 























Table 2.5 List of Primers. All primers were purchased from Sigma-Aldrich and stored at -
20°C. 
 
2.1.6 Bacteria Strain 
 MACH1 cells are derivatives of Escherichia coli (E. coli). Genotype: F- 
φ80(lacZ)ΔM15 ΔlacX74 hsdR(rK-mK+) ΔrecA1398 endA1 tonA. MACH1 cells were 
used for routine transformation and cloning (see 2.4 and 2.5). Cells purchased 
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2.2 Mammalian Cell Culture 
2.2.1 Cell Culture 
 All cells were routinely grown at 37°C in a humidified 95% (v:v) air/5% (v:v) CO2 
atmosphere in 75 cm² plastic tissue culture flask (BD Biosciences). The growth 
medium of each cell line is described in Table 2.1. 
 
2.2.2 Preparation of Primary Smooth Muscle Cells 
 Thoracic aorta smooth muscle cells were obtained using an explant method. 
Briefly, the thoracic aorta was excised and immediately placed in ice cold 
phosphate-buffered saline (PBS) supplemented with 1% (v:v) P/S and 0.1% (v:v) 
fungizone. The aorta was cleaned of surrounding fat tissue and nerves, 
transversally cut open and chopped into small pieces (~1 mm). Finally, the pieces 
were washed 3 times with sterile PBS and cultured as described in Table 2.1 and 
2.2.1. 
 
2.2.3 Subculturing of Mammalian Cells 
 Cells were subcultured upon reaching 80-90% confluency. Culture medium was 
aspirated and cells were then washed with PBS (without Ca2+ and Mg2+) (PBS-
CM). To detach adherent cells from the culture plate, cells were incubated in 
trypsin/EDTA (2-3 min, 37°C). An equal volume of fresh culture medium was 
added to neutralise the trypsin, before cells were transferred to a sterile centrifuge 
tube and collected by centrifugation (1,000 g, 5 min, RT). The cell pellet was 
resuspended in culture medium (10 mL) and cells were subcultured in a ratio of 
1:5 (HEK and HMEC cells) or 1:3 (TA-SMC). Culture medium was replaced every 
2-3 days.  
 
2.2.4 Preparation of Cells for Storage in Liquid Nitrogen 
 Cell pellets were resuspended in HIFBS containing 10% (v:v) DMSO and 
aliquots (1 mL) were placed into cryovials (Fisherbrand). Aliquots were placed in 
freezing container (Mr. Frosty, Nalgene®, Sigma-Aldrich) incubated (overnight, -
80°C) and then transferred to liquid nitrogen for long-storage. 
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2.2.5 Recovery of Mammalian Cells from Liquid Nitrogen Storage 
 Cells were thawed in a water bath (2-3 min, 37°C) and combined with fresh 
culture medium (9 mL) in a centrifuge tube. Cells were collected by centrifugation 
(1,000 g, 5 min), the pellet resuspended in fresh medium (10 mL) and then 
transferred to a culture flask. Cells were then cultured as described in 2.2.1. 
 
2.2.6 Transfection of Mammalian Cells 
Transient Transfection: 
 HEK-FLP cells were plated at 5x106 cells/well in 6-well plates or 35 mm dishes 
(BD Biosciences) in antibiotic-free medium 24 h prior to transfection. The following 
day plasmid DNA (3 µg/well) and lipofectamine (8 µL/well) were incubated in 
separate tubes with Opti-MEM® (250 µL, 5 min, RT). The DNA and lipofectamine 
mixes were then combined and incubated further (20 min, RT). The medium on 
the cells was replaced by fresh medium (1.5 mL), before addition of the 
DNA:Lipofectamine complexes in a drop-wise action. The cells were then 
incubated for 4-6 h before they were subcultured for subsequent experimentation. 
Alternatively, HMEC-1 cells were plated at 5x104 cells/well in 12-well plates (BD 
Biosciences). DNA:lipofectamine complexes were generated using the same 




 For stable transfection, the Flp-in™ system was used (Fig. 2.1). This system 
allows integration and expression of a gene of interest. The Flp-In™ System 
involves introduction of a Flp recombination target (FRT) site into the genome of 
HEK cells. An expression vector containing a FRT site and the gene of interest is 
then integrated into the genome via Flp recombinase-mediated DNA 
recombination (expressed by the vector pOG44) at the FRT site (O'Gorman et al., 
1991). 
 The same protocol as described above in transient transfection was used, as an 
exception that DNA pOG44 was added to the DNA of interest with a ratio of 9:1 
(2.7 µg pOG44 + 300 ng DNA). At the end of the incubation with the mixture 
DNA:Lipofectamine, cells were split and put into antibiotic-free medium for 24h. 
Then the cells were put into selection by adding Hygromycin B (50-200 µg/mL). 
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2.3 Biochemical Techniques 
2.3.1 Drug Treatments 
 HEK cells were seeded at: 1.2x106 cells/well in 12-well plate; 3x106 cells/well in 
6-well plate or 35 mm dishes; and 2-5x106 cells/dish in 100 mm dishes (BD 
Biosciences), all coated with poly-D-lysine (50 µg/mL). HMEC-1 and TA-SMC cells 
were seeded at: 7x104 cells/well in 12-well plate; 1.7x105 cells/well in 6-well plate 
or 35 mm dishes; and 1x106 cells/dish in 100 mm dishes. All cells were plated 48 h 
before experiment. Cells were washed 3 times with 1x PBS and incubated in 
appropriate serum-free medium supplemented with 0.1% bovine serum albumin 
(BSA) (DMEM-, MCDB-, SMC-BSA), with appropriate vehicle or inhibitors for 30 
min. Cells were stimulated with agonist (CGRP or ADM, 0.1-1 µM, 0-16 h, 37°C), 
washed 3 times with 1x PBS and incubated in agonist-free medium (± inhibitors) 
for 0-16 h (recovery time). In some experiments, cells were deprived of serum by 
incubating cells in medium containing 0.1% BSA (16 h). 
 
2.3.2 Lysis of Mammalian Cells 
 Cells were placed on ice, washed 3 times in ice-cold 1x PBS, and lysed in Lysis 
buffer (150-350 µL, 10 min, 4°C) with gentle rocking. Cells were then scraped and 
lysates were collected into microcentrifuge tubes and centrifuged (10,000 g, 10 
min, 4°C) to pellet insoluble cell debris. Supernatants were then transferred to 
fresh tubes. 
 
2.3.3 Protein Determination and Sample Preparation 
 Proteins concentrations were determined by BCA assay (Smith et al., 1985) and 
modified to a 96-well plate format (Hooper, 1993). Briefly, dilutions of BSA from 0-
10 µg/µL were used as a standard. Samples (3-10 µL) were added to deionized 
distilled water (DDW) to a final volume of 10 µL. BCA solution and 4% (w:v) 
CuSO4 solution of the BCA kit were mixed (50:1) and 200 µL of the mixture was 
added to each well. Plates were then incubated for 30 min at 37°C. Plates were 
read at 562 nm using a VersaMax plate reader (Molecular Devices) and analysed 
using SoftMax Pro 4.8 software (Molecular Devices). Samples (20-50 µg protein) 
for analysis by Western blotting were prepared by mixing with 5x SDS-loading 
buffer. Samples were then heated (3-5 min, 100°C) and centrifuged (10,000 g, 1 
min, RT) before analysis by SDS-PAGE and Western blotting (see 2.3.4). 
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2.3.4 SDS-PAGE Electrophoresis 




gel Resolving gel 
3% 8% 10% 12% 15% 
0.5 M Tris/HCl, pH 
6.8 
1.25 mL - - - - 
1.5 M Tris/HCl, pH 
8.8 
- 2.5 mL 2.5 mL 2.5 mL 2.5 mL 
10% (w:v) SDS 50 µL 100 µL 100 µL 100 µL 100 µL 
10% (w:v) APS* 50 µL 100 µL 100 µL 100 µL 100 µL 
40% (w:v) 
Acrylamide 
375 µL 2 mL 2.5 mL 3 mL 3.75 mL 
DDW 3.275 mL 5.3 mL 4.8 mL 4.3 mL 3.55 mL 
Temed 2.5 µL 5 µL 5 µL 5 µL 5 µL 
Total volume 5 mL 10 mL 10 mL 10 mL 10 mL 
Table 2.6 Composition of SDS-Acrylamide Gels. *APS = ammonium persulphate 
 
 The SDS gels were prepared using the Mini-PROTEAN Tetra Electrophoresis 
System (BioRad). The resolving gel (Table 2.6) was poured first and water 
saturated butan-2-ol layered on top and the gel left to polymerise for about 30 
minutes. After the resolving gel had set, the butan-2-ol was washed away using 
DDW and the stacking gel was then poured on top. A 10-well comb was then 
placed to form the wells for the loading of the protein and allowed to polymerise for 
another 15 minutes. Once set, the comb was gently removed and the gel mounted 
on the apparatus. The tank was filled in with running buffer and non-polymerised 
acrylamide was removed from by using a syringe to dispel buffer from each well. 
The samples were then loaded and gel was run at constant current (0.2 mA/gel) 
until the dye in the loading buffer emerged from the bottom of the gel. 
 
2.3.5 Transfer of Protein on PVDF Membrane 
 At the end of the separation the proteins were transferred onto a PVDF 
membrane, by wet-transfer procedure using Mini Trans-Blot® Electrophoretic 
Transfer Cell (BioRad). The gel was placed onto the membrane, sandwiched 
between two soaked-extra thick blot papers in child transfer buffer. The tank was 
filled in with transfer buffer and a constant current was applied (1 A, 1 h). The tank 
was cooled down by using dry ice changed every 20 minutes. 
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2.3.6 Western Blotting of Membranes 
 At the end of the transfer the membranes were rinsed in 1x PBS and blocked (1 
h, RT) in blocking. Membranes were incubated in fresh blocking buffer with the 
appropriate primary antibodies (overnight, 4°C) on a rocker. Membranes were 
washed (3x10 min) in 1x PBS-T and incubated with fresh blocking buffer 
containing appropriate secondary antibodies conjugated to horseradish peroxidase 
(1 h, RT) on a rocker. Membranes were washed (3x10 min) with PBS-T and 
immunoreactive proteins were detected by using chemiluminescence (incubation 
1-5 min, RT). Membranes were exposed to X-ray film (Kodak), developed, 
digitised (EPSON Perfection 1250) and quantified using ImageJ. Alternatively 
membranes were read using an ImageQuant RT ECL (GE Healthcare) and 
quantified with ImageQuantTL software. 
 In experiments looking at the effect of inhibitors or different conditions 
compared to control, results were normalised at 10 min time point, in order to be 
consistent between time course experiments. Results were either expressed in 
fold-increase over unstimulated cells, when the 10 min time point between control 
and treated cells was different; or expressed in % of maximal response, when the 
10 min time point between control and treated cells was similar. 
 
2.3.7 Removal of Antibodies from PVDF Membrane 
 PVDF membrane were incubated in stripping buffer (10-60 min, 60°C) and 




 HEK cells were plated on 100 mm dishes 48 h prior experiment. After treatment, 
cells were lysed in radio-immunoprecipitation assay (RIPA) buffer (2 mL, 10 min, 
4°C). Cells were then scraped, lysates were collected into centrifuge tubes and 
centrifuged (10,000 g, 10 min, 4°C). Samples were divided into two aliquots and 
immunoprecipitating antibodies added to isolate CLR or CLRΔ9KR (RK11, 1:2000) 
and RAMP2 (myc, 1:500) and incubated (overnight, 4°C) on rotation. Samples 
were then incubated (2 h, 4°C) with 20 µL/tube of protein A/G Plus on rotation and 
immuno-complexes captured by centrifugation (4,000 g, 1 min, RT). Immuno-
complexes were washed 3 times in of RIPA buffer (1 mL). After the final wash 
immuno-complexes were resuspended in 20 µL of 2x SDS-loading buffer. 
Samples were then analysed by SDS-PAGE and Western blotting (see 2.3.4). 
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2.3.9 Degradation Assays 
Degradation Assay Using Cycloheximide (CHX): 
 HEK cells were plated in 100 mm dishes 48 h prior experiment. Cells were 
washed 3 times in 1x PBS and incubated (30 min) in DMEM-BSA and 140 µM of 
CHX. Cells were stimulated with ADM or CGRP (100 nM, 10 min, 37°C), washed 3 
times with 1x PBS and incubated (16 h) in DMEM-BSA supplemented with CHX. 
Or instead, cells were stimulated continuously with ADM or CGRP (100 nM, 16 h, 
37°C) in DMEM-BSA supplemented with CHX. Cells were lysed and samples 
prepared for SDS-PAGE and Western blotting (see 2.3.4). 
 
Degradation Assay Using Biotin/Avidin Complex: 
 HEK cells were plated in 100 mm dishes 48 h prior experiment. Cells were 
washed 3 times in ice-cold 1x PBS and then cell surface proteins were labelled 
using Sulfo-NHS-SS-Biotin according to the manufacturer’s guidelines. Briefly, 
cells were incubated (30 min, 4°C) with ice cold 1x PBS containing Sulfo-NHS-SS-
Biotin with gentle shaking. Cells were washed 3 times with ice-cold 1x PBS and 
incubated (30 min, 37°C) in DMEM- or MCDB-BSA supplemented with vehicle, 
lysosome inhibitor cocktail (pepstatin A and E-64d, both at 10 µM; and Z-PAD at 
200 µM) or proteasome inhibitor MG-132 (20 µM). Cells were stimulated with ADM 
(100 nM, 0-16 h, 37°C), lysed in RIPA buffer (2 mL) and centrifuged (10,000 g, 10 
min, 4°C). Supernatants were transferred to fresh microcentrifuge tubes and 
rotated (overnight, 4°C) with 20 µL/tube of NeutrAvidin agarose. Complexes were 
collected by centrifugation (4,000 g, 1 min, 4°C), washed 3 times in RIPA buffer (1 
mL), supernatants discarded and the complexes resuspended in 20 µL of 2x SDS-




 HEK, HMEC-1 or TA-SMC cells were plated on coverslips (coated with poly-D-
lysine for HEK cells) in 6-well plate or 35 mm dishes 48 h prior experiment. After 
treatment, cells were washed 3 times in 1x PBS. Coverslips were then incubated 
(20 min, 4°C) in 4% (w:v) paraformaldehyde (PFA). Coverslips were incubated (30 
min, RT) in blocking solution and incubated with the appropriate primary 
antibodies (~45 µL/coverslip, overnight, 4°C). Coverslips were washed in blocking 
solution, incubated with appropriate secondary antibodies (~45 µL/coverslip, 1-2 h, 
RT) and washed (3x10 min) in blocking solution. Coverslips were rinsed with 1x 
PBS before mounting on microscope slides using Vectashield mounting medium 
with DAPI (Vector Laboratories). 
  Chapter 2: Materials and Methods 
 
67 
2.3.11 Confocal Microscopy 
 For confocal microscopy, cells mounted on slides (see 2.3.10) were observed 
with a Zeiss laser-scanning confocal microscope (LSM Meta 510) using EC Plan-
Neofluar 20x/0.5, EC Plan-Neofluar 40x/1.3 Oil DIC and Plan-Apochromat 63x/1.4 
Oil DIC objectives. Images were collected at a zoom of 1-2 and an iris of <3 µm, 
and at least five optical sections were taken at intervals of 0.5 µm. Single sections 
are shown. Images were processed using ImageJ and Adobe Photoshop software. 
 
2.3.12 Internalisation of Receptors 
 HEK cells were seeded in 12-well plate 48 h prior experiment. Cells were 
washed 1 time in 1x PBS and incubated (30 min, 37°C) with anti-Myc antibody 
(1/250) in DMEM-BSA. Cells were washed once with 1x PBS and stimulated with 
ADM (100 nM, 0-30 min). Cells were washed once with 1x PBS and incubated (0-
60 min, 37°C) in DMEM-BSA agonist-free. Cells were washed with 1x PBS-CM 
and incubated in trypsin/EDTA (250 µL/well, 2-3 min, 37°C). Cells were detached 
by pipetting up and down and collected into a microcentrifuge tube. Cells were 
centrifuged (1,000 g, 5 min, 4°C). Supernatant was discarded and pellet 
resuspended in ice cold PBS-CM (500 µL). An anti-rabbit DyLight 649 (1/500) was 
added to each tube and incubated (1 h, 4°C) on rotation. Cells were washed 3 
times, centrifuged (1,000 g, 1 min, 4°C) in PBS-CM and resuspended in ice cold 
PBS-CM. Cells were analysed using Fluorescence-activated cell sorting (FACS) 
flow cytometry method assessed on a FACSCanto II (BD Biosciences) and 
analysed with BDFacs DiVa software. 
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2.4 Molecular Biology Techniques 
2.4.1 Extraction of RNA 
 RNA was extracted using TRIzol® Reagent (Invitrogen, 15596-026) according to 
the manufacturer’s guidelines. In brief, cells were cultured in 35 mm dish, media 
was removed from the culture dish and TRIzol® (1 mL) was added directly on the 
cells. Cells were lysed by pipetting up and down on the dish. The homogenised 
sample was transferred in a fresh microcentrifuge tube and incubated (5 min, RT). 
Chloroform (0.2 mL) was added to the tube, shacked vigorously for 15 seconds 
and left incubated (5 min, RT). The mixture was then centrifuged (12,000 g, 15 
min, 4°C). The mixture is separated in two phases. The top colourless phase 
(containing the RNA) was transferred in a fresh tube. Propanol-2-ol (500 µL) was 
added to the tube, incubated (10 min, RT) and centrifuged (12,000 g, 10 min, 4°C). 
The supernatant was discarded and the pellet was washed with 75% (v:v) 
ethanol/DDW (1 mL), vortexed briefly and centrifuged (7,500 g, 5 min, 4°C). The 
supernatant was discarded and the tube was left air dry (5 min, RT). The RNA was 
resuspended (50 µL) in DEPC-H2O by pitting up and down. The solution was then 
incubated (10-15 min, 55-60°C) and quantified (see 2.4.2). The RNA was used 
immediately or stored at -80°C. 
 
2.4.2 Quantification of Nucleic Acids 
 The quantification of nucleic acids (DNA or RNA) was determined by using the 
Beer Lambert Law reading the absorbance at 260 nm, where A260 = 1 for 40 
µg/mL of RNA and A260 = 1 for 50 µg/mL of DNA. The purity was measured using 
the ratio of the absorbance at 260 and 280 nm (A260/280). The absorbance was 
read using BioPhotometer (Eppendorf). 
 
2.4.3 Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) 
 TaqMan® Reverse Transcription Reagents (Invitrogen, N8080234) was used to 
generate complementary DNA (cDNA) from RNA. The reaction mix was made 
according to the manufacturer’s guidelines (Table 2.7). Samples were placed into 
a thermal cycler and subjected to cycling as follows: 
25°C, 10 min 
48°C, 30 min 
99°C, 5 min 
 The cDNA produced were used as a template for PCR or stored at -20°C. 
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Component Volume (µL) Final concentration 
10x Reverse Transcriptase buffer 4 1x 
10 mM dNTPs 8 2 µM 
25 mM MgCl2 8.8 5.5 mM 
Oligo d(T)16 or Random Hexamers 2 2.5 µM 
RNAse inhibitor 0.8 0.4 U/µL 
MultiScribe Reverse Transcriptase 1 1.25 U/µL 
RNA (1-4 µg) varied - 
DEPC-H2O Until 40 - 
Table 2.7 Reaction mix for RT-PCR. 
 
2.4.4 PCR Following cDNA Production 
 PCR reagents were from Qiagen (201203). The reaction mix was made 
according to the manufacturer’s guidelines (Table 2.8) Samples were placed into a 
thermal cycler and subjected to cycling as follows: 
94°C, 10 min 
94°C, 30 s 
60°C, 30 s 35 cycles 
72°C, 1 min 
72°C, 10 min 
 The PCR products were ran on agarose gel electrophoresis or stored at -20°C 
(see 2.4.6). 
 
Component Volume (µL) Final concentration 
10x PCR buffer 5 1x 
cDNA (template) (≈1 µg) 5 ≈0.2 M 
Forward primer 2 0.5 µM 
Reverse primer 2 0.5 µM 
Taq 0.05 5x10-3 U/µL 
DDW Until 50 µL - 
Table 2.8 Reaction Mix for PCR following cDNA production. 
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2.4.5 Screening of Bacterial Colonies 
 Single colonies were picked from LB-agar plates (see Appendix II) and 
resuspended in DDW (10 µL). An aliquot (2 µL) of this mix was then used as 
template for PCR. PCR reagents were from Qiagen (201203). The reaction mix 
was made according to the manufacturer’s guidelines (Table 2.9). Samples were 
placed into a thermal cycler and subjected to cycling as follows: 
96°C, 10 min 
96°C, 30 s 
55°C, 30 s 35 cycles 
72°C, 1 min 
72°C, 10 min 
 PCR products were then analysed by DNA gel electrophoresis as described 
(see 2.4.6). 
 
Component Volume (µL) Final concentration 
10x PCR buffer 2 1x 
10 mM dNTPs 0.4 0.2 µM 
Template 2 - 
Forward primer 1 0.5 µM 
Reverse primer 1 0.5 µM 
Taq (5U/µL) 0.05 1.25x10-3 U/µL 
DDW Until 20 µL - 
Table 2.9 Reaction mix for colony PCR. 
 
2.4.6 Electrophoresis of DNA 
 Separation of DNA was performed on agarose gel electrophoresis. 1-2% (w:v) 
of agarose (Fisher Scientific, BP1356) was melted in 1x Tris-acetate EDTA (TAE) 
buffer. The mixture was allowed to cool down, ethidium bromide was added (0.1 
µg/mL) and the gel was poured into a gel casting tray until it sets. The gel was 
then placed into an electrophoresis tank with 1x TAE and the samples were mixed 
with 0.5 µL of 10x DNA loading buffer, loaded and ran at constant voltage (5-20 
V/cm). Gel was then exposed under UV light to visualise the DNA. Images of the 
gel were captured in a Syngene UV transluminator using Genesnap software. 
 
  Chapter 2: Materials and Methods 
 
71 
2.4.7 Restriction Enzyme Digestion of DNA 
 Restriction enzymes were used to cut at specific site the DNA. All the enzymes 
were purchased from New England BioLabs (NEB). The reactions were performed 
in total volume of 20 µL (Table 2.10). The reaction mix was then incubated at 37°C 
for at least 2 h. The digestion products were ran on agarose gel electrophoresis or 
stored at -20°C (see 2.4.6). 
 
Component Volume (µL) Final concentration 
10x buffer 1-4 (according to the enzyme(s) 
used) 2 1x 
10x BSA (10 mg/mL) 2 1 mg/mL 
Enzyme(s) Total of 1 µL Varied 
Template (DNA) (1-5 µg) Varied Varied 
DDW Until 20 µL - 
Table 2.10 Reaction Mix for Digestion of Restriction Enzyme. For double digestion, 
the volume of enzymes added was adjusted to keep an equivalent activity (i.e. 50:50). The 
maximum volume of enzymes was 1 µL (5% of glycerol) to avoid any star activity. 
 
2.4.8 Extraction of DNA 
 The bands of interest were excise of a gel using a sterile blade and DNA was 
purified using Qiagen QIAquick Gel Extraction Kit (28704) according to the 
manufacturer’s guidelines. Briefly, the agarose gel was melted (50°C, water bath) 
and the DNA fragment was purified by bind-wash-elute procedure. 
 
2.4.9 Ligation of DNA Fragments 
 The fragments were ligated using the T4 DNA ligase (NEB, M0202T) in 10 µL of 
reaction (Table 2.11). The reaction was incubated in a thermal cycler (14°C, 4-16 
h) and an aliquot (1-5 µL) used to transform chemically competent E. coli (2.1.6). 
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Component Volume (µL) Final concentration 
10x Ligase buffer 1 1x 
Inserts Ratio 1:1 to 1:3 Varied 
Ligase 0.5 1.5 Weiss U*/µL 
DDW Until 10 µL - 
Table 2.11 Reaction Mix for Ligation. *1 Cohesive End unit from NEB=0.015 Weiss unit 
 
2.4.10 Purification of Plasmid DNA 
 A QIAprep Spin Miniprep Kit (27104) or EndoFree Plasmid Maxi Kit (12362) 
from Qiagen were used to purify plasmid DNA following the manufacturer’s 
guidelines. Cultures were set up as described in 2.5.4. The plasmid DNA was 
dissolved in water, quantified as described in 2.4.2 and stored at -20°C. 
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2.5 Bacterial Work 
2.5.1 Bacterial Broth 
 Two broths were used: Lysogeny broth (LB) a nutritionally rich medium, used 
routinely to culture bacteria; and super optimal broth (SOB) was used to culture 
cells when preparing chemically competent cells. See Appendix II for broth 
preparation. 
 
2.5.2 Preparation of Competent Cells 
 The protocol described by Inoue et al. was used to prepare competent cells 
(Inoue et al., 1990). In brief, bacteria were spread and grown on an antibiotic-free 
LB-agar plate (overnight, 37°C). Then 10-12 colonies were picked and incubate in 
SOB media (250 mL, 24-48 h, 18°C) until the bacteria growth reach a value of 
optical density at 600 nm (OD600) of 0.5-0.6, read on a BioPhotometer 
(Eppendorf). Bacteria were then put on ice (10 min), centrifuged (2,500 g, 10 min, 
4°C) and the pellet was resuspended (80 mL) in transformation buffer (TB). 
Bacteria were incubated on ice (10 min) and centrifuged again (2,500 g, 10 min, 
4°C). Finely, the pellet was resuspended (20 mL) in TB buffer + 7% (v:v) of DMSO. 
Cells were then aliquoted (250 µL) and frozen directly in liquid nitrogen. Cells were 
stored in -80°C. 
 
2.5.3 Transformation of Bacteria 
 Chemically competent E. coli (50 µL) were thawed on ice. After thawing, E. coli 
were incubated with plasmid DNA (~20 ng) or ligation mix (1-5 µL) on ice (30 min). 
Bacteria were heat-shocked (30 s, 42°C) using a water bath and then allowed for 
recover on ice (5 min), before spreading on LB-agar (see Appendix II) containing 
ampicillin (100 mg/mL in 50% (v:v) ethanol/DDW). Plates were then inverted and 
placed in an incubator overnight to allow growth to proceed. MACH1 cells were 
grown at 37°C. 
 
2.5.4 Culture of Bacteria 
 Single colonies were picked from LB-agar plates and LB broth (5 mL) containing 
ampicillin (100 mg/mL in 50% (v:v) ethanol/DDW), inoculated and placed in a 
shaking incubator (200 rpm, overnight, 37°C). For larger culture volumes (250 mL) 
a starter culture (5 mL) was set up as described, grown during the day and then 
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used to inoculate the larger volume. The larger volume culture was then placed in 
a shaking incubator (200 rpm, overnight, 37°C). 
 
2.5.5 Preparation of Bacterial Glycerol Stocks 
 To prepare glycerol stocks of bacterial cultures, an aliquot of an overnight 
culture (1 mL) was mixed with glycerol (250 µL) and then stored at -80°C. 
 
2.6 Analysis and Statistics 
 Experiments were repeated n≥3 times. Data are presented as mean ± standard 
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3.1 Background and Objectives 
 The mitogenic-activated protein kinase (MAPK) pathways play a key role in the 
development and the cell cycle. One of these pathways, the extracellular signal-
regulated kinase (ERK)1-2 module is involved in many biological responses and is 
notably responsible for cell proliferation and survival (reviewed in (Pearson et al., 
2001; Seger and Krebs, 1995)). Typically, ERK1-2 is activated by two types of cell-
surface receptor, the receptor tyrosine kinases (RTK) and G protein-coupled 
receptors (GPCR). 
 CGRP has been found to induce ERK activation in different cell types. CGRP 
induces proliferation in ERK-dependent manner in alveolar epithelial cells 
(Kawanami et al., 2009) and primary rat osteoblast (Han et al., 2010), whereas it 
has been shown to inhibit proliferation in aortic smooth muscle cells and 
pulmonary artery smooth muscle cells (Chattergoon et al., 2005). Moreover 
CGRP-induced ERK1-2 activation has been found to promote iNOS upregulation 
in trigeminal ganglion glial cells (Vause and Durham, 2009). 
 Several signalling pathways can lead to GPCR-dependent ERK activation as 
reviewed in (Rozengurt, 2007) (Fig. 3.1). By using different inhibitors, three main 
pathways were investigated in CGRP-induced ERK activation, that is the 
cAMP/PKA, PLC/PKC/Ca2+ or the transactivation of the epidermal growth factor 
receptor (ErbB1) pathway in HEK cells. Additionally, the G protein-independent 
mediated by β-arrestins was also investigated in CGRP-induced ERK activation.  
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3.2 CGRP-Induced ERK Activation 
 Like many GPCRs, CLR•RAMP1 induces ERK activation in many different cell 
types (Cady et al., 2011; Kawanami et al., 2009; Kawase et al., 1999; Vause and 
Durham, 2009; Yu et al., 2006). To determine whether HEK-CLR•RAMP1 cells are 
a suitable model for studying CGRP-induced ERK activation, HEK-CLR•RAMP1 
cells were incubated in serum-free medium and stimulated with CGRP (0-60 min). 
Levels of phosphorylated ERK (pERK) 1, pERK2 and ERK2 were determined by 
Western blotting. In unstimulated cells levels of pERK1 and 2 were low (Fig. 3.2). 
CGRP treatment increased dramatically pERK1 and 2 with a peak at 2 min and 
then progressively decreased (Fig. 3.2B, 24.4±10.5 for pERK1; and 7.9±10.5 for 
pERK2 fold-increase compared to basal at 2 min). This result shows that CGRP is 
able to induce ERK activation in HEK-CLR•RAMP1 cells, which suggest that HEK-
CLR•RAMP1 cells are a suitable model. 
 
3.3 CGRP Induces Transactivation of the 
Epidermal Growth Factor Receptor 
 Many GPCRs can activate mitogenic signalling by transactivating ErbB1 ((Daub 
et al., 1996) and reviewed in (Goldsmith and Dhanasekaran, 2007; Rozengurt, 
2007)). The molecular mechanism of this pathway is not fully understood and 
varies from cell-type to cell-type and GPCR to GPCR. However, in many cases 
GPCRs induce activation of cell-surface peptidases to release EGF-like ligands 
such as HB-EGF or TGF-α that directly activate ErbB1 leading to ERK activation. 
To determine whether CGRP induces transactivation of the ErbB1 a specific 
ErbB1 inhibitor, AG1478 (Osherov and Levitzki, 1994), was used. HEK-
CLR•RAMP1 cells were incubated with vehicle (DMSO) or AG1478, stimulated 
with CGRP (0-10 min), washed, incubated in CGRP-free medium ± AG1478 (0-50 
min) and levels of pERK1, pERK2 and ERK2 determined by Western blotting. In 
unstimulated cells, levels of pERK1 and 2 were low (Fig. 3.3). CGRP (10 min) 
caused a prompt increase in levels of pERK1 and 2 in both vehicle- and AG1478-
treated cells. However, the increase in AG1478-treated cells was reduced 
compared to vehicle-treated cells (Fig. 3.3B, 65.2±29.7 (vehicle) versus 19.1±9.1 
(AG1478) for pERK1 and 18.6±6.5 (vehicle) versus 8.6±3.0 (AG1478) for pERK2; 
fold-increase at 10 min compared to basal). Indeed, when expressed in fold-
decrease over vehicle-treated cells, AG1478 significantly reduced levels of pERK1 
and 2 at all time points examined (Fig. 3.3D and E). Furthermore, basal levels of 
pERK1 and 2 were not affected by AG1478 (Fig. 3.3C). Thus, CGRP can activate 
ERK by causing transactivation of ErbB1 in HEK cells.  








Figure 3.2 CGRP induces ERK activation. (A) Serum-starved HEK-CLR•RAMP1 cells 
were stimulated with CGRP (100 nM, 0-60 min) and levels of pERK1, pERK2 and ERK2 
determined by Western blotting. Blots were quantified using ImageJ and ratio of 
pERK1:ERK2 and pERK2:ERK2 calculated. Representative blots are shown. (B) Results, 
expressed in fold-increase over basal, show that CGRP induces a prompt increase of 
pERK1 and 2 levels, which is sustained by decreases over time. Thus CGRP promotes 
ERK activation in HEK-CLR•RAMP1 cells. n=4. 
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Figure 3.3 CGRP induces ErbB1-dependent ERK activation. (A) Serum-starved HEK-
CLR•RAMP1 cells were incubated with vehicle or AG1478 (1 µM), stimulated with CGRP 
(100 nM, 0-10 min), washed, incubated in CGRP-free medium ± AG1478 (0-50 min) and 
levels of pERK1, pERK2 and ERK2 determined by Western blotting. Blots were quantified 
using ImageJ and ratio of pERK1:ERK2 and pERK2:ERK2 calculated. Representative 
blots are shown. The red box highlights the difference between vehicle- and AG1478-
treated cells. (B) The maximal CGRP-induced ERK phosphorylation, expressed in fold-
increase over basal, is higher in vehicle- compared to AG1478-treated cells. (C) Basal 
levels of pERK1 and 2 are expressed in fold-increase over vehicle-treated cells. The effect 
of AG1478 on the basal of pERK1 and 2 shows no significant difference compared to 
vehicle-treated cells. (D, E) The CGRP-induced ERK activation of the full time course, 
expressed in fold-decrease over vehicle of pERK1 (D) and pERK2 (E) is significantly 
reduced in AG1478-treated cells. Thus, the CGRP-mediated ERK activation is ErbB1-
dependent, suggesting that CGRP induces transactivation of ErbB1 in HEK cells. n=4, 
*=p<0.05 and **=p<0.01 compared to vehicle-treated cells at the same time point.  
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3.4 CGRP-Induced ERK Activation is Src-
Dependent 
 The tyrosine kinase Src plays a central role in the GPCR-mediated ERK 
activation (reviewed in (McGarrigle and Huang, 2007)). Src has been involved in 
all the ERK pathways described in this study (Daub et al., 1997; Dikic et al., 1996; 
Eguchi et al., 1998; Luttrell et al., 1999; Schmitt and Stork, 2002). However, Src 
has been mostly described and characterised within the transactivation of ErbB1. 
Indeed, Src has been found to be required to promote ERK activation following 
ErbB1 transactivation, either downstream of ErbB1 (Daub et al., 1997) or involved 
in the activation of ErbB1 itself (Buteau et al., 2003; Eguchi et al., 1998). To 
determine whether CGRP induces ERK in a Src-dependent manner a specific Src 
inhibitor, PP2 (Bain et al., 2007; Hanke et al., 1996), was used. HEK-CLR•RAMP1 
cells were serum-starved, incubated with vehicle (DMSO) or PP2, stimulated with 
CGRP (0-10 min), washed, incubated in CGRP-free medium ± PP2 (0-50 min) and 
levels of pERK1, pERK2 and ERK2 determined by Western blotting. In 
unstimulated cells, levels of pERK1 and 2 were low (Fig. 3.4). CGRP (10 min) 
caused a prompt increase in levels of pERK1 and 2 in both vehicle- and PP2-
treated cells. However, the increase in PP2-treated cells was significantly reduced 
compared to vehicle-treated cells (Fig. 3.4B, 5.3±1.0 (vehicle) versus 2.7±0.4 
(PP2) for pERK1 and 3.9±0.5 (vehicle) versus 2.4±0.3 (PP2) for pERK2; fold-
increase at 10 min compared to basal). Indeed, when expressed in fold-decrease 
over the vehicle-treated cells, PP2 significantly reduced levels of pERK1 and 2 at 
all time points examined (Fig. 3.4D and E). Furthermore, basal levels of pERK1 
and 2 were not affected by PP2 (Fig. 3.4C). Thus, CGRP-induced ERK1-2 
activation is Src-dependent in HEK cells. 
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Figure 3.4 CGRP-induced ERK activation is Src-dependent. (A) Serum-starved HEK-
CLR•RAMP1 cells were incubated with vehicle or PP2 (10 µM), stimulated with CGRP 
(100 nM, 0-10 min), washed, incubated in CGRP-free medium ± PP2 (0-50 min) and 
levels of pERK1, pERK2 and ERK2 determined by Western blotting. Blots were quantified 
using ImageQuantTL and ratio of pERK1:ERK2 and pERK2:ERK2 calculated. 
Representative blots are shown. The red box highlights the difference between vehicle- 
and PP2-treated cells. (B) The maximal CGRP-induced ERK phosphorylation, expressed 
in fold-increase over basal, is higher in vehicle- compared to PP2-treated cells. (C) Basal 
levels of pERK1 and 2 are expressed in fold-increase over vehicle-treated cells. The effect 
of PP2 on the basal of pERK1 and 2 shows no significant difference compared to vehicle-
treated cells. (D, E) The CGRP-induced ERK activation of the full time course, expressed 
in fold-decrease over vehicle of pERK1 (D) and pERK2 (E) is significantly reduced in PP2-
treated cells. Thus, the CGRP-mediated ERK activation is Src-dependent in HEK cells. 
n=5, *=p<0.05 and **=p<0.01 ***=p<0.001 compared to vehicle-treated cells at the same 
time point.  
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3.5 CGRP-Induced ERK Activation is not 
Promoted by Endosomal Signalosome 
 ECE-1-dependent degradation of SP (Roosterman et al., 2007) and CGRP 
(Padilla et al., 2007) only occurs at acidic pH and can be prevented by inhibiting 
the proteolytic activity of ECE-1 or by preventing endosomal acidification. This 
degradation induces disruption of the endosomal complexes comprising 
SP/NK1R/β-arrestin and CGRP/CLR•RAMP1/β-arrestin to promote recycling of 
NK1R and CLR•RAMP1 to the cell-surface (Padilla et al., 2007; Roosterman et al., 
2007), and also terminates SP-induced, β-arrestin-dependent ERK signalling 
(Cottrell et al., 2009). It was hypothesised that by inhibiting ECE-1 or preventing 
endosomal acidification, the endosomal complex of CGRP/CLR•RAMP1/β-arrestin 
would be stabilised and thus, promote sustained CGRP-induced ERK activation. 
 
3.5.1 CGRP-Induced ERK Activation is not Regulated by Proteolytic 
Activity of ECE-1 
 To determine if ECE-1 regulates CGRP-induced ERK signalling a specific ECE-
1 inhibitor, SM-19712 (Umekawa et al., 2000), was used. HEK-CLR•RAMP1 cells 
were serum-starved, all incubated with AG1478, as a large proportion of the 
CGRP-induced ERK signalling is ErbB1-dependent. Then by blocking this pathway 
only G protein-dependent ERK activation would be observed. Cells were also 
incubated with vehicle (DDW) or SM-19712, stimulated with CGRP (10 min), 
washed and incubated in CGRP-free medium ± SM-19712 (0-110 min). Levels of 
pERK1, pERK2 and ERK2 were quantified by Western blotting. In unstimulated 
cells, levels of pERK1 and 2 were similarly low (Fig. 3.5). CGRP (10 min) similarly 
increased levels of pERK1 and 2 in both vehicle- and SM-19712-treated cells (Fig. 
3.5B, 15.8±3.4 (vehicle) versus 14.7±4.3 (SM-19712) for pERK1 and 9.9±1.9 
(vehicle) versus 9.8±4.2 (SM-19712) for pERK2; fold-increase at 10 min compared 
to basal). In vehicle-treated cells, levels of pERK1 and 2 slowly returned to basal 
levels following removal of CGRP. Incubation with the ECE-1 inhibitor, SM-19712 
had no effect on the magnitude or the duration of CGRP-induced ERK activation 
(Fig. 3.5D and E, 35.1±9.0% (vehicle) versus 42.8±11.8% (SM-19712) for pERK1 
and 39.9±12.2% (vehicle) versus 46.2±12.7% (SM-19712) for pERK2; at 110 min 
of % of maximal response). Furthermore, SM-19712 was not affecting the basal 
levels of pERK1 and 2 compared to vehicle-treated cells (Fig. 3.5C). Thus, the 
proteolytic activity of ECE-1 does not regulate CGRP-induced ERK activation.  
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Figure 3.5 ECE-1 does not affect CGRP-induced ERK activation. (A) Serum-starved 
HEK-CLR•RAMP1 cells were incubated with AG1478 (1 µM) and with vehicle or SM-
19712 (10 µM), stimulated with CGRP (100 nM, 10 min), washed, incubated in CGRP-free 
medium ± SM-19712 (0-110 min) and levels of pERK1, pERK2 and ERK2 determined by 
Western blotting. Blots were quantified using ImageJ and ratio of pERK1:ERK2 and 
pERK2:ERK2 calculated. Representative blots are shown. (B) The maximal CGRP-
induced ERK phosphorylation, expressed in fold-increase over basal, show no difference 
in vehicle- compared to SM-19712-treated cells. (C) Basal levels of pERK1 and 2 are 
expressed in fold-increase over vehicle-treated cells. The effect of SM-19712 on the basal 
of pERK1 and 2 shows no significant difference compared to vehicle-treated cells. (D, E) 
The CGRP-induced ERK activation of the full time course, expressed in % maximal of 
response (10 min) of ERK1 (D) and ERK2 (E), is similar in both vehicle- and SM-19712-
treated cells. Thus, CGRP does not induce ERK activation dependent on the proteolytic 
activity of ECE-1 in HEK cells. n=4.  
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3.5.2 Inhibition of Endosomal Acidification does not Affect CGRP-
Induced ERK Activation 
 It has previously been shown that ECE-1-depedent degradation of SP and 
CGRP only occurs at endosomal pH (Johnson et al., 1999; Padilla et al., 2007). 
Preventing endosomal acidification with bafilomycin A1, inhibits ECE-1-dependent 
cleavage of SP, the recycling of NK1R to the cell-surface (Roosterman et al., 2007) 
and sustains SP-induced, β-arrestin-dependent ERK activation (Cottrell et al., 
2009). To determine the effect of endosomal acidification on CGRP-induced ERK 
activation, bafilomycin A1 a vacuolar H+-ATPase inhibitor was used (Gagliardi et 
al., 1999). HEK-CLR•RAMP1 cells were all treated with AG1478, to only look at 
the G protein-dependent ERK activation. Cells were then incubated with vehicle 
(DMSO) or bafilomycin A1, stimulated with CGRP (10 min), washed and incubated 
in CGRP-free medium ± inhibitors (0-110 min). Levels of pERK1, pERK2 and 
ERK2 were quantified by Western blotting. In unstimulated cells, levels of pERK1 
and 2 were similarly low (Fig. 3.6). CGRP (10 min) similarly increased levels of 
pERKs in both vehicle- and bafilomycin A1-treated cells (Fig. 3.6B, 6.1±3.5 
(vehicle) versus 5.4±2.1 (bafilomycin A1) for pERK1 and 3.4±1.4 (vehicle) versus 
3.5±0.8 (bafilomycin A1) for pERK2; fold-increase at 10 min compared to basal). In 
vehicle-treated cells, levels of pERK1 and 2 slowly returned to basal levels 
following removal of CGRP. Incubation with bafilomycin A1 had no effect on the 
magnitude or the duration of CGRP-induced ERK activation (Fig. 3.6D and E, 
24.8±4.2% (vehicle) versus 37.8±6.3% (bafilomycin A1) for pERK1 and 28.8±2.9% 
(vehicle) versus 37.9±5.6% (bafilomycin A1) for pERK2; at 110 min of % of 
maximal response). Although, the inhibition of endosomal acidification does not 
have an effect on CGRP-induced ERK activation, bafilomycin A1 significantly 
increases the basal level of pERK1 and 2 (Fig. 3.6C, 1.8±0.3 (pERK1) and 
1.7±0.2 (pERK2) fold-increase over control). Thus, the effect of bafilomycin A1 on 
CGRP-induced ERK activation required further investigation. 
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Figure 3.6 Inhibition of endosomal acidification does not affect CGRP-induced ERK 
activation. (A) Serum-starved HEK-CLR•RAMP1 cells were incubated with AG1478 (1 
µM) and with vehicle or bafilomycin A1 (1 µM), stimulated with CGRP (100 nM, 10 min), 
washed, incubated in CGRP-free medium ± bafilomycin A1 (0-110 min) and levels of 
pERK1, pERK2 and ERK2 determined by Western blotting. Blots were quantified using 
ImageJ and ratio of pERK1:ERK2 and pERK2:ERK2 calculated. Representative blots are 
shown. (B) The maximal CGRP-induced ERK phosphorylation, expressed in fold-increase 
over basal, shows no difference in vehicle- compared to bafilomycin A1-treated cells. (C) 
Basal levels of pERK1 and 2 are expressed as fold-increase over vehicle-treated cells. 
The effect of bafilomycin A1 on the basal of pERK1 and 2 shows a significant increase 
compared to vehicle-treated cells. (D, E) The CGRP-induced ERK activation of the full 
time course, expressed in % maximal of response (10 min) of ERK1 (D) and ERK2 (E), is 
similar in both vehicle- and bafilomycin A1-treated cells. Thus, CGRP does not induce 
ERK activation dependent on the endosomal acidification in HEK cells, which suggests 
that CGRP does not induce endosomal signalling of ERK. n=4, *=p<0.05 compared to 
vehicle-treated cells at the same time point.  
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3.5.3 β-arrestin1 is not Involved in CGRP-Induced ERK Activation 
 It is now clear that β-arrestin recruits many catalytically active proteins, which 
then induce ERK activation ((DeFea et al., 2000a; DeFea et al., 2000b) and 
reviewed in (Luttrell and Gesty-Palmer, 2010; Murphy et al., 2009)). Moreover, 
ECE-1 has been shown to regulate the SP-induced β-arrestin-dependent ERK 
activation (Cottrell et al., 2009). To further investigate the mechanism by which 
CGRP can induce ERK activation, a β-arrestin1 mutant was used. HEK cells were 
transiently transfected with CLR•RAMP1 and β-arrestin1 WT or β-arrestin1 P91G 
P121E (a mutant that is unable to bind Src (Luttrell et al., 1999)). This mutant has 
two main actions, first it prevents the internalisation of the receptor, because Src 
phosphorylates dynamin to facilitate internalisation (Ahn et al., 1999); and 
secondly, it prevents β-arrestin-dependent signalling, as Src activates MAPK while 
bind to β-arrestin (Luttrell et al., 1999). HEK-CLR•RAMP1 cells were stimulated 
with CGRP (0-10 min), washed and incubated in CGRP-free medium (0-50 min). 
Levels of pERK1, pERK2 and ERK2 were quantified by Western blotting. In 
unstimulated cells basal levels of pERK1 and 2 were similarly low (Fig. 3.7). 
CGRP (10 min) similarly increased levels of pERK1 and 2 in both cell types (Fig. 
3.7B, 9.4±2.9 (WT) versus 11.1±2.0 (mutant) for pERK1 and 3.6±1.1 (WT) versus 
3.9±0.6 (mutant) for pERK2; fold-increase at 10 min compared to basal). In 
vehicle-treated cells, levels of pERK1 and 2 slowly returned to basal levels 
following removal of CGRP. There was no significant difference in the magnitude 
or duration of ERK activation in β-arrestin1 WT- or β-arrestin1 P91G P121E-
expressing cells (Fig. 3.7D and E, 39.5±12.1% (WT) versus 31.2±4.7% (mutant) 
for pERK1 and 52.8±9.7% (WT) versus 51.4±5.6% (mutant) for pERK2; at 110 min 
of % of maximal response). Moreover, β-arrestin1 P91G P121E expression did not 
have an effect on the basal level of pERK1 and 2 compared to β-arrestin1 WT-
expressing cells (Fig. 3.7C). Thus, CGRP does not induce ERK activation 
dependent on β-arrestins. 
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Figure 3.7 β-arrestin1 does not affect CGRP-induced ERK activation. (A) Serum-
starved HEK-FLP cells were transfected with CLR•RAMP1 (CLR•R1) and β-arrestin1 WT 
(β-arr1 WT) or β-arrestin1 P91G P121E (β-arr1 P91G P121E). Cells were then stimulated 
with CGRP (100 nM, 0-10 min), washed, incubated in CGRP-free medium (0-110 min) 
and levels of pERK1, pERK2 and ERK2 determined by Western blotting. Blots were 
quantified using ImageJ and ratio of pERK1:ERK2 and pERK2:ERK2 calculated. A 
representative blot is shown. (B) The maximal CGRP-induced ERK phosphorylation, 
expressed in fold-increase over basal, show no difference in β-arrestin1 WT- compared to 
β-arrestin1 mutant-expressing cells. (C) Basal levels of pERK1 and 2 are expressed in 
fold-increase over β-arrestin1 WT-expressing cells. Expression of β-arrestin1 P91G 
P121E on the basal of pERK1 and 2 shows no significant difference compared to β-
arrestin1 WT-expressing cells. (D, E) The CGRP-induced ERK activation of the full time 
course, expressed in % maximal of response of ERK1 (D) and ERK2 (E), is similar in both 
β-arrestin1 WT- and β-arrestin1 mutant-expressing cells. Thus, CGRP does not induce 
ERK activation depending on β-arrestin1 in HEK cells. n=3.  
  Chapter 3: Results 
89 
3.6 CGRP-Induced ERK Activation is Protein 
Kinase A-Dependent 
 GPCRs coupled to Gαs stimulate the activation of AC to promote the increase of 
intracellular cAMP levels (reviewed in (Gilman, 1984a; Gilman, 1984b)) that 
subsequently activates PKA (Brostrom et al., 1970; Gill and Garren, 1971; Tao et 
al., 1970). GPCRs that activate Gαs proteins have also been shown to regulate the 
ERK1-2 module, either by promoting activation of ERK via activation of B-Raf 
pathway, or by promoting inhibition of ERK activation via inhibition of Raf-1. As 
CLR•RAMP1 has been shown to be coupled to Gαs (activation of adenylate 
cyclase and accumulation of cAMP) (Aiyar et al., 1999; Van Valen et al., 1990), it 
was hypothesized that CGRP would induce ERK phosphorylation via the 
cAMP/PKA pathway. To determine whether CGRP induces cAMP/PKA-dependent 
ERK activation, HEK-CLR•RAMP1 cells were incubated with vehicle (DMSO) or H-
89, a PKA inhibitor (Chijiwa et al., 1990). Cells were stimulated with CGRP (0-10 
min), washed and incubated in CGRP-free medium ± H-89 (0-50 min). Levels of 
pERK1, pERK2 and ERK2 were quantified by Western blotting. In unstimulated 
cells, levels of pERK1 and 2 were similarly low (Fig. 3.8). CGRP (10 min) caused 
a prompt increase in levels of pERK1 and 2 in both vehicle- and H-89-treated 
cells. However, the increase in H-89-treated cells was significantly reduced 
compared to vehicle-treated cells (Fig. 3.8B, 10.2±0.7 (vehicle) versus 3.5±0.7 (H-
89) for pERK1 and 5.4±0.5 (vehicle) versus 2.6±0.4 (H-89) for pERK2; fold-
increase at 10 min compared to basal). Indeed, when expressed in fold-decrease 
over vehicle-treated cells, H-89 significantly reduced levels of pERK1 and 2 at all 
time points examined (Fig. 3.8D and E). Basal levels of pERK1 and 2 show not 
significant difference between vehicle- and H-89-treated cells (Fig. 3.8C). Thus, 
CGRP induces ERK activation in a PKA-dependent manner in HEK cells. 
 H-89 has been reported to have non-specific activities by inhibiting other 
kinases (reviewed in (Lochner and Moolman, 2006)). Therefore the effects of a 
lower concentration of H-89 (10 µM) was also examined (Fig. 3.9). In unstimulated 
vehicle- and H-89-treated cells, levels of pERK1 and 2 were similarly low. CGRP 
(10 min) caused a prompt increase in levels of pERK1 and 2 in both vehicle- and 
H-89-treated cells. However, the increase in H-89-treated cells was reduced 
compared to vehicle-treated cells (Fig. 3.9B, 10.6±2.9 (vehicle) versus 6.0±1.3 (H-
89) for pERK1 and 8.1±2.3 (vehicle) versus 4.5±0.9 (H-89) for pERK2; fold-
increase at 10 min compared to basal). Indeed, when expressed in fold-decrease 
over vehicle-treated cells, H-89 significantly reduced levels of pERK1 and 2 at 
almost all time points examined (Fig. 3.9D and E). Even though, basal levels of 
pERK1 and 2 show a slight increase in H-89- compared to vehicle-treated cells 
(Fig. 3.9C, 1.5±0.3 (pERK1) and 1.5±0.2 (pERK2) fold-increase over control), 
CGRP-induced ERK2 activation is PKA-dependent in HEK cells.  
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Figure 3.8 CGRP-induced ERK activation is PKA-dependent. (A) Serum-starved HEK-
CLR•RAMP1 cells were incubated with vehicle (DMSO) or H-89 (50 µM), stimulated with 
CGRP (100 nM, 0-10 min), washed, incubated in CGRP-free medium ± H-89 (0-50 min) 
and levels of pERK1, pERK2 and ERK2 determined by Western blotting. Blots were 
quantified using ImageQuantTL and ratio of pERK1:ERK2 and pERK2:ERK2 calculated. 
Representative blots are shown. The red box highlights the difference between vehicle- 
and H-89-treated cells. (B) The maximal CGRP-induced ERK phosphorylation, expressed 
in fold-increase over basal, is higher in vehicle- compared to H-89-treated cells. (C) Basal 
levels of pERK1 and 2 are expressed in fold-increase over vehicle-treated cells. The effect 
of H-89 on the basal of pERK1 and 2, show no significant difference compared to vehicle-
treated cells. (D, E) The CGRP-induced ERK activation of the full time course, expressed 
in fold-decrease over vehicle of pERK1 (D) and pERK2 (E) is significantly reduced in H-
89-treated cells. Thus, the CGRP-mediated ERK activation is PKA-dependent in HEK 
cells. n=6, **=p<0.01 and ***=p<0.001 compared to vehicle-treated cells at the same time 
point.  
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Figure 3.9 Effect of lower concentration of H-89 on CGRP-induced ERK activation. 
(A) Serum-starved HEK-CLR•RAMP1 cells were incubated with vehicle (DMSO) or H-89 
(10 µM), stimulated with CGRP (100 nM, 0-10 min), washed, incubated in CGRP-free 
medium ± H-89 (0-50 min) and levels of pERK1, pERK2 and ERK2 determined by 
Western blotting. Blots were quantified using ImageQuantTL and ratio of pERK1:ERK2 
and pERK2:ERK2 calculated. Representative blots are shown. The red box highlights the 
difference between vehicle- and H-89-treated cells. (B) The maximal CGRP-induced ERK 
phosphorylation, expressed in fold-increase over basal, is higher in vehicle- compared to 
H-89-treated cells. (C) Basal levels of pERK1 and 2 are expressed in fold-increase over 
vehicle-treated cells. The effect of H-89 on the basal of pERK1 and 2 shows an increase 
compared to vehicle-treated cells. (D, E) The CGRP-induced ERK activation of the full 
time course, expressed in fold-decrease over vehicle of pERK1 (D) and pERK2 (E) is 
significantly reduced in H-89-treated cells. Thus, the CGRP-mediated ERK activation is 
PKA-dependent in HEK cells. n=4, *=p<0.05, **=p<0.01 and ***=p<0.001 compared to 
vehicle-treated cells at the same time point.  
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3.7 Effect of the PKC/PLC Pathway in the CGRP-
Induced ERK Activation 
 Stimulation of Gαq/11 leads to the activation of PLC (reviewed in (Rhee, 2001)), 
which in turn catalyses the hydrolysis of phosphatidylinositol 4,5-biphosphate into 
two second messengers: IP3 and DAG. IP3 induces mobilisation of Ca2+ from 
endoplasmic reticulum (ER) (Putney, 1986). Together Ca2+ and DAG act in 
synergy to activate PKC. Once activated, PKC phosphorylates Raf kinase inhibitor 
protein (RKIP), which inhibits Raf-1-mediated phosphorylation of mitogen-
activated protein kinase kinase (MEK) by binding to Raf-1. The PKC-mediated 
phosphorylation of RIKP leads to the dissociation of the complex RKIP/Raf-1 and 
thereby to the activation of MEK and ERK (Corbit et al., 2003). As CGRP has been 
shown to induce Ca2+ mobilisation through Gαq/11-mediated activation of PLC-β1 in 
OHS-4 cells (human bone cell line) (Drissi et al., 1998), it was expected that 
CGRP promotes ERK activation through the PKC/PLC/Ca2+ pathway. To 
determine if the PKC/PLC/Ca2+ pathway is involved in CGRP-induced ERK 
activation specific inhibitors of this pathway were used. 
 
3.7.1 CGRP-Induced ERK Activation is PLC-Independent 
 Activation of most PKC isoforms requires upstream activation of PLC (reviewed 
in (Zeng et al., 2012)). To determine if PLC is involved in the CGRP-induced ERK 
activation, HEK-CLR•RAMP1 cells were incubated with vehicle (DMSO) or U-
73122, a pan inhibitor of PLC (Bleasdale et al., 1990). Cells were stimulated with 
CGRP (0-10 min), washed and incubated in CGRP-free medium ± U-73122 (0-50 
min). Levels of pERK1, pERK2 and ERK2 were quantified by Western blotting. In 
unstimulated vehicle- and U-73122-treated cells, levels of pERK1 and 2 were 
similarly low (Fig. 3.10). CGRP (10 min) caused a prompt increase in levels of 
pERK1 and 2 similarly in both vehicle- and U-73122-treated cells (Fig. 3.10B, 
4.3±1.0 (vehicle) versus 5.1±2.6 (U-73122) for pERK1 and 4.2±0.8 (vehicle) 
versus 4.0±1.6 (U-73122) for pERK2; fold-increase at 10 min compared to basal). 
Indeed, when expressed in % of maximal response, U-73122 had no effect on 
ERK activation compared to vehicle-treated cells (Fig. 3.10D and E). U-73122 
does not affect the basal levels of pERK1 and 2, compared to vehicle-treated cells 
(Fig. 3.10C). Thus, CGRP-induced ERK activation does not require PLC. 
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Figure 3.10 CGRP-induced ERK activation is not PLC-dependent. (A) Serum-starved 
HEK-CLR•RAMP1 cells were incubated with vehicle or U-73122 (100 µM), stimulated with 
CGRP (100 nM, 0-10 min), washed, incubated in CGRP-free medium ± U-73122 (0-50 
min) and levels of pERK1, pERK2 and ERK2 determined by Western blotting. Blots were 
quantified using ImageQuantTL and ratio of pERK1:ERK2 and pERK2:ERK2 calculated. 
Representative blot are shown. (B) The maximal CGRP-induced ERK phosphorylation, 
expressed in fold-increase over basal show no difference in vehicle- compared to U-
73122-treated cells. (C) Basal levels of pERK1 and 2 are expressed in fold-increase over 
vehicle-treated cells. The effect of U-73122 on the basal of pERK1 and 2 shows no 
difference compared to vehicle-treated cells. (D, E) The CGRP-induced ERK activation of 
the full time course, expressed in % of maximal response of pERK1 (D) and pERK2 (E), 
shows no difference between vehicle- and U-73122-treated cells, suggesting that CGRP 
activates ERK in PLC-independent manner in HEK cells. n=3.  
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3.7.2 Effect of PKC Inhibitors on the CGRP-Induced ERK Activation 
 To determine if CGRP induces PKC-dependent ERK activation, HEK-
CLR•RAMP1 cells were incubated with vehicle (DMSO) or Gö6976, a conventional 
PKC (cPKC) isoform inhibitor (Martiny-Baron et al., 1993). Cells were stimulated 
with CGRP (0-10 min), washed and incubated in CGRP-free medium ± Gö6976 
(0-50 min). Levels of pERK1, pERK2 and ERK2 were quantified by Western 
blotting. In unstimulated cells, levels of pERK1 and 2 were similarly low (Fig. 
3.11). CGRP (10 min) caused a prompt increase in levels of pERK1 and 2 in both 
vehicle- and Gö6976-treated cells. However, the increase in Gö6976-treated cells 
was significantly reduced compared to vehicle-treated cells (Fig. 3.11B, 9.0±1.9 
(vehicle) versus 4.0±0.9 (Gö6976) for pERK1 and 3.2±0.3 (vehicle) versus 2.2±0.2 
(Gö6976) for pERK2; fold-increase at 10 min compared to basal). Indeed, when 
expressed in fold-decrease over vehicle-treated cells, Gö6976 reduced levels of 
pERK1 and 2 significantly only after the initial stimulation (2 and 10 min) (Fig. 
3.11D and E). This result implicates cPKC isoforms in the early stages of CGRP-
induced ERK activation. However, Gö6976 significantly increases the basal levels 
of pERK1 and 2 compared to vehicle-treated cells (Fig. 3.11C, 2.0±0.1 (pERK1) 
and 1.7±0.0 (pERK2) fold-increase over control). Thus, involvement of cPKC in 
CGRP-induced ERK activation required further investigation. 
 Additionally, a pan inhibitor of PKC isoforms, Gö6983 (Gschwendt et al., 1996), 
was also used. HEK-CLR•RAMP1 cells were incubated with vehicle (DMSO) or 
Gö6983. Cells were stimulated with CGRP (0-10 min), washed and incubated in 
CGRP-free medium ± Gö6983 (0-50 min). Levels of pERK1, pERK2 and ERK2 
were quantified by Western blotting. In unstimulated vehicle- and Gö6983-treated 
cells, levels of pERK1 and 2 were similarly low (Fig. 3.12). CGRP (10 min) caused 
similarly a prompt increase in levels of pERK1 and 2 in both vehicle- and Gö6983-
treated cells (Fig. 3.12B, 23.4±10.2 (vehicle) versus 18.5±7.6 (Gö6983) for pERK1 
and 16.9±6.4 (vehicle) versus 14.8±6.2 (Gö6983) for pERK2; fold-increase at 10 
min compared to basal). In vehicle-treated cells, levels of pERK1 and 2 slowly 
returned to basal levels following removal of CGRP. Incubation with the PKC 
inhibitor, Gö6983 had no significant effect on CGRP-induced ERK activation (Fig. 
3.12D and E). These data show that PKC is not involved in CGRP-induced ERK 
activation. However, as Gö6983 significantly reduces the basal levels of pERK, 
compared to the vehicle (Fig. 3.12C, 0.7±0.0 (pERK1) and 0.7±0.0 (pERK2) fold-
decrease over control), then, this result is again difficult to interpret. However, 
together the data obtained with Go6976 and Go6983 imply that PKC has little, if 
any effect on CGRP-induced ERK activation. 
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Figure 3.11 CGRP-induced ERK activation is PKC-dependent. (A) Serum-starved 
HEK-CLR•RAMP1 cells were incubated with vehicle (DMSO) or Gö6976 (10 µM), 
stimulated with CGRP (100 nM, 0-10 min), washed, incubated in CGRP-free medium ± 
Gö6976 (0-50 min) and levels of pERK1, pERK2 and ERK2 determined by Western 
blotting. Blots were quantified using ImageJ and ratio of pERK1:ERK2 and pERK2:ERK2 
calculated. Representative blots are shown. The red box highlights the difference between 
vehicle- and Gö6976-treated cells. (B) The maximal CGRP-induced ERK phosphorylation, 
expressed in fold-increase over basal, is higher in vehicle- compared to Gö6976-treated 
cells. (C) Basal levels of pERK1 and 2 are expressed in fold-increase over vehicle-treated 
cells. The effect of Gö6976 on the basal of pERK1 and 2 shows a significant increase 
compared to vehicle-treated cells. (D, E) The CGRP-induced ERK activation of the full 
time course, expressed in fold-decrease over vehicle of pERK1 (D) and pERK2 (E) is 
significantly reduced in Gö6976-treated cells only at 2 and 10 min. Thus, CGRP partially 
activates ERK in PKC-dependent manner in HEK cells. n=4, *=p<0.05, **=p<0.01 and 
***=p<0.001 compared to vehicle-treated cells at the same time point.  
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Figure 3.12 CGRP-induced ERK activation is PKC-independent. (A) Serum-starved 
HEK-CLR•RAMP1 cells were incubated with vehicle (DMSO) or Gö6983 (10 µM), 
stimulated with CGRP (100 nM, 0-10 min), washed, incubated in CGRP-free medium ± 
Gö6983 (0-50 min) and levels of pERK1, pERK2 and ERK2 determined by Western 
blotting. Blots were quantified using ImageQuantTL and ratio of pERK1:ERK2 and 
pERK2:ERK2 calculated. Representative blots are shown. (B) The maximal CGRP-
induced ERK phosphorylation, expressed in fold-increase over basal, shows no difference 
in vehicle- compared to Gö6983-treated cells. (C) Basal levels of pERK1 and 2 are 
expressed in fold-increase over vehicle-treated cells. The effect of Gö6983 on the basal of 
pERK1 and 2 shows a significant decrease compared to vehicle-treated cells. (D, E) The 
CGRP-induced ERK activation of the full time course, expressed in fold-decrease over 
vehicle of pERK1 (D) and pERK2 (E), is similar in vehicle- and Gö6983-treated cells. 
Thus, CGRP activates ERK in PKC-independent manner in HEK cells. n=4, ***=p<0.001 
compared to vehicle-treated cells at the same time point.  
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3.7.3 CGRP-Induced ERK Activation is Extracellular Ca2+-
Independent 
 Ca2+ is required for the activation of conventional PKC isoforms ((Ogawa et al., 
1981) and reviewed in (Zeng et al., 2012)). To determine the effect of extracellular 
Ca2+, HEK-CLR•RAMP1 cells were incubated in medium with Ca2+ (Ca2+-plus) or 
without Ca2+ (Ca2+-free). Cells were stimulated with CGRP (0-10 min), washed and 
incubated in CGRP-free Ca2+-plus or -free buffer (0-50 min). Levels of pERK1, 
pERK2 and ERK2 were quantified by Western blotting. In unstimulated Ca2+-plus- 
and -free-treated cells, levels of pERK1 and 2 were similarly low (Fig. 3.13). 
CGRP (10 min) caused similarly a prompt increase in levels of pERK1 and 2 in 
both Ca2+-plus- and –free-treated cells (Fig. 3.13B, 11.9±2.5 (plus) versus 
11.9±3.1 (free) for pERK1 and 5.6±1.5 (plus) versus 5.8±1.4 (free) for pERK2; 
fold-increase at 10 min compared to basal). Indeed, when expressed in % of 
maximal response, Ca2+-free had no difference on ERK activation compared to 
Ca2+-plus-treated cells (Fig. 3.13D and E). Thus, extracellular Ca2+ is not required 
in CGRP-induced ERK activation. However, Ca2+-free increases the basal of 
pERK1 and 2, compared to the Ca2+-plus-treated cells (Fig. 3.13C, 1.3±0.2 
(pERK1) 1.2±0.1 (pERK2) fold-increase over control). 
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Figure 3.13 CGRP-induced ERK activation is not dependent on extracellular Ca2+. (A) 
Serum-starved HEK-CLR•RAMP1 cells were incubated with Ca2+ or Ca2+ Free, stimulated 
with CGRP (100 nM, 0-10 min), washed, incubated in CGRP-free Ca2+ or Ca2+-free buffer 
(0-50 min) and levels of pERK1, pERK2 and ERK2 determined by Western blotting. Blots 
were quantified using ImageQuantTL and ratio of pERK1:ERK2 and pERK2:ERK2 
calculated. Representative blot are shown. (B) The maximal CGRP-induced ERK 
phosphorylation, expressed in fold-increase over basal, shows no difference in Ca2+ 
compared to Ca2+ Free-treated cells. (C) Basal levels of pERK1 and 2 are expressed in 
fold-increase over Ca2+-treated cells. The effect of Ca2+ Free on the basal of pERK1 and 2 
shows a significant increase compared to Ca2+-treated cells. (D, E) The CGRP-induced 
ERK activation of the full time course, expressed as % of maximal response of pERK1 (D) 
and pERK2 (E), shows no difference between Ca2+- and Ca2+ Free-treated cells, 
suggesting that CGRP activates ERK in extracellular Ca2+-independent manner in HEK 
cells. n=4, *=p<0.05 compared to Ca2+-treated cells at the same time point.  
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3.8 Discussion 
 HEK cells stably transfected with CLR•RAMP1, have already been used to 
study CGRP-induced ERK activation (Parameswaran et al., 2000a) where it has 
been shown that CGRP induces a concentration-dependent increase of ERK 
phosphorylation. I also showed that CGRP induces ERK activation in HEK cells, 
suggesting that HEK cells are a good model to study CGRP-induced ERK 
activation. 
 Many GPCRs have been shown to induce transactivation of ErbB1 (Daub et al., 
1996; Eisinger and Ammer, 2008; Maudsley et al., 2000; Zajac et al., 2011). This 
signalling pathway is G protein-independent and could mask any subtle changes 
in CLR•RAMP1-mediated ERK activation. I was then interested to see whether 
CGRP can induce transactivation of ErbB1 by using a specific ErbB1 inhibitor, 
AG1478 (Osherov and Levitzki, 1994). I showed for the first time, that CGRP can 
cause transactivation of ErbB1 to activate ERK1-2 in HEK cells. ErbB1 
transactivation has been reported to play an important role in cancer-related 
disorders (reviewed in (Fischer et al., 2003)), including by promoting angiogenesis 
(de Jong et al., 1998; Schreiber et al., 1986). Moreover, CGRP has also been 
shown to enhance tumour-associated angiogenesis (reviewed in (Majima et al., 
2011)). However, the CGRP-mediated molecular mechanism of angiogenesis 
remains unknown. It is then possible to think that CGRP induce angiogenesis via 
transactivation of ErbB1. Interestingly, β1-AR has been shown to also induce 
transactivation of ErbB1 in HEK cells, however only stimulation with EGF and not 
catecholamine causes pERK1-2 translocation into the nucleus (Tilley et al., 2009). 
These results suggest that GPCR-mediated transactivation of ErbB1 induce 
activation of ERK that promotes activation of cytoplasmic mediators only. It is 
currently unknown if CGRP-induced ErbB1 transactivation causes translocation of 
pERK1-2 into the nucleus. However, as HEK cells do not express endogenously 
CLR•RAMP1, it would be first necessary to verify that CGRP induces ErbB1 
transactivation in cells naturally expressing CGRP receptors. Further experiments 
remain to determine the role and the mechanisms of CGRP-induced ErbB1 
transactivation. I showed that CGRP-induced ErbB1 transactivation provides about 
60% of total CGRP-induced ERK signal. Therefore, when performing experiments 
to determine the effects of ECE-1 inhibition and endosomal acidification, I inhibited 
this pathway so that only the G protein-dependent ERK activation would be 
observed. 
 The tyrosine kinase Src is known to play an important role in GGRP-mediated 
ERK activation (reviewed in (McGarrigle and Huang, 2007)). Moreover, Src has 
been described to be involved in ERK activation through cAMP/PKA, 
PKC/PLC/Ca2+ and β-arrestins-dependent pathways (Dikic et al., 1996; Luttrell et 
al., 1999; Schmitt and Stork, 2002). However, many studies reported that the 
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protein kinase Src was mediating ErbB1 transactivation (Buteau et al., 2003; Daub 
et al., 1997; Eguchi et al., 1998). By using PP2, a Src inhibitor, I showed that 
CGRP-induced ERK activation was reduced. Thus, Src is required for CGRP-
induced ERK activation. I showed that CGRP-induced ERK activation was mainly 
mediated through the cAMP/PKA pathway and the transactivation of ErbB1. As, 
Src has been described to be involved in both pathways, further experiments 
remain to determine in which pathway Src induces ERK activation. 
 ECE-1 regulates the recycling and the SP-induced β-arrestin-dependent ERK 
signalling of NK1R (Cottrell et al., 2009; Roosterman et al., 2007). Furthermore, 
CLR•RAMP1 trafficking is also regulated by ECE-1 (Padilla et al., 2007). I was 
then expected that ECE-1 would similarly regulate CGRP-induced β-arrestin-
dependent ERK activation. Surprisingly, preventing endosomal acidification with 
bafilomycin A1 and inhibiting ECE-1 had no effect on the magnitude or duration of 
CGRP-induced ERK activation. Thus, it seems that ECE-1 does not regulate 
CGRP-induced β-arrestin-dependent ERK activation. Besides, it has been shown 
that CGRP can be cleaved by other metalloprotease such as insulin-degrading 
enzyme (Kim et al., 2012). Theoretically, it is then possible that CGRP can be 
cleaved by other endosomal metalloproteases, which would regulate CGRP-
induced β-arrestin-dependent ERK activation. However, it is unlikely as when 
inhibiting ECE-1 alone, CLR•RAMP1 has been showed to be sequestered in 
endosomes (Padilla et al., 2007). These results suggest that only ECE-1 degrades 
CGRP in endosome, because if another metalloprotease was able to degrade 
CGRP, by inhibiting ECE-1 only, CLR•RAMP1 would not be blocked in endosome. 
Moreover, it is known that enzymes in general, are pH sensitive and required 
optimal pH to be fully active, meaning that the pH of every cellular organelles must 
be strictly regulated (reviewed in (Demaurex, 2002)). I showed that inhibiting the 
endosomal acidification does not affect CGRP-induced ERK activation, which 
again shows that it is unlikely that other metalloproteases are able to degrade 
CGRP. Another explanation would be that CGRP-induced ERK activation is not 
depending on β-arrestin, and therefore would not be regulated by the endosomal 
proteases activity as it has been shown for NK1R (Cottrell et al., 2009). It is known 
that many GPCRs can activate ERK via β-arrestin-dependent pathways (Cottrell et 
al., 2009; Luttrell et al., 2001; Shenoy et al., 2006). Even though, CGRP induces 
the translocation of β-arrestin to the cell-surface and traffic together with 
CLR•RAMP1 to early endosome (Padilla et al., 2007), I hypothesised that CGRP 
would not induce a β-arrestin-dependent ERK activation. To assess this 
hypothesis, I use a β-arrestin1 mutant. I did not use the ErbB1 inhibitor, AG1478 in 
these experiments as β-arrestins have also been shown to play a role in ErbB1 
transactivation. β1-AR-induced ErbB1 transactivation depends on a mechanism in 
which GRK phosphorylation recruits β-arrestins and Src to the cell-surface to 
promote ErbB1 transactivation (Noma et al., 2007; Tilley et al., 2009). By using the 
dominant-negative β-arrestin1 mutant (β-arrestin1 P91G P121E) that cannot bind 
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to Src, I showed that CGRP-induced ERK activation was not altered, suggesting 
as expected that CGRP does not promote a β-arrestin-dependent ERK activation. 
In contrast, expression of this mutant does affect the isoproterenol-induced ERK 
activation of the β2-AR (Luttrell et al., 1999). Together, these data suggest that 
CGRP does not activate ERK via a β-arrestin-dependent mechanism, nor does it 
use the endosome as a signalling platform to activate ERK. However, it does not 
mean that CGRP does not induce β-arrestin-dependent endosomal signalling. β-
arrestins are binding partners for many other signalling proteins, including p38 
(Gong et al., 2008), Akt (Cianfrocca et al., 2010) and JNK (McDonald et al., 2000). 
It remains to be determined whether CGRP promotes a β-arrestins-dependent 
activation of other MAPK. 
 The cAMP/PKA pathway is commonly involved in GPCR-induced ERK 
activation (reviewed in (Goldsmith and Dhanasekaran, 2007; Rozengurt, 2007)). 
CLR•RAMP1 is known to couple Gαs subunit (Aiyar et al., 1999; Van Valen et al., 
1990), which leads to accumulation of cAMP. I then expected that CGRP would 
induce ERK phosphorylation via the cAMP/PKA pathway. Indeed, by using H-89, a 
PKA inhibitor (Chijiwa et al., 1990), I showed that CGRP-induced ERK activation 
was PKA-dependent. This result is consistent with another study (Parameswaran 
et al., 2000a), which showed that 20 µM of H-89 was sufficient to reduced CGRP-
induced ERK activation. H-89 has been commonly used at 50 µM (Chao and 
Hamilton, 2009; Lee and Linstedt, 2000; Murphy et al., 2010). However, it has 
been shown that H-89 can inhibit other kinases (reviewed in (Lochner and 
Moolman, 2006)), which suggests that the effect seen could be due to off-target 
effects. Therefore, I used two different concentrations of H-89 and obtained similar 
results. The lower concentration (10 µM) of H-89 gives a more specific inhibition of 
PKA. Thus, I can say with more certainty that CGRP activates ERK through PKA. 
However, it would be interesting to use other PKA inhibitors and confirm that the 
same effect is observed. It should be noted that I did not use AG1478 in these 
experiments as it has been shown that ErbB1 transactivation can be mediated by 
PKA (Donnini et al., 2007) and therefore promote CGRP-induced ERK activation. 
However, further experiments remains to determine whether PKA is involved in 
CGRP-mediated ErbB1 transactivation. 
 GPCRs can also induce ERK activation through the PLC/PKC/Ca2+ pathway 
(reviewed in (Belcheva and Coscia, 2002; Goldsmith and Dhanasekaran, 2007; 
Rozengurt, 2007)) either through the coupling with a Gαq subunit or through 
βγ subunits-dependent mechanism of the G protein. Moreover, CGRP has been 
described to promote Ca2+ mobilisation through Gαq subunit-mediated PLC 
activation in human bone cells OHS-4 (Drissi et al., 1998). Interestingly, it has 
been shown in HEK cells that expression and stimulation of the CGRP receptor, 
promotes ERK activation in a PKA- and PI3K-dependent manner (Parameswaran 
et al., 2000b). Conversely, in COS-7 cells, expression and stimulation of CGRP 
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receptor leads to ERK activation predominantly through PI3K activation (Conner et 
al., 2008). I was then interested to see if this pathway was involved in CGRP-
induced ERK activation. I then used different inhibitors targeting three components 
of this pathway: PLC, PKC and Ca2+.  
 When I used a PLC inhibitor, I showed no effect on CGRP-induced ERK 
activation, neither on the basal level nor on the initial activation of pERK. 
Therefore, PLC is not involved in the CGRP-induced ERK activation. This result 
suggests that CGRP-induced ERK activation is not mediated through the 
PLC/PKC/Ca2+ pathway. Interestingly, when I used Gö6976, a cPKC inhibitor 
(Martiny-Baron et al., 1993), I showed that CGRP-induced ERK phosphorylation 
was reduced. This result suggests that cPKC are involved in CGRP-induced ERK 
activation, which contradicts the effects seen with the PLC inhibitors, as cPKC 
required activation of PLC to be activated (reviewed in (Webb et al., 2000)). One 
explanation is that Gö6976 inhibits CGRP-induced ERK activation through off-
target effects. Indeed, it has been shown that Gö6976 was able to inhibit other 
kinases including Janus kinase 2 (Grandage et al., 2006). Another explanation is 
that I showed that Gö6976 significantly increased the basal level of pERK. This 
basal activity has already been observed in another study (Sellers et al., 2001). It 
becomes then difficult to interpret the effect of the inhibitor, as the reduction of 
pERK seen in the initial activation of ERK could be due to the fact that starting 
from higher level of phosphorylation, ERK would reach its maximum 
phosphorylation level more rapidly. Then by comparing the level of pERK over the 
basal, it would appear to be reduced in the Gö6976-treated cells compared to 
vehicle-treated cells. Interestingly, it has been shown that cPKC isoforms were 
responsible of a negative feedback on ErbB1 phosphorylation (Santiskulvong and 
Rozengurt, 2007). Therefore, by inhibiting PKC, basal phosphorylation level of 
ErbB1 can increase, leading to an augmentation of ERK activation. This could 
explain why Gö6976 increases basal level of pERK. 
 I then decided to use Gö6983, a broad-spectrum of PKC isoforms inhibitor 
(Gschwendt et al., 1996). Gö6983 has already been shown to inhibit GPCR-
induced ERK activation (Shah et al., 2005). Even though, Gö6983 reduces 
significantly the basal level of pERK, I showed that CGRP-induced ERK activation 
was not reduced in Gö6976-treated cells compared to vehicle-treated cells. This 
result suggests that CGRP does not induce ERK activation through PKC, which 
confirms the results observed with the PLC inhibitor and that the effect seen with 
Gö6976 seems to be due to off-target effects. Thus, it is likely that CGRP-induced 
ERK activation is PLC/PKC-independent. 
 Finally, I wanted to see the effect of Ca2+ on the CGRP-induced ERK activation. 
It is known that some isoforms of PKC required Ca2+ to be activated (Ogawa et al., 
1981) and reviewed in (Rozengurt, 2007; Zeng et al., 2012)). To assess the role of 
Ca2+, I stimulated the cells in presence or not of extracellular Ca2+. I am aware that 
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it is mainly a mobilisation of Ca2+ from intracellular store that trigger PKC 
activation. However, it is known that this rapid Ca2+ mobilisation is followed by a 
slower entry of Ca2+ from the outside (reviewed in (Parekh and Putney, 2005)). It 
also has been shown that this entry of Ca2+ could sustain PKC and ERK activation 
(Numaga et al., 2010). In our experiment, I showed that extracellular Ca2+ did not 
seem to have any effect on the CGRP-induced ERK activation. Which again, 
suggests that Ca2+-dependent PKC isoforms are not involved in the CGRP-
induced ERK activation, because I should have seen a faster decrease in pERK 
level in the Ca2+-free treated cells. However, the fact that the basal level of pERK 
was significantly higher in Ca2+-free treated cells complicates the interpretation of 
the involvement of Ca2+ in the CGRP-induced ERK activation, but could also be 
explain by the negative feedback of Ca2+-dependent PKC isoforms. It should be 
noted that I did not use AG1478 in these experiments as it has been shown that 
ErbB1 transactivation can be mediated by PKC (Stewart and O'Brian, 2005). 
Altogether, these results suggest that the PLC/PKC/Ca2+ pathway is not involved 
in the CGRP-induced ERK activation. 
 
3.9 Summary and Conclusion 
 To investigate the mechanism of CGRP-induced ERK-dependent upregulation 
of iNOS, I first determined whether CGRP activates ERK in HEK-CLR•RAMP1 
cells. I used transfected HEK cells as they are an easy model to manipulate and 
provide strong signals to analyse. Using these findings, key experiments could 
then be repeated in a more appropriate model such as primary thoracic artery 
smooth muscle cells. 
 As expected, CGRP induces ERK activation in HEK-CLR•RAMP1 cells. By 
using different inhibitors I show that CGRP-induced ERK activation is mainly 
activated through two major pathways. I show for the first time that CGRP induces 
transactivation of ErbB1, which then lead to the activation of ERK (Fig. 3.14). This 
pathway seems to be quite important as the use of an ErbB1 inhibitor reduces 
CGRP-induced ERK activation by about 60%. Surprisingly, even if ECE-1 is 
regulating the traffic of CLR•RAMP1 (Padilla et al., 2007), the inhibition of ECE-1 
or the endosomal acidification did not affect the magnitude or duration of CGRP-
induced ERK signalling, as it has been shown for NK1R (Roosterman et al., 2007). 
Moreover, I showed that CGRP-induced ERK activation is β-arrestin1-
independent. The other pathway involved in the CGRP-induced ERK activation is 
the cAMP/PKA pathway, which was expected as is has been shown that 
CLR•RAMP1 couples with a Gαs subunit (Aiyar et al., 1999; Van Valen et al., 
1990). By using a PKA inhibitor, I showed that CGRP-induced ERK activation was 
reduced by about 50% (Fig. 3.14). I also showed that Src is involved in CGRP-
induced ERK activation, potentially involved either in the transactivation of ErbB1 
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pathway or the cAMP/PKA pathway. Also, I showed that the PLC/PKC/Ca2+ 
pathway is not involved in CGRP-induced ERK activation. Altogether those results 
give us a better understanding of the CGRP-induced ERK signalling in HEK-
CLR•RAMP1 cells.  







Figure 3.14 Schematic representation of ERK pathways involved in CGRP-induced 
ERK activation. CGRP induce transactivation of ErbB1 which leads to the activation of 
ERK. This pathway can be blocked by using ErbB1 inhibitor: AG1478. However, the exact 
mechanism of CGRP-induced ErbB1 transactivation remains to be determined. The other 
pathway involved in CGRP-induced ERK activation is cAMP/PKA, where H-89, a PKA 
inhibitor, was shown to reduce CGRP-induced ERK activation. By using PP2 a Src 
inhibitor, Src has been shown to be also involved in CGRP-induced ERK activation. The 
role of Src remains to be determined: Src can either be involved in the transactivation of 
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4.1 Background and Objectives 
 It is known that CGRP can induce ERK activation in different cell types 
(Kawanami et al., 2009; Kawase et al., 1999; Yu et al., 2006), which is mainly 
involved in the proliferation of those cell types. However, CGRP has also been 
shown to regulate other biological responses in ERK dependent manner, such as 
inducing expression of VEGF in HaCat keratinocyte cells (Yu et al., 2006), 
promoting inflammation in astrocytes and microglia cells (Wang et al., 2009) and 
inducing iNOS in trigeminal ganglion glial cells (Vause and Durham, 2009). 
 iNOS produces large amounts of NO (Nathan and Xie, 1994) and is upregulated 
in different pathologies such as migraine (Olesen and Jansen-Olesen, 2000), 
atherosclerosis (Ginnan et al., 2008) and sepsis (Hauser et al., 2005). CGRP is 
similarly upregulated in migraine and sepsis (Goadsby et al., 1990; Zhou et al., 
2001). CGRP has been shown to upregulate iNOS and NO release in trigeminal 
ganglion glial cells in a p38- and ERK-dependent mechanism (Vause and Durham, 
2009). Moreover, when SMCs are pretreated with interleukin-1β, CGRP also 
promotes upregulation of iNOS and NO release by inducing elevation of cAMP, 
whereas CGRP alone had no effect on iNOS expression (Schini-Kerth et al., 
1994). However, the specific molecular mechanisms of CGRP-induced iNOS 
upregulation remain unknown. First, to determine if primary rat thoracic artery 
SMCs (TA-SMCs) are a suitable model to study CGRP-induced iNOS 
upregulation, cells were isolated, cultured and then characterised. The aim of this 
study is to investigate if CGRP promotes ERK-dependent iNOS expression in TA-
SMC.  
 
4.2 Characterisation of Primary Smooth Muscle 
Cells from Rat Thoracic Aorta 
4.2.1 TA-SMC Express α-Smooth Muscle Actin 
 CGRP induces ERK activation in HEK-CLR•RAMP1 cells. However, these cells 
do not express endogenously CLR•RAMP1, and do not represent the best 
physiological model to study whether CGRP-induced iNOS upregulation in an ERK 
activation dependent manner. Indeed, CGRP was unable to induce iNOS 
expression in HEK-CLR-RAMP1 cells (unpublished observation, G.S. Cottrell). 
Therefore, primary rat TA-SMCs were used. Cells were extracted by an explant 
method. Explants were then cultured until the cells formed a monolayer. To 
determine if the cells were actual SMC, the cells in cultures were characterised 
using a specific SMC markers: α-smooth muscle actin (α-SMA) (Skalli et al., 
1989). Primary TA-SMCs were fixed and α-SMA and DAPI (DNA marker) detected 
by immunofluorescence and confocal microscopy (Fig. 4.1A). α-SMA staining 




shows characteristic actin fibres. Thus, the cultures from rat thoracic aorta contain 
SMCs. 
 
4.2.2 TA-SMC Express mRNA for CLR and RAMP1 
 The cells issued from an explant method are SMC. In order to be a suitable 
model these cells must express all the components of the CGRP receptor. To 
determine if TA-SMCs express CLR, RAMP1, 2 and 3, mRNA was extracted from 
TA-SMC culture. Reverse transcriptase (RT)-PCR was then performed with or 
without reverse transcriptase polymerase (MultiScribe) in order to generate cDNA. 
By using specific primers for CLR, RAMP1, 2 and 3, cDNA were then amplified by 
PCR and products were run on 1.5% agarose gel (Fig. 4.1B). In the absence of 
MultiScribe, no product was amplified for any reaction. However, in reaction with 
Multiscribe products of expected size for CLR (442 bp), RAMP1 (277 bp), RAMP2 
(446 bp) and RAMP3 (313 bp) were detected. Thus, TA-SMC endogenously 
express mRNA for CGRP and ADM receptors. Altogether, these results suggest 
that TA-SMC have the potential to respond to CGRP. 
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4.3 CGRP Induces iNOS Expression in TA-SMC 
 TA-SMCs express mRNA for CLR•RAMP1, suggesting that these cells are able 
to respond to CGRP. Therefore, to confirm this hypothesis, TA-SMCs were 
stimulated with CGRP and iNOS expression analysed by Western blotting and by 
immunofluorescence and confocal microscopy. In our primary cells culture, a 
higher concentration of CGRP (1 µM) was used, similarly to previous study 
(Schini-Kerth et al., 1994). 
 
4.3.1 Western Blot Analysis of CGRP-Induced iNOS Production 
 To determine if primary smooth muscle cells can promote iNOS upregulation, 
cells were stimulated with CGRP (0-6 h) and analysed by Western blotting for the 
presence of iNOS and β-actin (loading control). In unstimulated cells there was a 
low basal level of iNOS (Fig. 4.2). After 6 h, a significant increase of iNOS signal 
was observed (Fig. 4.2B, 4.3±1.3 fold-increase over basal). Thus, CGRP induces 
iNOS production in TA-SMC. 
 
4.3.2 Confocal Analysis of CGRP-Induced iNOS Production 
 To determine if CGRP can promote iNOS expression TA-SMCs, cells were 
stimulated with CGRP (6 h) and iNOS and α-SMA (used to identify SMCs) were 
simultaneously analysed by immunofluorescence and confocal microscopy (Fig. 
4.3). Each image was analysed by ImageJ, where extracellular background 
signals have been manually removed and level of cellular signals were quantified. 
Ratio of iNOS:SMA was calculated and expressed as fold-increase over control. In 
unstimulated cells, analysis showed low levels of iNOS (Fig. 4.3A). Stimulation 
with CGRP induced a significant increase of iNOS signal (Fig. 4.3B, 1.7±0.1 fold-

















Figure 4.2 CGRP induces iNOS production in TA-SMCs. (A) TA-SMCs were stimulated 
with CGRP (1 µM, 0-6 h). Blots were probed for levels of iNOS and β-actin. 
Immunoreactive bands were quantified by ImageQuantTL. Representative blots are 
shown. (B) Ratios of iNOS:β-actin calculated and results expressed in fold-increase over 
unstimulated cells. Basal levels of iNOS are low. CGRP induces a significant iNOS 
upregulation at 6 h. n=4, *p<0.05 compared to unstimulated cells. 
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4.4 CGRP-Induced iNOS Upregulation is ERK-
Dependent in TA-SMC 
 CGRP induces iNOS expression in TA-SMC. However, the exact molecular 
mechanism of CGRP-induced iNOS upregulation remains unknown. As a first step 
to determine if CGRP-induced iNOS upregulation in TA-SMC is ERK dependent, a 
MEK inhibitor, U-0126 (Favata et al., 1998), was used. TA-SMCs were incubated 
with vehicle (DMSO) or U-0126 (30 min), stimulated with CGRP (0-6 h) and levels 
of iNOS and β-actin determined by Western blotting. In unstimulated vehicle- and 
U-0126-treated cells, levels of iNOS were low (Fig. 4.4). CGRP caused increase in 
levels of iNOS in both vehicle- and U-0126-treated cells. However, the increase in 
U-0126-treated cells was reduced compared to vehicle-treated cells (Fig. 4.4B, 
10.4±1.4 (vehicle) versus 2.8±0.5 (U-0126) fold-increase over basal at 6 h). Thus, 
CGRP-induced iNOS upregulation is ERK-dependent in TA-SMC. Furthermore, 
these results suggest that TA-SMC is a suitable model to study the involvement of 
ERK activation in CGRP-induced iNOS upregulation. 
 
  







Figure 4.4 CGRP-induced iNOS upregulation is ERK-dependent. (A) TA-SMCs were 
incubated with vehicle (DMSO) or U-0126 (10 µM), stimulated with CGRP (1 µM, 0-6 h) 
and levels of iNOS and β-actin determined by Western blotting. Blots were quantified by 
ImageQuantTL. Representative blots are shown. (B) The CGRP-induced iNOS production 
expressed in fold-increase over basal of iNOS:β-actin, is significantly reduced at 6 h in U-
0126-treated cells compared to vehicle-treated cells, indicating that CGRP induces iNOS 
upregulation in a ERK-dependent manner. n=3, **=p<0.01 compared to vehicle-treated 
cells at each time point. 
 
  





 As HEK-CLR•RAMP1 cells do not endogenously express CLR•RAMP1 and 
CGRP does not induce iNOS expression in these cells, I required a more 
physiological model to evaluate the role of CGRP-induced ERK activation in the 
upregulation of iNOS. Many studies have shown that primary SMCs respond to 
CGRP leading to an increase of cAMP (Schini-Kerth et al., 1994; Vallotton et al., 
1989; Wisskirchen et al., 1999). I then decided to use SMC issued from rat 
thoracic artery. I isolated cells using an explant method. Other groups have 
already used this method to isolate this type of cells (Campbell and Campbell, 
1993; Xu et al., 2009). The cells were then characterised by using a specific 
marker of SMC that is α-SMA (Skalli et al., 1989) in order to confirm that the cells 
issued from the explant were SMC. I also determined if these cells were 
expressing components of the CGRP receptor. PCR products amplified from 
cDNA generated from mRNA extracted from TA-SMC, indicated the presence of 
mRNA for CLR, RAMP1, RAMP2 and RAMP3. As this type of cell has already 
been shown to respond to CGRP, it was not surprising to find that they express 
CLR and RAMP1. Moreover, the fact that TA-SMCs also express RAMP2 and 3, 
suggests that they may also express a functional ADM receptor. Indeed, studies 
have shown that ADM inhibits the proliferation of SMCs, indicating that SMCs can 
express a functional ADM receptor (Kano et al., 1996). Altogether, I showed that 
TA-SMCs are expressing mRNA for CLR•RAMP1. Furthermore, I also show that 
TA-SMCs responded to CGRP and promoted upregulation of iNOS. However, it is 
not an unfamiliar result, as a previous study showed that CGRP also induces 
iNOS upregulation in TA-SMC (Schini-Kerth et al., 1994). Interestingly, in this 
study the authors showed that CGRP (1 µM) on its own was not sufficient to 
induce iNOS upregulation. Indeed, only when the cells were pretreated with IL-1β, 
CGRP was able to promote iNOS upregulation. In contrast, my results showed 
that when applied alone the same concentration of CGRP (1 µM) is sufficient to 
induce iNOS expression. Moreover, by using the MEK inhibitor, U-0126 I show 
that CGRP-induced iNOS upregulation was reduced. The fact that CGRP is used 
at high concentration, could induce stimulation of CLR•RAMP2 or 3. Therefore to 
confirm these effects a CGRP inhibitor could be used and see whether iNOS 
upregulation is affected or not. If not it means that the effect of CGRP are not 
mediated by CLR•RAMP1. Nevertheless, this result suggests that CGRP-induced 
iNOS production is ERK-dependent. However, I noticed that the TA-SMC tends to 
lose the expression of CLR•RAMP1. Indeed, some explants after few weeks were 
not responding at all to CGRP, which make it difficult to carry out any experiments 
due to the inconsistency of the results. Other studies also reported that primary 
SMC put on culture tend to lose expression of some cell-surface protein such as 
the α7 integrin (Yao et al., 1997) and the muscarinic acetylcholine receptor M2 
(Hsieh and Farley, 2002) due to differentiation of these cells. I also observed a 
similar process where cells after 5 passages start to change morphology 




becoming smaller and epithelial-like shape (Fig. 4.5). Further experiment and 
characterisation would be necessary to confirm these observations. As a 
consequence, one way to overcome the loss of CGRP receptor would be to use 
exogenously expressed CLR and RAMP1 in TA-SMC, for example by using the 
lentivirus or adenovirus system. 
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4.6 Summary and Conclusion 
 I aimed to determine a suitable model to study the molecular mechanisms 
regulating CGRP-induced iNOS upregulation. I used primary smooth muscle cells 
isolated from rat thoracic aorta. I first confirmed that the cells isolated from the 
explants were SMC, by confirming the expression of a specific marker of SMC, α-
SMA, which is a characteristic constituent of the cytoskeleton of SMC (Skalli et al., 
1989). I then investigated whether these cells expressed mRNA for CLR and 
RAMP1. Using RT-PCR, I amplified products for CLR, RAMP1, RAMP2 and 
RAMP3. Thus, primary smooth muscle cells issued from rat thoracic artery 
express α-SMA, which confirms that they are smooth muscle cells; and express all 
the components for CGRP and ADM receptors. I then investigated whether CGRP 
promotes iNOS upregulation in TA-SMC. Indeed, I showed by Western blotting 
and by confocal microscopy that stimulation with CGRP induces a significant 
increase of iNOS expression. Moreover, when I incubated TA-SMC cells with U-
0126, a MEK inhibitor, CGRP-mediated iNOS upregulation was reduced, which 
suggests that iNOS production is ERK-dependent. Therefore, these results 
suggest that TA-SMCs are a suitable model to study the molecular mechanisms 
that regulate CGRP-induced iNOS production. Further experiments would be 
necessary to determine which particular ERK pathway is involved in CGRP-














Chapter 5. Post-Endocytic Sorting of 










5.1 Background and Objectives 
 GPCRs represent the largest family of membrane receptors and are involved in 
many diseases and dysfunctions. Understanding the molecular mechanisms that 
regulate GPCRs is critical for the development of new therapies. 
 CGRP and ADM are widely distributed throughout the body and play important 
roles in cardiovascular homeostasis, nociception and development. They are 
implicated in many diseases including migraine, heart failure and sepsis and as 
such mechanisms regulating their functions could be sites potential therapeutic 
intervention. However, as many aspects of the mechanisms regulating the 
receptors for ADM and CGRP are still poorly understood, it is then important to 
define these regulatory mechanisms. 
 CGRP and ADM receptors are heterodimeric complexes composed of a 
common class B GPCR, the calcitonin receptor-like receptor (CLR), and a receptor 
activity-modifying protein (RAMP). There are three types of RAMP: RAMP1, 
RAMP2 and RAMP3. Association with RAMP1 gives a high affinity CGRP 
receptor, whereas association with RAMP2 or RAMP3 gives high affinity ADM 
receptors. The same group, who identified ADM, showed that CGRP or ADM-
mediated stimulation induces CLR and RAMPs internalisation via clathrin-coated 
vesicles (Kuwasako et al., 2000). They also reported that after internalisation, CLR 
and RAMPs did not recycle back to the cell-surface and were targeted to acidic 
vesicles believed to be lysosomes. However, other studies showed that both 
CLR•RAMP3 (Bomberger et al., 2005) and CLR•RAMP1 (Cottrell et al., 2007) 
were recycled back to the cell-surface after transient stimulation. Still, little is 
known about the mechanisms regulating CLR•RAMP2. Therefore, the 








5.2 Characterisation of a HEK-CLR•RAMP2 Cell 
Line 
 Tagged HA-CLR and myc-RAMP2 were stably transfected into HEK-FLP cells 
to facilitate the study of the post-endocytic sorting of CLR•RAMP2. HEK cells are a 
good model as they are easy to manipulate e.g. transfection, overexpression of 
receptors, which gives strong signals to analyse. 
 
5.2.1 Expression of CLR•RAMP2 and Trafficking 
 ADM induces internalisation of CLR•RAMP2 in HEK cells (Kuwasako et al., 
2000). To determine if CLR•RAMP2 is expressed at the cell-surface, and 
internalises normally upon ADM stimulation, cell-surface receptors were labelled 
by incubating (30 min) HEK-CLR•RAMP2 cells with antibodies to extracellular CLR 
(HA) and RAMP1 (myc) epitopes. Cells were then stimulated with ADM (30 min). 
Receptors were then localised by immunofluorescence and confocal microscopy 
(Fig. 5.1). In unstimulated cells, CLR is localised at the cell-surface as well as 
RAMP2. Stimulation with ADM induces internalisation of CLR and RAMP2 
together in the same intracellular vesicles. Thus, CLR•RAMP2 is expressed at the 
cell-surface and ADM causes its internalisation, which suggest that CLR•RAMP2 
is functional. 
 
5.2.2 ADM-Induced ERK Activation 
 It has been shown that ADM induces ERK activation in many different cell types 
(Kim et al., 2003; Niu et al., 2004; Uzan et al., 2008). To determine if ADM was 
able to induce ERK activation in HEK-CLR•RAMP2, cells were incubated in 
serum-free medium and stimulated with ADM (0-60 min). Levels of phosphorylated 
ERK1 and 2 (pERK1 and pERK2) and ERK2 were determined by Western blotting. 
In unstimulated cells levels of pERK1-2 were low (Fig. 5.2). ADM treatment 
increased dramatically pERK1-2 with a peak at 2 min and then progressively 
decreased (Fig. 5.2B, 11.0±3.0 for pERK1; and 4.6±0.8 for pERK2 fold increase 
compare to basal at 2 min). This result shows that ADM is able to induce ERK 
activation in HEK-CLR•RAMP2 cells. Thus, CLR•RAMP2 forms a functional 
receptor in HEK cells and this model system represents a suitable model to study 
the regulation of CLR•RAMP2. 
  









Figure 5.1 ADM induces internalisation of CLR•RAMP2. HEK-CLR•RAMP2 cells were 
incubated (30 min, 37°C) with antibody against the extracellular epitope tag of CLR (HA) 
and RAMP2 (myc), stimulated with ADM (100 nM, 30 min). Immunoreactive proteins were 
then detected by immunofluorescence and analysed by confocal microscopy. In 
unstimulated cells, CLR and RAMP2 are present at the cell-surface (arrowheads). ADM 
induces trafficking of CLR and RAMP2 together in intracellular vesicles (arrows). Thus 
CLR•RAMP2 is expressed at the cell-surface of HEK-CLR•RAMP2 and internalised upon 
ADM stimulation. Scale bar = 10 µm. 
  







Figure 5.2 ADM induces ERK activation. (A) Serum-starved HEK-CLR•RAMP2 cells 
were stimulated with ADM (100 nM, 0-60 min) and levels of pERK1-2 and ERK2 
determined by Western blotting, where a representative blot is shown. Blots were 
quantified using ImageJ. (B) Ratios of pERK1:ERK2 and pERK2:ERK2 calculated and 
expressed as fold increase over basal, show that ADM induces a prompt increase level of 
pERK1-2 activation, which is sustained by decreases over time. n=4.  




5.3 ADM Induces Degradation of CLR•RAMP2 
 Compared to our understanding of the trafficking of CLR•RAMP1, nothing is 
known about the post-endocytic sorting of CLR•RAMP2. It has been shown that 
following a transient stimulation (1 h) with CGRP, CLR•RAMP1 recycles back to 
the cell-surface in about 6 h. However, following a continuous stimulation (16 h), 
CLR•RAMP1 is degraded and therefore does not recycle (Cottrell et al., 2007). 
 Moreover, it has been shown that CGRP is degraded in endosome by ECE-1, 
which then promotes the recycling of CLR•RAMP1 to the cell-surface (Padilla et 
al., 2007). As ADM is degraded by ECE-1 at endosomal pH (5.5) and not 
extracellular pH (7.4) (unpublished data, G. S. Cottrell) and that both CGRP and 
ADM receptor share a common GPCR, it was anticipated that following a transient 
stimulation with ADM, ECE-1 would regulate the recycling of CLR•RAMP2 to the 
cell-surface, similarly to CLR•RAMP1. 
 
5.3.1 Quantification of CLR•RAMP2 Degradation by Western Blot 
 To determine if CLR•RAMP2 traffics in a similar way to CLR•RAMP1, the 
degradation of CLR following both transient and continuous stimulation with ADM 
was examined. HEK-CLR•RAMP1 and HEK-CLR•RAMP2 cells were incubated 
with cycloheximide (CHX), an inhibitor of protein synthesis (Obrig et al., 1971), to 
block the production of newly synthesised receptors. Cells were transiently 
stimulated with CGRP or ADM (10 min), washed and incubated in agonist-free 
medium (16 h). Alternatively, cells were continuously stimulated with CGRP or 
ADM (16 h). Levels of CLR and β-actin (loading control) were quantified by 
Western blotting (Fig. 5.3). As expected for CLR•RAMP1, transient stimulation 
with CGRP did not induce degradation of CLR (Fig. 5.3B, 84.6±9.7% compared to 
control). However, when CLR•RAMP1 are continuously stimulated with CGRP, 
CLR are almost completely degraded (Fig. 5.3B, 13.0±2.7% compared to control). 
In contrast, stimulation of CLR•RAMP2 with ADM induced degradation of CLR 
irrespective of whether the stimulation was transient or continuous (Fig. 5.3D, 
25.1±6.9% (10 min) and 0.7±0.4% (16 h) compared to control). Thus, 
CLR•RAMP2 is degraded following stimulation with ADM and does not recycle. 
  







Figure 5.3 Effect of transient and continuous stimulation on levels of CLR•RAMP1 
and CLR•RAMP2. (A) HEK-CLR•RAMP1 and (C) HEK-CLR•RAMP2 cells incubated with 
CHX (140 µM), stimulated transiently with agonist (100 nM, 10 min), washed and 
incubated in agonist-free medium (16 h); or stimulated continuously with agonist (100 nM, 
16 h) and levels of CLR and β-actin determined by Western blotting. There were no 
signals for CLR in untransfected HEK-FLP cells, indicating specificity of the anti-CLR (HA) 
antibody. (A, C) Representative blots are shown. (B, D) Blots were quantified using 
ImageJ, ratios of CLR:β-actin calculated and results expressed as the % of appropriate 
unstimulated controls. (B) Continuous stimulation (16 h) with CGRP induces significant 
degradation of CLR. In contrast, transient stimulation (10 min) does not cause degradation 
of CLR. (D) Continuous and transient stimulation of ADM causes significant degradation 
of CLR. n=4, ***=p<0.001 compared to vehicle-treated cells at the same time point.  




5.3.2 Localisation of CLR•RAMP2 by Immunostaining 
 To confirm that CLR•RAMP2 does not recycle after transient stimulation, the 
localisation of CLR•RAMP2 was analysed by confocal microscopy. The same 
method has already been used to show that CGRP-induced CLR•RAMP1 recycles 
back to the cell-surface after 6 h recovery (Padilla et al., 2007). Cell-surface 
receptors were labelled by incubating (30 min) HEK-CLR•RAMP2 cells with 
antibodies to extracellular RAMP1 (myc) epitopes. Cells were then stimulated with 
ADM (10 min), washed and incubated in ADM-free medium (0-6 h). Receptors 
were then localised by immunofluorescence and confocal microscopy (Fig. 5.4). In 
unstimulated cells, RAMP2 is at the cell-surface. Stimulation with ADM induces 
internalisation of RAMP2 to intracellular vesicles. After 6 h of recovery, the 
receptor has not recycled to the membrane. Moreover, the signal has almost 
completely disappeared, showing that the antibodies have been degraded, which 
suggests that the receptor is also degraded. Thus, CLR•RAMP2 does not recycle 
after transient stimulation. 
 
5.4 ADM Induces Ubiquitination of CLR, but not 
RAMP2 
 Ubiquitin is a small regulatory protein which can be covalently attached to lysine 
residues of targets proteins. Modification by ubiquitination plays important roles in 
the life of a GPCR (reviewed by (Hanyaloglu and von Zastrow, 2008; Marchese et 
al., 2008)), such as to target GPCR for degradation. Therefore, as ADM induces 
degradation of CLR, it was investigated whether ADM also causes ubiquitination of 
CLR•RAMP2. To determine if CLR•RAMP2 was ubiquitinated, HEK-CLR•RAMP2 
cells were stimulated with ADM (0-60 min) and CLR and RAMP2 
immunoprecipitated and analysed by Western blotting for the presence of 
ubiquitin. In unstimulated HEK-CLR•RAMP2 cells there was a low basal level of 
ubiquitination of CLR compared to untransfected cells (Fig. 5.5). ADM stimulation, 
after 60 minutes, ADM induces further ubiquitination of CLR (Fig. 5.5C, 4.7±1.2 
fold increase over basal). Under the same conditions ubiquitination of RAMP2 was 
not observed (Fig. 5.5B). There were no signals in untransfected HEK-FLP cells 
indicating specificity of the immunoprecipitating antibodies. Thus, ADM induces 
ubiquitination of CLR, but not RAMP2. 
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Figure 5.5 ADM induces ubiquitination of CLR. (A, B) HEK-CLR•RAMP2 cells were 
stimulated with ADM (100 nM, 0-60 min) and CLR and RAMP2 immunoprecipitated with 
anti-CLR (RK11) and anti-myc antibodies. Blots were probed for levels of ubiquitin, CLR 
(anti-HA) and RAMP2 (anti-myc). Immunoreactive bands were quantified using ImageJ. 
Representative blots are shown. (C) Ratios of Ub:CLR calculated and results expressed 
as fold over the unstimulated control. There were no signals in untransfected HEK cells, 
indicating specificity of the immunprecipitating antibodies. Basal levels of ubiquitinated 
CLR are low compared to untransfected cells. ADM significantly further enhances 
ubiquitination of CLR at 60 min. (B) ADM does not induce ubiquitination of RAMP2. n=4, 
NT=non transfected *=p<0.05 compared to vehicle-treated cells at the same time point.  




5.5 Construction of CLR Mutant: CLRΔ9KR 
 ADM induces ubiquitination of CLR. Ubiquitin is commonly known for its role to 
target GPCRs to lysosome to be degraded, such as the β2-AR, CXCR4 and PAR2 
(Jacob et al., 2005; Marchese et al., 2003; Shenoy et al., 2001). However, 
ubiquitin has been show to have other roles. In yeast, ubiquitination is required to 
drive internalisation of the GPCR Ste2 (Hicke and Riezman, 1996), whereas for 
the ubiquitination of δOR, it affects the rate of degradation of the receptor (Hislop 
et al., 2009). In order to determine the role of ADM-induced CLR ubiquitination, a 
CLR mutant was made. By using a site-directed mutagenesis method, all 
intracellular facing lysine residues (site of binding of ubiquitin to its target protein) 
of CLR were replaced by arginine residues. 
 
5.5.1 Identification of the Lysine Residues and Design of the Method 
 The sequence of CLR was retrieved from UniProtKB database (Q16602). All 
lysine residues were then identified on the predicted intracellular loops and the C-
terminal tail of CLR (Fig. 5.6). In total, 9 lysine residues were identified. 
 Lysine residues are defined by the genetic code by two sets of codon: AAA or 
AAG, while arginine residues are defined by six sets of codon: AGA, AGG, CGU, 
CGC, CGA or CGG. However, only the two sets of codon AGA and AGG are 
relevant to substitute the middle nucleic acid to change a lysine into arginine: 
  AAA or AAG = Lysine 
 
  AGA or AGG = Arginine 
 
 The PCR site-directed mutagenesis method was employed to create the CLR 
mutant (Ho et al., 1989). This method consists of designing sets of oligonucleotide 
primers, overlapping the lysine residues, which contain the nucleic acid 
substitution coding for arginine. This method requires multistep PCR and 
restriction site nearby the mutagenesis site in order to divide the sequence into 
several fragments. As the 9 lysine residues are spread along the sequence, three 
unique restriction sites were identified within the sequence to facilitate the design 
of the primers. Thus, the restriction sites lead to the formation of three main 
fragments. 
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5.5.2 Production of the Different Fragment by PCR Site-Directed 
Mutagenesis Method 
 In order to construct this mutant, the plasmid pcDNA5/FRT-IgκHACLR was 
used as a template. 
 
5.5.2.1 Production of the First Fragment 
 For the production of the first fragment, a two-step PCR was required (Fig. 5.7). 
Two pairs of oligonucleotide primers were designed, where in red is represented 
the codon containing the substitution that codes for arginine residue. The blue 
sequence represents the restriction site: 
− Primer 1: rCLRBamHIfor  5’-TCATGCAGGATCCCATTC-3’ 
 
− Primer 2: rCLRK167Rrev  5’-TTTATTTCAGGAGCCTAAGT-3’ 
 
− Primer 3: rCLRK249Kfor  5’-TTGCAGAGAGGCAGCACTTG-3’ 
 
− Primer 4: rCLRAflIIIrev 5’-ATTGTACGTGTTCTCATCACC-3’ 
 
 First, two PCR were performed simultaneously using primers 1 and 2 that 
resulted on the formation of a product called 1-2; and primers 3 and 4 that formed 
the product 3-4. Then the products 1-2 and 3-4 were used as mega-primer in the 
second PCR to form the fragment 1-4. The final product was then digested using 
BamH I and Afl III enzymes and ready to be ligated. 
 
5.5.2.2 Production of the Second Fragment 
 For the production of the second fragment, a two-step PCR was required (Fig. 
5.8). Three oligonucleotide primers were designed, where in red is represented the 
codon containing the substitution that codes for arginine residue. The blue 
sequence represents the restriction site: 
− Primer 5: rCLRAflIIIK319,321Rfor    
5’-ATATTGTACGTGTTCTCATCACCAGGTTGAGAGTTACAC-3’ 
 
− Primer 6: rCLRK333Rfor  5’-TCTACATGAGAGCTGTAAGAG-3’ 
 
− Primer 7: rCLRKpnIrev  5’-CATCTTGGTACCACTACTTG-3’ 




 First, PCR using primers 6 and 7 was performed that resulted on the formation 
of a product called 6-7. Then in the second PCR, the primer 5 and the product 6-7 
were used to form the fragment 5-7. The final product was then digested using Afl 
III and Kpn I enzymes and ready to be ligated. 
 
5.5.2.3 Production of the Third Fragment 
 Finally, for the production of the third and last fragment, a two-step PCR was 
required (Fig. 5.9). Three oligonucleotide primers were design, where in red is 
represented the codon containing the substitution that codes for arginine residue. 
The blue sequence represents the restriction site: 
− Primer 8: rCLRKpnIfor  5’-CATCTTGGTACCACTACTTG-3’ 
 
− Primer 9: rCLRK403Rrev  5’-CCAGTATAGAATCCAATTTG-3’ 
 




 First, PCR was performed using the primers 8 and 9 that resulted on the 
formation of a product called 8-9. Then the product 8-9 and the primer 10 were 
used in the second PCR to form the fragment 8-10. The final product was then 
digested using Kpn I and Not I enzymes and ready to be ligated. 
 
  












Figure 5.7 Schematic representation of the production of the fragment 1-4. The 
pcDNA5/FRT-IgκHACLR was used as template, where the rectangular box 
represents the sequence of CLR with Igκ and HA tags highlighted in grey. The 
lysine residues have been highlighted in green and the arginine residues in red. A 
two-step PCR led to the formation of the first fragment 1-4 (circle). Two 
simultaneously PCR were performed, using the primers (semi-arrows, with the red 
segment representing the substitution of arginine) 1 and 2 to produce the fragment 
1-2 and primers 3 and 4 to produce the fragment 3-4. The fragments 1-2 and 3-4 
were used as mega-primers to perform the second PCR, which formed the fragment 
















Figure 5.8 Schematic representation of the production of the fragment 5-7. The 
pcDNA5/FRT-IgκHACLR was used as template, where the rectangular box 
represents the sequence of CLR with Igκ tag highlighted in grey. The lysine residues 
have been highlighted in green and the arginine residues in red. A two-step PCR led 
to the formation of the second fragment 5-7 (circle). A PCR was performed, using 
the primers (semi-arrows, with the red segment representing the substitution of 
arginine) 6 and 7, to produce the fragments 6-7. The primer 5 and the fragments 6-7 
were used as mega-primers to perform the second PCR, which formed the fragment 
5-7 containing the arginine-coding sequence. The restriction sites are highlighted in 
blue. 
  














Figure 5.9 Schematic representation of the production of the fragment 8-10. 
The pcDNA5/FRT-IgκHACLR was used as template, where the rectangular box 
represents the sequence of CLR with Igκ tag highlighted in grey. The lysine residues 
have been highlighted in green and the arginine residues in red. A two-step PCR led 
to the formation of the third fragment 8-10 (circle). A PCR was performed, using the 
primers (semi-arrows, with the red segment representing the substitution of arginine) 
8 and 9, to produce the fragments 8-9. The fragments 8-9 and the primer 10 were 
used as mega-primers to perform the second PCR, which formed the fragment 8-10 
containing the arginine-coding sequence. The restriction sites are highlighted in 
blue. 
  




5.5.2.4 Ligation of the Plasmid pcDNA5/FRT-IgκHACLRΔ9KR 
 The vector pcDNA5/FRT-IgκHACLR was digested by using the restriction 
enzymes BamH I and Not I. The digest was then run on a 1% agarose gel. BamH I 
and Not I cut only once in the vector, so two fragments was obtained on the gel: 
one of ~5000 base pair (bp) that contains the vector sequence and one of ~1200 
bp that contain the CLR sequence. The higher fragment was then excised, which 
contains the vector sequence. Then the three mutated-fragments and the vector 
where ligated together (Fig. 5.10). 
 
5.5.3 Production and Transfection of the Plasmid pcDNA5/FRT-
IgκHACLRΔ9KR•RAMP2 into HEK Cells 
 The plasmid was then transformed into MACH1 bacterium. The DNA of a 
positive clone was then purified to yield a pcDNA5/FRT-IgκHACLRΔ9KR vector. 
Finally, the plasmid was transfected into HEK-FLP and cells were selected to 
express the receptor in a stable manner. 
  














Figure 5.10 Schematic representation of the ligation procedure. The vector 
pcDNA5/FRT-IgκHACLR was cut open using BamH I and Not I enzyme. The CLR 
sequence was discarded and the vector sequence purified and ready to be mixed 
with the three mutated-fragments previously produced. All the fragments were 
ligated together, and the product was transform into MACH1 bacterium. After 
ligation the product forms a pcDNA5/FRT-IgκHACLRΔ9KR vector. The restriction 
enzyme sites are in blue and the substituted-arginine in red. 
 
  




5.6 Characterisation of HEK-CLRΔ9KR•RAMP2 
Cell Line 
 ADM induces ubiquitination of CLR. Ubiquitin is commonly known for its role to 
target GPCRs to lysosome to be degraded, such as the CXCR4 (Marchese et al., 
2003) and PAR2 (Jacob et al., 2005). However, ubiquitin has been show to 
promote other responses. In yeast, ubiquitination is required to drive internalisation 
of the GPCR Ste2 (Hicke and Riezman, 1996), whereas for the δOR ubiquitination 
affects the rate of degradation (Hislop et al., 2009). In order to determine the role 
of ADM-induced ubiquitination, a CLR mutant was made (see 5.6) and stably 
transfected into HEK-FLP cells. The receptor was then characterised and tested to 
confirm that it was functional. 
 
5.6.1 CLRΔ9KR•RAMP2 Expression and Trafficking 
 ADM induces internalisation of CLR•RAMP2 in HEK cells. To determine if 
CLRΔ9KR•RAMP2 internalises normally, HEK-CLRΔ9KR•RAMP2 cells were 
stimulated with ADM (30 min) and CLRΔ9KR (HA) simultaneously localised with 
RAMP2 (myc) by immunofluorescence and confocal microscopy (Fig. 5.11). In 
unstimulated cells, CLRΔ9KR is localised at the cell-surface as well as RAMP2. 
Stimulation with ADM induces internalisation of CLRΔ9KR together with RAMP2 in 
the same intracellular vesicles. Thus, CLRΔ9KR•RAMP2 is expressed at the cell-
surface and ADM causes its internalisation, which suggest that CLRΔ9KR•RAMP2 
is functional. 
 
5.6.2 ADM-Induced ERK Activation in HEK-CLRΔ9KR•RAMP2 Cells 
 ADM induces ERK activation in HEK-CLR•RAMP2. To determine if ADM 
induces ERK activation in HEK-CLRΔ9KR•RAMP2, cells were incubated in serum-
free medium and stimulated with ADM (0-60 min). Levels of pERK1-2 and ERK2 
were determined by Western blotting. In unstimulated cells levels of pERK1-2 
were low (Fig. 5.12). ADM treatment increased dramatically pERK1-2 with a peak 
at 2 min and then progressively decreased (Fig. 5.12B, 17.5±1.7 for pERK1; and 
8.1±3.8 for pERK2 fold increase compare to basal at 2 min). This result shows that 
ADM is able to induce ERK activation in HEK-CLRΔ9KR•RAMP2 cells. 
  










Figure 5.11 ADM induces internalisation of CLRΔ9KR•RAMP2. HEK-
CLRΔ9KR•RAMP2 cells were stimulated with ADM (100 nM, 30 min), immunoreactive 
proteins were detected by immunofluorescence and analysed by confocal microscopy. In 
unstimulated cells, CLRΔ9KR and RAMP2 are co-localised at the cell-surface 
(arrowheads). ADM induces internalisation of CLRΔ9KR and RAMP2 together in the same 
intracellular vesicles (arrows). Thus CLRΔ9KR•RAMP2 is expressed at the cell-surface 
and ADM induces its internalisation. Scale bar = 10 µm. 
  








Figure 5.12 ADM induces ERK activation in HEK-CLRΔ9KR•RAMP2. (A) Serum-
starved HEK-CLRΔ9KR•RAMP2 cells were stimulated with ADM (100 nM, 0-60 min) and 
levels of pERK1-2 and ERK2 determined by Western blotting, where a representative blot 
is shown. Blots were quantified using ImageJ. (B) Ratios of pERK1:ERK2 and 
pERK2:ERK2 calculated and expressed as fold increase over basal, show that ADM 
induces a prompt increase level of pERK1-2 activation, which is sustained by decreases 
over time. n=3. 
  




5.6.3 ADM does not Induce CLRΔ9KR Ubiquitination 
 A lysine-less mutant of CLR was made to study the role of ubiquitination in the 
regulation of CLR•RAMP2. To verify that CLRΔ9KR•RAMP2 was not ubiquitinated, 
HEK-CLRΔ9KR•RAMP2 cells were stimulated with ADM (0-60 min) and CLRΔ9KR 
immunoprecipitated and analysed by Western blotting for the presence of 
ubiquitin. Either in unstimulated or stimulated HEK-CLRΔ9KR•RAMP2 cells, the 
presence of ubiquitination of CLRΔ9KR was not detected (Fig. 5.13). There were 
no signals in HEK-FLP cells for CLRΔ9KR indicating specificity of the 
immunoprecipitating antibodies. Thus, ADM does not induce ubiquitination of 
CLRΔ9KR. 
 
5.7 Determination of the Role of Ubiquitin in 
CLR•RAMP2 Post-Endocytic Sorting 
 ADM stimulation of HEK-CLRΔ9KR•RAMP2 induces ERK activation and 
CLRΔ9KR•RAMP2 internalisation, suggesting that this receptor is fully functional. 
Moreover, ADM does not induce ubiquitination of CLRΔ9KR. Therefore, HEK-
CLRΔ9KR•RAMP2 is suitable model to study the role of ubiquitination in the post-
endocytic sorting of CLR•RAMP2. 
 
5.7.1 ADM-Induced Trafficking of CLR•RAMP2 and 
CLRΔ9KR•RAMP2 
5.7.1.1 Trafficking to Early Endosomes 
 Many GPCRs undergo agonist-induced endocytosis in order to terminate 
GPCR-dependent cell membrane signalling (reviewed in (Doherty and McMahon, 
2009; Ferguson, 2001)). Generally, following internalisation, GPCRs traffic to a 
sorting vesicle named early endosome, where they can either be targeted to 
lysosome for degradation, or redirected to the cell-surface to recycle (reviewed in 
(Mellman, 1996)). To determine if CLR•RAMP2 and CLRΔ9KR•RAMP2 traffics to 
early endosomes, HEK-CLR•RAMP2 and HEK-CLRΔ9KR•RAMP2 cells were 
stimulated with ADM (30 min) and CLR and CLRΔ9KR (RK11) simultaneously 
localised with EEA1 (an early endosome marker) by immunofluorescence and 
confocal microscopy (Fig. 5.14). In unstimulated cells, both CLR (Fig. 5.14A) and 
CLRΔ9KR (Fig. 5.14B) are localised at the cell-surface and EEA1 is detected in 
intracellular vesicles. Stimulation with ADM induces internalisation of CLR and 
CLRΔ9KR to co-localise with EEA1-positive vesicles. Thus, ADM causes 
trafficking of CLR•RAMP2 and CLRΔ9KR•RAMP2 to early endosomes, which 




suggest that ubiquitin is not involved in the trafficking of CLR•RAMP2 to 
endosome. 
 
5.7.1.2 Trafficking to Lysosomes 
 To be degraded, GPCRs are generally targeted to lysosomes via ubiquitin-
dependent mechanisms such as the CXCR4 receptor (Marchese and Benovic, 
2001) or -independent mechanisms such as CLR•RAMP1 (Cottrell et al., 2007). To 
determine if CLR•RAMP2 traffics to the lysosome in an ubiquitin-dependent 
manner, HEK-CLR•RAMP2 and HEK-CLRΔ9KR•RAMP2 cells were incubated (30 
min) with lysosomal protease inhibitors (pepsatin A, E-64d and Z-PAD) to prevent 
possible degradation of the receptor and facilitate visualisation in lysosome. Cells 
were then stimulated with ADM (4 h) and CLR and CLRΔ9KR (RK11) 
simultaneously localised with LAMP1 (a lysosomal marker) by 
immunofluorescence and confocal microscopy (Fig. 5.15). In unstimulated cells, 
both CLR (Fig. 5.15A) and CLRΔ9KR (Fig. 5.15B) are localised at the cell-surface 
and LAMP1 is detected in intracellular vesicles. Stimulation with ADM induces 
internalisation of CLR and CLRΔ9KR to co-localise with LAMP1-positive vesicles. 
Thus, ADM causes trafficking of CLR•RAMP2 and CLRΔ9KR•RAMP2 to 
lysosomes, which suggests that ubiquitin is not involved in the ADM-induced traffic 
of CLR•RAMP2 to lysosomes. 
  








Figure 5.13 ADM does not induce ubiquitination of CLRΔ9KR. HEK-
CLRΔ9KR•RAMP2 cells were stimulated with ADM (100 nM, 0-60 min) and CLRΔ9KR 
immunoprecipitated with anti-CLR (RK11). Blots were probed for levels of ubiquitin and 
CLR (anti-HA). Representative blots are shown. Probing for Ubiquitin shows no signal in 
treated cells, indicating that ADM does not induce ubiquitination of CLRΔ9KR. Gel was 
reprobed for CLR (anti-HA) and shows strong signal for CLR. There were no signals in 
untransfected HEK cells, indicating specificity of the immunprecipitating antibodies. n=4. 
  





Figure 5.14 CLR•RAMP2 and CLRΔ9KR•RAMP2 traffic to early endosomes upon 
ADM stimulation. HEK-CLR•RAMP2 (A) and HEK-CLRΔ9KR•RAMP2 (B) cells were 
stimulated with ADM (100 nM, 0-30 min), immunoreactive proteins were detected by 
immunofluorescence and analysed by confocal microscopy. In unstimulated cells, CLR 
and CLRΔ9KR are present at the cell-surface (arrowheads) and EEA1 (early endosomal 
marker) is detected in intracellular vesicles. ADM induces internalisation of both CLR and 
CLRΔ9KR to co-localise with EEA1-positive vesicles (arrows). Thus, ADM induces traffic 
of CLR•RAMP2 and CLRΔ9KR•RAMP2 to early endosomes, which suggests that ubiquitin 
is not involved in the traffic of CLR•RAMP2 to endosomes. Scale bar = 10 µm.  





Figure 5.15 CLR•RAMP2 and CLRΔ9KR•RAMP2 traffic to lysosomes upon ADM 
stimulation. HEK-CLR•RAMP2 (A) and HEK-CLRΔ9KR•RAMP2 (B) cells were incubated 
with lysosomal protease inhibitors: pepsatin A (10 µM), E-64d (10 µM) and Z-PAD (200 
µM), stimulated with ADM (100 nM, 4 h) and immunoreactive proteins detected by 
immunofluorescence and analysed by confocal microscopy. In unstimulated cells, CLR 
and CLRΔ9KR are present at the cell-surface (arrowheads) and LAMP1 (lysosomal 
marker) is detected in intracellular vesicles. ADM induces internalisation of both CLR and 
CLRΔ9KR to co-localise with LAMP1-positive vesicles (arrows). Thus, ADM induces traffic 
of CLR•RAMP2 and CLRΔ9KR•RAMP2 to lysosomes, which suggest that ubiquitin is not 
involved in the traffic of CLR•RAMP2 to lysosomes. Scale bar = 10 µm.  




5.7.2 ADM-Induced Degradation of CLR•RAMP2 is Ubiquitin-
Independent 
5.7.2.1 ADM Induces Degradation of CLR•RAMP2 and CLRΔ9KR•RAMP2 
 ADM promotes trafficking of both CLR•RAMP2 and CLRΔ9KR•RAMP2 to 
lysosomes. Given that CLRΔ9KR•RAMP2 is not ubiquitinated, it was concluded 
that ubiquitination is not involved in the trafficking of CLR•RAMP2 to lysosomes. 
Next, the role of CLR ubiquitination was investigated, whether it is involved in the 
degradation of CLR. As CLR is ubiquitinated, a cell-surface biotinylation assay 
was used to monitor the degradation of CLR and CLRΔ9KR, as CHX can affect 
the pool of free ubiquitin within the cell (Hanna et al., 2003). HEK-CLR•RAMP2 
and HEK-CLRΔ9KR•RAMP2 cells were stimulated with ADM continuously (16 h) 
or transiently (30 min) and incubated in agonist-free medium (0-16 h). Levels of 
CLR, CLRΔ9KR, RAMP2 and transferrin receptor (TfR) (loading control: this 
receptor internalises and recycles back to the cell-surface (reviewed in (Mayle et 
al., 2012))) were determined by Western blotting (Fig. 5.16 and Fig. 5.17). 
Following continuous stimulation with ADM both CLR and CLRΔ9KR are similarly 
degraded (Fig. 5.16B, 7.5±3.5% (CLR) and 5.4±1.9% (CLRΔ9KR) of control). 
RAMP2 was also degraded to similar extents in both cell lines (Fig. 5.17B, 
20.7±4.9% (CLR) and 14.2±7.5% (CLRΔ9KR) of control). In transient stimulation 
with ADM in both CLR and CLRΔ9KR are similarly degraded (Fig. 5.16D, 
74.2±2.6% (CLR) and 60.6±8.0% (CLRΔ9KR) of control); RAMP2 was also 
degraded to similar extents in both cell lines (Fig. 5.17D, 72.1±0.8% (CLR) and 
60.0±2.9% (CLRΔ9KR) of control). Thus, ADM induces in both continuous and 
transient stimulation, degradation of CLR•RAMP2 and CLRΔ9KR•RAMP2, which 
suggests that ubiquitination is not involved in CLR•RAMP2 degradation. 
  





Figure 5.16 ADM-induced degradation of CLR is ubiquitin-independent. Cell-surface 
proteins of HEK-CLR•RAMP2 and HEK-CLRΔ9KR•RAMP2 cells were labelled with biotin. 
The cells were then stimulated with ADM (100 nM) continuously (16 h) (A, B) or 
transiently (30 min) (C, D). Cells were lysed and biotinylated proteins isolated by 
immunoprecipitation with Neutravidin. Levels of CLR, CLRΔ9KR and TfR were then 
analysed by Western blotting. (A, C) Representative blots are shown. Blots were 
quantified using ImageJ and ImageQuantTL, ratios of CLR:TfR calculated and results 
expressed as % of expression compared to the appropriate unstimulated control. In 
continuous stimulation (B), both CLR and CLRΔ9KR are almost completely degraded. In 
transient stimulation (D), CLR and CLRΔ9KR are significantly degraded compared to 
control. Thus, ADM induces degradation of CLR and CLRΔ9KR, which suggests that 
ubiquitin is not involved in the degradation of CLR. n≥3, **=p<0.01 and ***=p<0.001 
compared to basal of the same cell line.  





Figure 5.17 ADM-induced degradation of RAMP2 is ubiquitin-independent. Cell-
surface proteins of HEK-CLR•RAMP2 and HEK-CLRΔ9KR•RAMP2 cells were labelled 
with biotin. The cells were then stimulated with ADM (100 nM) continuously (16 h) (A, B) 
or transiently (30 min) (C, D). Cells were lysed and biotinylated proteins isolated by 
immunoprecipitation with Neutravidin. Levels of RAMP2 and TfR in the isolated protein 
samples were then analysed by Western blotting. (A, C) Representative blots are shown. 
Blots were quantified using ImageJ and ImageQuantTL, ratios of RAMP2:TfR calculated 
and results expressed as % of expression compared to the appropriate unstimulated 
control. In continuous stimulation (B), in both cell lines, RAMP2 is largely degraded. In 
transient stimulation (D), in both cell lines, RAMP2 is significantly degraded compared to 
control. Thus, ADM induces degradation of RAMP2 in both cell lines, which suggests that 
ubiquitin of CLR is not involved in the degradation of RAMP2. n≥3, **=p<0.01 and 
***=p<0.001 compared to basal of the same cell line.  




5.7.2.2 Cell-Surface Expression and Internalisation of CLR•RAMP2 and 
CLRΔ9KR•RAMP2 
 In previous experiment looking at the degradation of CLR•RAMP2 using CHX 
(see 5.3.1), transient ADM stimulation was shown to induce larger amount of 
degradation (see Fig. 5.3A, 28.2±5.4% expression over control), than observed in 
the biotinylation assay experiments (see Fig. 5.16D, 74.2±2.6% expression over 
control). To investigate this difference, the level of cell-surface expression and 
internalisation upon ADM stimulation of CLR•RAMP2 and CLRΔ9KR•RAMP2, 
were investigated. HEK-CLR•RAMP2 and HEK-CLRΔ9KR•RAMP2 cells were 
incubated (30 min) with an antibody (myc) against the receptor, stimulated with 
ADM (30 min) and incubated in agonist-free medium (0-1 h). Cells were then 
detached, suspended in ice-cold PBS and incubated (1 h, 4°C) with 
immunoreactive protein. Cells were then analysed using FACS flow cytometry 
method (Fig. 5.18). The measure of the fluoresence intensity of each cell 
population shows that in unstimulated cells, the level of fluorescence intensity is 
higher compared to stimulated cells (Fig. 5.18A). The quantification of the mean 
fluorescence intensity of all the different cell population reveals a significant 
reduction of intensity in both cell lines upon stimulation (Fig. 5.18B, 61.3±1.1% at 
30 min vs 50.1±2.0% at 30 min+1 h Recovery (CLR) and 60.8±1.7% at 30 min vs 
54.4±3.1% at 30 min+1 h Recovery (CLRΔ9KR); expression over unstimulated). 
Those results suggest that after stimulation, both receptors CLR•RAMP2 and 
CLRΔ9KR•RAMP2 are internalised. Furthermore, those experiments show that 
HEK-CLRΔ9KR•RAMP2 express less receptors at the cell-surface than HEK-
CLR•RAMP2 (Fig. 5.18C, 82.4±0.4% of CLRΔ9KR•RAMP2 over CLR•RAMP2). 
Altogether, transient ADM stimulation promotes internalisation of CLR•RAMP2 
(about 40%), which coincide with the percentage of receptor degraded (about 30-
40%), as seen in the previous experiment (see Fig. 5.16). Thus, all receptors 
internalised are degraded, which confirms the results of the CHX experiment (see 
Fig. 5.3). 
  





Figure 5.18 Cell-surface expression and internalisation of CLR•RAMP2 and 
CLRΔ9KR•RAMP2 upon ADM stimulation. HEK-CLR•RAMP2 and HEK-
CLRΔ9KR•RAMP2 cells were incubated with myc antibody (30 min, 37°C), stimulated with 
ADM (100nM, 30 min) and incubated in agonist-free medium (0-1 h). Cells were then 
detached, suspended in ice-cold PBS and incubated (1 h, 4°C) with immunoreactive 
protein. Cells were then analysed using FACS flow cytometry method. (A) Examples of 
cell population stimulated with ADM or not are shown. (B) The mean fluorescence 
intensity of each condition (as indicated in the figure) was quantified and expressed as % 
of unstimulated cell population. Those results show a decrease of fluorescence intensity 
upon ADM stimulation compared to unstimulated population. (C) The cell-surface 
expression of both cell line were quantify and expressed as % of CLR•RAMP2 population. 
Those results show that in HEK-CLRΔ9KR•RAMP2 less receptors are expressed at the 
cell-surface than in HEK-CLR•RAMP2. n=4, * represent control vs stimulated where 
***=p< 0.001.  




5.7.3 ADM-Induced ERK Activation is Ubiquitin-Independent 
 It has been shown for IGF-1 receptor, that ubiquitination was involved in the 
activation of ERK (Vasilcanu et al., 2008). To determine the role of ubiquitin in the 
ADM-induced ERK activation, HEK-CLR•RAMP2 and HEK-CLRΔ9KR•RAMP2 
cells were stimulated with ADM (10 min), incubated in agonist-free medium (0-110 
min) and levels of pERK1-2 and ERK2 determined by Western blotting. In 
unstimulated CLR•RAMP2 and CLRΔ9KR•RAMP2 cells, levels of pERK1-2 were 
low (Fig. 5.19). ADM (10 min) caused a prompt increase in levels of pERK1-2 in 
both cell lines. However, the increase in CLRΔ9KR•RAMP2 cells was reduced 
compared to CLR•RAMP2 cells, but not significantly for both pERK1 (Fig. 5.19B, 
3.9±1.1 (CLR) and 2.7±0.4 (CLRΔ9KR) for pERK1 and 3.9±0.7 (CLR) and 2.9±0.3 
(CLRΔ9KR) for pERK2; fold-increase at 10 min compare to basal). When 
expressed as % of maximal response they were no difference in the magnitude or 
duration of pERK1 and 2 levels in both cell lines (Fig. 5.19D, pERK1 51.5±9.6% 
(CLR) and 62.0±2.0% (CLRΔ9KR); and Fig. 5.19E, pERK2 46.3±8.6% (CLR) and 
54.7±6.7% (CLRΔ9KR) at 110 min of maximal (10 min) response). Furthermore, 
the basal level of pERK was not affected by CLRΔ9KR•RAMP2 (Fig. 5.19C, 
pERK1 1.0±0.05 and pERK2 1.1±0.1 fold increase over CLR•RAMP2). Thus, ADM 
induces similar level of phosphorylated ERK1 and 2, which suggests that ubiquitin 
is not involved in the ADM-induced ERK activation. 
 
5.7.4 Kinetics of ADM-Induced Degradation of CLR•RAMP2 and 
CLRΔ9KR•RAMP2 
 Ubiquitin of CLR does not seem to be involved in the degradation of 
CLR•RAMP2. However, it has been shown for the δ-opioid receptor, that 
ubiquitination of the receptor stimulates its degradation but is not essential (Henry 
et al., 2011; Hislop et al., 2009). To investigate this possibility, degradation of the 
receptor was looked for at an earlier time point. 
  





Figure 5.19 Ubiquitination does not affect ADM-induced ERK activation. (A) Serum-
starved HEK-CLR•RAMP2 and HEK-CLRΔ9KR•RAMP2 cells stimulated with ADM (100 
nM, 10 min), washed, incubated in ADM-free medium (0-110 min) and levels of pERK1-2 
and ERK2 determined by Western blotting. Blots were quantified using ImageQuantTL. 
Representative blots are shown. (B) The maximal ADM-induced phosphorylation of ERK1 
and 2, expressed in fold-increase over basal of pERK1:ERK2 and pERK2:ERK2, show no 
significant difference between both cell lines. (C) The effect of CLRΔ9KR•RAMP2 on the 
basal of pERK1-2, expressed in fold-increase over the basal, show no difference of pERK 
basal compared to CLR•RAMP2. The ADM-induced ERK activation, expressed as % 
maximal of response (10 min) of pERK1:ERK2 (D) and pERK2:ERK2 (E) are similar in 
both cell line. Thus, ADM induces similar level of ERK activation in both cell line, 
indicating that ubiquitin is not involved in ADM-induced ERK activation in HEK cells. n=3.  




5.7.4.1 ADM Stimulation for 8 Hours 
 HEK-CLR•RAMP2 and HEK-CLRΔ9KR•RAMP2 cells were stimulated with ADM 
continuously (8 h). Levels of CLR, CLRΔ9KR, RAMP2 and TfR were determined 
by Western blotting (Fig. 5.20) and results express as % of expression compared 
to control. After 8 h stimulation, ADM induces in both cell line, almost complete 
degradation of CLR and CLRΔ9KR (Fig. 5.20B, 29.1±20.0% (CLR) and 
12.5±8.9% (CLRΔ9KR) over control); and RAMP2 (Fig. 5.20D, 9.2±4.0% (CLR) 
and 26.6±2.6% (CLRΔ9KR) over control). Although, there were no significant 
differences between the degradation of CLR and CLRΔ9KR, the results show a 
significant difference in the degradation of RAMP2 between both cell lines, 
suggesting that the degradation of RAMP2 in the lysine-less mutant is slower than 
in the WT at 8 h. Altogether, these results show that ADM induces similar 
degradation profile in both cell lines, which suggests that ubiquitination is not 
involved in the degradation of CLR•RAMP2 at 8 h. 
 
5.7.4.2 ADM Stimulation for 4 Hours 
 HEK-CLR•RAMP2 and HEK-CLRΔ9KR•RAMP2 cells were stimulated with ADM 
continuously (4 h). Levels of CLR, CLRΔ9KR, RAMP2 and TfR were determined 
by Western blotting (Fig. 5.21) and results express as % of expression compared 
to control. After 4 h stimulation, ADM induces significant degradation of CLR, 
whereas CLRΔ9KR is untouched (Fig. 5.21B, 64.2±3.5% (CLR•RAMP2) vs 
109.5±10.3% (CLRΔ9KR•RAMP2) over control); and significant degradation of 
RAMP2 in both cell lines (Fig. 5.21D, 47.4±8.5% (CLR•RAMP2) and 85.9±4.9% 
(CLRΔ9KR•RAMP2) over control). However, ADM-induced degradation of 
CLR•RAMP2 is significantly higher than CLRΔ9KR•RAMP2, for both component of 
the receptor. These results show that ADM induces a greater degradation in the 
WT cell line than in the mutant, which suggests that ubiquitination is involved in 
the degradation of CLR•RAMP2 at 4 h. Altogether, the role of ubiquitination of CLR 
is involved in the rate of degradation of CLR, by accelerating the process. 
  





Figure 5.20 Ubiquitination is not involved in ADM-induced degradation of 
CLR•RAMP2 at 8 h. Cell-surface proteins of HEK-CLR•RAMP2 and HEK-
CLRΔ9KR•RAMP2 cells were labelled with biotin. The cells were then stimulated with 
ADM (100 nM) continuously (8 h). Cells were lysed and biotinylated proteins isolated by 
immunoprecipitation with Neutravidin. Levels of CLR, CLRΔ9KR, RAMP2 and TfR in the 
isolated protein samples were then analysed by Western blotting. (A, C) Representative 
blots are shown. (B, D) Blots were quantified using ImageJ and ratios of CLR:TfR and 
RAMP2:TfR were calculated. The results were expressed as % of expression compared 
to the appropriate unstimulated control. (A, B) Both CLR and CLRΔ9KR are similarly 
degraded after ADM stimulation. Thus, ADM induces degradation of both CLR WT and 
mutant, which suggests that ubiquitin is not involved in the degradation of CLR at 8 h. (C, 
D) ADM induces degradation of RAMP2 in both cell lines, however RAMP2 in WT cell line 
was significantly more degraded that in mutant cell line. Thus, ADM induces a slower 
degradation of RAMP2 in the mutant cell line at 8 h, which suggests that ubiquitin is 
involved in the degradation process of RAMP2. n=3, *=p<0.05 and ***=p<0.001 compared 
to untreated cells, and §=p<0.05 compared to WT cell line at the same time point.  





Figure 5.21 Ubiquitination is involved in ADM-induced degradation CLR•RAMP2 at 4 
h. Cell-surface proteins of HEK-CLR•RAMP2 and HEK-CLRΔ9KR•RAMP2 cells were 
labelled with biotin. The cells were then stimulated with ADM (100 nM) continuously (4 h). 
Cells were lysed and biotinylated proteins isolated by immunoprecipitation with 
Neutravidin. Levels of CLR, CLRΔ9KR, RAMP2 and TfR in the isolated protein samples 
were then analysed by Western blotting. (A, C) Representative blots are shown. (B, D) 
Blots were quantified using ImageQuantRT and ratios of CLR:TfR and RAMP2:TfR were 
calculated. The results were expressed as % of expression compared to the appropriate 
unstimulated control. (A, B) ADM induces degradation of only CLR at 4 h, whereas 
CLRΔ9KR is untouched. This result suggests that ubiquitin is involved in the degradation 
of CLR at 4 h. (C, D) ADM induces degradation of RAMP2 in both cell lines, however 
RAMP2 in WT cell line was significantly more degraded that in mutant cell line. Thus, 
ADM induces a slower degradation of RAMP2 in the mutant cell line at 4 h, which 
suggests that ubiquitin is involved in the degradation process of RAMP2. n≥6, *=p<0.05 
and ***=p<0.001 compared to untreated cells, and §§=p<0.01 compared to WT cell line at 
the same time point.  




5.8 ADM-Induced Degradation is Partially Blocked 
by Lysosome or Proteasome Inhibitors 
5.8.1 Effect of Lysosomal Protease Inhibitors and MG-132, 
Proteasome Inhibitor on ADM-Induced Degradation 
 GPCRs are generally degraded by proteolytic activities of the lysosome (Bouley 
et al., 2005; Cottrell et al., 2007; Jacob et al., 2005; Xia et al., 2008). However, 
some studies showed that the proteasome could also be involved in the 
degradation of GPCR (Chaturvedi et al., 2001; Cook et al., 2003). ADM induces 
CLR•RAMP2 trafficking to lysosomes. Therefore, it was anticipated that 
CLR•RAMP2 would be degraded by the lysosome. To investigate which proteolytic 
site is involved in the down-regulation of CLR•RAMP2, HEK-CLR•RAMP2 and 
HEK-CLRΔ9KR•RAMP2 cells were incubated with vehicle (control), a lysosomal 
protease inhibitors cocktail or a proteasome inhibitor, stimulated with ADM (16 h) 
and levels of CLR, CLRΔ9KR, RAMP2 and TfR determined by Western blotting 
(Fig. 5.22 and Fig. 5.23). In vehicle-treated cells ADM induced degradation of 
CLR and CLRΔ9KR to a similar level as observed in the previous degradation 
experiment (see 5.7.2) (Fig. 5.22B, 25.9±4.5% (CLR) and 23.5±8.7% (CLRΔ9KR) 
compared to untreated cells). In cells treated with lysosomal protease inhibitors, 
degradation of CLR was only partially prevented compared to vehicle-treated cells 
(Fig. 5.22B, 45.9±12.0% (CLR) and 44.6±13.3% (CLRΔ9KR) compared to 
untreated cells). Surprisingly, in cells treated with a proteasome inhibitor, MG-132 
(Tsubuki et al., 1993), the degradation of CLR was also prevented. Moreover, MG-
132 shows a higher significant effect on CLR, compared to CLRΔ9KR (Fig. 5.22B, 
62.4±10.1% (CLR) versus 42.3±11.2% (CLRΔ9KR) compared to untreated cells), 
which suggests that CLR is degraded by the proteasome and that ubiquitin seems 
involved in this process. 
 Similar results were observed with RAMP2 (Fig. 5.23). ADM induces similar 
degradation of RAMP2 in vehicle-treated cells, in both cell lines (Fig. 5.23B, 
24.6±4.3% (CLR) and 34.1±10.5% (CLRΔ9KR) compared to untreated cells). 
Incubation with lysosomal protease inhibitors, partially prevented the degradation 
of RAMP2 in both cell lines (Fig. 5.23B, 54.1±12.9% (CLR) and 45.2±9.5% 
(CLRΔ9KR) compared to untreated cells); and incubation with proteasome 
inhibitor also prevented the degradation of RAMP2. Likewise CLR, degradation of 
RAMP2 in WT cell line was significantly higher, than in mutant cell line (Fig. 
5.23B, 78.2±5.4% (CLR) versus 51.8±5.3% (CLRΔ9KR) compared to untreated 
cells), suggesting again that RAMP2 is degraded by the proteasome and that 
ubiquitin is also involved in this process. 




 Altogether, these results suggest that ADM-induced degradation of 
CLR•RAMP2 require the proteolytic activity of both lysosome and proteasome. 
Moreover, the proteasomal activity seems to require ubiquitination of CLR. 
 
5.8.2 Proteasomal Activity: Investigation of its Role in ADM-Induced 
Degradation of CLR•RAMP2 
5.8.2.1 MG-132 does not Inhibit ADM-Induced Internalisation 
 The internalisation of certain cell-surface receptors has been found to be 
ubiquitin-dependent (Hicke, 1999; Marmor and Yarden, 2004; Strous and Govers, 
1999). Moreover, it has been shown that MG-132 blocks the internalisation and 
thus the degradation of the β2-adrenergic receptor (Shenoy et al., 2001). To 
determine if MG-132 affects the internalisation of CLR•RAMP2, HEK-CLR•RAMP2 
and HEK-CLRΔ9KR•RAMP2 cells were incubated (30 min) with vehicle (DMSO) or 
MG-132. Cells were then stimulated with ADM (30 min) and CLR and CLRΔ9KR 
(RK11) localised by immunofluorescence and confocal microscopy (Fig. 5.24). In 
unstimulated cells, both CLR (Fig. 5.24A) and CLRΔ9KR (Fig. 5.24B) are 
localised at the cell-surface. Stimulation with ADM induces internalisation of CLR 
and CLRΔ9KR to intracellular vesicles in both vehicle- and MG-132-treated cells. 
Thus, ADM-induced internalisation of CLR•RAMP2 is not blocked by the 
proteasome inhibitor, which suggests that MG-132 does not affect the 
internalisation of the receptor. 
 
5.8.2.2 Effect of Epoxomicin on ADM-Induced Degradation 
 To confirm the role of the proteasome in the ADM-induced degradation of 
CLR•RAMP2, another proteasome inhibitor was used. MG-132 has been shown to 
have some activity on other proteases, included lysosomal proteases (i.e. 
cathepsins) (Kisselev and Goldberg, 2001; Tawa et al., 1997). Therefore, to 
investigate the role of the proteasome in the ADM-induced degradation of 
CLR•RAMP2, HEK-CLR•RAMP2 cells were incubated with vehicle (DMSO) or 
another proteasome inhibitor, epoxomicin, which shows more specificity in the 
inhibition of the proteasome (Meng et al., 1999). Cells were stimulated with ADM 
(16 h) and levels of CLR, RAMP2 and TfR determined by Western blotting (Fig. 
5.25). In vehicle-treated cells ADM induced degradation of CLR•RAMP2 to a 
similar level as observed in the previous degradation experiment (see 5.2.7) (Fig. 
5.25B and Fig. 5.25D, 17.1±7.2% (CLR) and 31.4±7.0% (RAMP2) compared to 
control). In cells treated with epoxomicin, ADM also induces the degradation of 
CLR•RAMP2 to a similar level as observed in vehicle-treated cells (Fig. 5.25B and 
Fig. 5.25D, 36.2±18.6% (CLR) and 30.6±5.1% (RAMP2) compared to control). 




These results show that the proteasome inhibitor does not prevent ADM-induced 
degradation of CLR•RAMP2. Thus, ADM-induced degradation of CLR does not 
seem to require proteolytic activity of the proteasome and the effects of MG-132 
observed may be not specific of the proteasome.  







Figure 5.22 ADM-induced degradation of CLR and CLRΔ9KR is partially prevented 
by inhibiting lysosomal and proteasomal proteolytic activities. Cell-surface proteins 
of HEK-CLR•RAMP2 and HEK-CLRΔ9KR•RAMP2 cells were labelled with biotin. The 
cells were then incubated with vehicle, lysosomal protease inhibitors (L.I.): pepsatin A (10 
µM), E-64d (10 µM) and Z-PAD (200 µM) or MG-132 (20 µM), stimulated with ADM (100 
nM, 16 h). Cells were lysed and biotinylated proteins isolated by immunoprecipitation with 
Neutravidin. Levels of CLR, CLRΔ9KR and TfR in the isolated protein samples were then 
analysed by Western blotting. There were no signals for CLR and CLRΔ9KR in 
untransfected HEK-FLP cells, indicating specificity of the anti-CLR (HA) antibody. (A) 
Representative blots are shown. (B) Blots were quantified using ImageJ and 
ImageQuantTL, ratios of CLR:TfR calculated and results expressed as % of the 
appropriate unstimulated control. In vehicle-treated cells ADM-induced significant 
degradation of both CLR and CLRΔ9KR. Incubation with lysosomal protease inhibitors 
partially prevented degradation of receptors in both cell lines. By inhibiting the proteolytic 
activity of the proteasome, the degradation of CLR but not CLRΔ9KR, was significantly 
prevented. Thus, the ADM-induced degradation of CLR required both lysosomal and 
proteasomal activities, moreover ubiquitin seem to be involved in the proteasomal 
degradation. n≥5, *=p<0.05, **=p<0.01 and ***=p<0.001 compared to untreated cells, and 
#=p<0.05 compared to vehicle-treated cells at the same time point.  







Figure 5.23 ADM-induced degradation of CLR•RAMP2 and CLRΔ9KR•RAMP2 is 
partially prevented by inhibiting lysosomal and proteasomal proteolytic activities. 
Cell-surface proteins of HEK-CLR•RAMP2 and HEK-CLRΔ9KR•RAMP2 cells were 
labelled with biotin. The cells were then incubated with vehicle, lysosomal protease 
inhibitors (L.I.): pepsatin A (10 µM), E-64d (10 µM) and Z-PAD (200 µM) or MG-132 (20 
µM), stimulated with ADM (100 nM, 16 h). Cells were lysed and biotinylated proteins 
isolated by immunoprecipitation with Neutravidin. Levels of RAMP2 and TfR in the 
isolated protein samples were then analysed by Western blotting. (A) Representative blots 
are shown. (B) Blots were quantified using ImageJ and ImageQuantTL, ratios of 
RAMP2:TfR calculated and results expressed as % of the appropriate unstimulated 
control. In vehicle-treated cells ADM-induced significant degradation of RAMP2 in both 
cell lines. Incubation with lysosomal protease inhibitors partially prevented degradation in 
both cell lines. By inhibiting the proteolytic activity of the proteasome, the degradation of 
RAMP2 in WT but not in mutant cell line, was significantly prevented. Thus, the ADM-
induced degradation of RAMP2 required both lysosomal and proteasomal activities, 
moreover ubiquitin seem to be involved in the proteasomal degradation of RAMP2. n≥5, 
*=p<0.05, **=p<0.01 and ***=p<0.001 compared to untreated cells, ###=p<0.001 
compared to vehicle-treated cells at the same time point, and §=p<0.05 compared to WT 
cell line at the same time point.  










Figure 5.24 CLR•RAMP2 and CLRΔ9KR•RAMP2 ADM-induced internalisation is not 
blocked by MG-132. HEK-CLR•RAMP2 (A) and HEK-CLRΔ9KR•RAMP2 (B) cells were 
stimulated with ADM (100 nM, 0-30 min), immunoreactive proteins were detected by 
immunofluorescence and analysed by confocal microscopy. In unstimulated cells, CLR 
and CLRΔ9KR are present at the cell-surface (arrowheads). ADM induces internalisation 
of both CLR and CLRΔ9KR to localise in intracellular vesicles (arrows) in both vehicle- 
and MG-132-treated cells. Thus, ADM induces internalisation of CLR•RAMP2 and 
CLRΔ9KR•RAMP2 regardless the presence or not of MG-132, which suggests that the 
proteasomal activity is not involved in the internalisation of CLR•RAMP2. Scale bar = 10 
µm.  





Figure 5.25 ADM-induced degradation of CLR•RAMP2 is not prevented by 
epoxomicin. Cell-surface proteins of HEK-CLR•RAMP2 cells were labelled with biotin. 
The cells were then incubated with vehicle or epoxomicin (5 µM), stimulated with ADM 
(100 nM, 16 h). Cells were lysed and biotinylated proteins isolated by immunoprecipitation 
with Neutravidin. Levels of CLR, RAMP2 and TfR in the isolated protein samples were 
then analysed by Western blotting. (A, C) Representative blots are shown. (B, D) Blots 
were quantified using ImageJ, ratios of CLR:TfR and RAMP2:TfR calculated and results 
expressed as % of the appropriate unstimulated control. In vehicle-treated cells, ADM 
induces significant degradation of CLR•RAMP2. Incubation of cells with epoxomicin, ADM 
also induces significant degradation of CLR•RAMP2 to a similar level observed in vehicle-
treated cells. Thus, the ADM-induced degradation of CLR•RAMP2 is not prevented by 
epoxomicin. n=3, *=p<0.05 and ***=p<0.001 compared to untreated cells.  




5.9 Expression and Trafficking of CLR•RAMP2 
and CLRΔ9KR•RAMP2 in HMEC-1 Cells 
 ADM stimulation of HEK-CLR•RAMP2 promotes the degradation of the receptor 
and therefore, is not recycled back to the cell-surface. Moreover, ADM induces 
ubiquitination of CLR, which accelerates the rate of degradation of the receptor. 
However, HEK cells do not naturally express the receptor, which could suggest 
that the observed effects are due to artefact. Therefore, the need of another model 
is necessary. HMEC-1 cells are a human microvascular endothelial cell line that 
express both components of the receptor CLR and RAMP2 (unpublished data, 
G.S. Cottrell). However, the level of expression of CLR•RAMP2 is insufficient to 
allow biochemical analyses. Thus, HMEC-1 were transfected to facilitate 
biochemical analysis and to express both CLR•RAMP2 and CLRΔ9KR•RAMP2. 
 HMEC-1 cells were first transfected according to the protocol described in 
Materials and Methods (Chap. 2.2.6). However, this method leads to the cell death 
of HMEC-1 due to high sensitivity to the transfection reagent of these cells. The 
protocol was then optimised by varying the quantity of DNA transfected, the 
volume of transfection reagent as well as the number of cells plated. The optimal 
protocol was as follows: HMEC-1 cells were seeded 48 h prior transfection at 
5x104 cells per well in 12-well plate, the quantity of DNA was 1 µg per well and the 
volume of Lipofectamine was 1 µL per well (ratio 1:1). After 24 h, transfected 
HMEC-CLR•RAMP2 and -CLRΔ9KR•RAMP2 cells were stimulated with ADM (30 
min or 4 h) and CLR and CLRΔ9KR (both RK11) simultaneously localised with 
EEA1 or LAMP1 by immunofluorescence and confocal microscopy (Fig. 5.26). In 
unstimulated cells, both CLR (Fig. 5.26A and Fig. 5.26C) and CLRΔ9KR (Fig. 
5.26B and Fig. 5.26D) are localised at the cell-surface and EEA1 and LAMP1 are 
detected in intracellular vesicles. Stimulation with ADM induces internalisation of 
CLR and CLRΔ9KR to co-localise with EEA1- and LAMP1-positive vesicles. Thus, 
ADM causes trafficking of CLR•RAMP2 and CLRΔ9KR•RAMP2 to early endosome 
and lysosomes, which suggests that both receptor traffic in HMEC-1 as observed 
in HEK cells. 
  









Figure 5.26 CLR•RAMP2 and CLRΔ9KR•RAMP2 traffic to early endosomes and 
lysosomes upon ADM stimulation in HMEC-1 cells. HMEC-CLR•RAMP2 (A, C) and 
HMEC-CLRΔ9KR•RAMP2 (B, D) cells were stimulated with ADM (100 nM, 0-4 h), 
immunoreactive proteins were detected by immunofluorescence and analysed by confocal 
microscopy. In unstimulated cells, CLR and CLRΔ9KR are present at the cell-surface 
(arrowheads), whereas (A, B) EEA1 and (C, D) LAMP1 are detected in intracellular 
vesicles. ADM induces internalisation of both CLR and CLRΔ9KR to co-localise with 
EEA1- or LAMP1-positive vesicles (arrows). Thus, ADM induces traffic of CLR•RAMP2 
and CLRΔ9KR•RAMP2 to early endosomes and lysosomes, which suggests that both 
receptors traffic normally in HMEC-1. Scale bar = 10 µm.  





 The receptor CLR•RAMP2 was stably transfected into HEK cells, in order to 
study its post-endocytic sorting. This cellular model has already been used for 
studying the traffic of CLR•RAMP2, where ADM stimulation induces internalisation 
of the receptor (Kuwasako et al., 2000). I also show by confocal microscopy that 
exposure to ADM induces a rapid internalisation of CLR•RAMP2 in HEK-cells. 
Studies have shown that ADM induces ERK1-2 activation in HMEC-1 (human 
microvascular endothelial cell line) and HUVEC (human umbilical vein endothelial 
cells) (Kim et al., 2003; Schwarz et al., 2006). I also show that ADM induces 
ERK1-2 activation in HEK-CLR•RAMP2, which suggests that the receptor is 
normally expressed and functional in HEK cells. 
 To investigate the post-endocytic sorting of CLR•RAMP2 I first examined the 
agonist-induced degradation of CLR•RAMP2 by using CHX to inhibit new protein 
synthesis and compared the results to CLR•RAMP1. It has been previously shown 
that following transient exposure to CGRP, it induces recycling of CLR•RAMP1 
back to the cell-surface. However, in continued presence of CGRP, CLR•RAMP1 
is trafficked to lysosomes for degradation via an ubiquitin-independent mechanism 
(Cottrell et al., 2007). Following transient and continuous stimulation with CGRP 
on HEK-CLR•RAMP1, I also show similar results, suggesting that CLR•RAMP1 
does recycle back to the cell-surface. However, stimulation with ADM on HEK-
CLR•RAMP2 induces degradation of CLR•RAMP2 following both transient and 
continuous stimulation. This result clearly shows a difference between agonist-
induced degradation between CLR•RAMP1 and CLR•RAMP2 and confirm the 
suggestion made by another study, where it has been suggested that following a 
transient stimulation with ADM (30 min), CLR•RAMP2 is internalised and less than 
10% of CLR•RAMP2 recycles back to cell-surface after 2 h (Kuwasako et al., 
2000). However, in our study, I looked at a much longer recovery point (16 h) as it 
has been shown that CLR•RAMP1 recycles back to the cell-surface very slowly (at 
least 6 h) (Cottrell et al., 2007). In contrast to CLR•RAMP2, CLR•RAMP3, the 
other receptor for ADM, has been shown to internalise and recycle back to the 
cell-surface following agonist exposure (Bomberger et al., 2005). Thus, it appears 
that RAMPs play an important role in the post-endocytic sorting of CLR following 
agonist stimulation and can change the fate of CLR•RAMP complex. 
 The small regulatory protein ubiquitin has been involved in the degradation of 
many GPCRs (reviewed by (Hanyaloglu and von Zastrow, 2008; Marchese et al., 
2008)). As I show that ADM stimulation induces CLR•RAMP2 degradation, I was 
interested to see if ubiquitination was involved in this process. Indeed, I show for 
the first time that ADM promotes ubiquitination of CLR, but not RAMP2. 
Interestingly, it has been shown that sustained stimulation of CGRP did not cause 
ubiquitination of either CLR nor RAMP1 (Cottrell et al., 2007). However, it is 
currently unknown if stimulation of CLR•RAMP3 by ADM induces or not 




ubiquitination of CLR and/or RAMP3. It is interesting to note that I also observed a 
basal level of CLR ubiquitination, indicating that perhaps that CLR is constitutively 
ubiquitinated. This is not unusual as PAR1, that mediates thrombin sensitivity to 
cells is constitutively ubiquitinated (Wolfe et al., 2007). However, as oppose to 
PAR1, which is deubiquitinated following stimulation, ADM further enhanced the 
basal ubiquitination of CLR. Interestingly, ADM-induced ubiquitination is not rapid 
and probably does not occur at the cell-surface, compared to many other GPCRs 
(Hicke and Riezman, 1996; Jacob et al., 2005; Shenoy et al., 2001). I then believe 
that ubiquitination of CLR occurs between early endosomes and lysosomes, 
perhaps in the MVB or in late endosomes. It is interesting to see that the same 
receptor CLR is ubiquitinated upon ADM stimulation but not upon CGRP 
stimulation. Moreover, as I saw that CLR was constitutively ubiquitinated when 
associated with RAMP2, it suggests that association with RAMP1 or RAMP2 
modify CLR ability to bind ubiquitin. It is then possible to imagine that the C-
terminal tail of RAMP1 mask all the lysine residues and block any ubiquitination of 
CLR, while RAMP2 can allow it. However, it is unlikely as they both have short C-
terminal tails (McLatchie et al., 1998). Further experiments are necessary to 
understand the mechanisms of CLR ubiquitination. 
 Ubiquitination has been shown to be involved in different process of the post-
endocytic sorting of GPCRs, such as promoting (Hicke and Riezman, 1996) or 
blocking (Wolfe et al., 2007) internalisation, targeting to degradation (Shenoy et 
al., 2001) or increasing the rate of degradation (Hislop et al., 2009). To further 
understand the role of ADM-induced ubiquitination of CLR, I made a lysine-less 
mutant of CLR, where all intracellular facing lysine residues were replaced by 
arginine residues. I called this mutant CLRΔ9KR. This method that prevents 
covalent binding of ubiquitin to the receptor, has already been used in other 
studies to help understand the role of ubiquitination in GPCRs regulation (Shenoy 
et al., 2001; Tanowitz and Von Zastrow, 2002; Wolfe et al., 2007). I show that 
expression of CLRΔ9KR•RAMP2 did not affect its cellular localisation, 
internalisation and signalling, suggesting that the receptor was functional. But 
more importantly, I show that ADM did not induce ubiquitination of CLRΔ9KR. I 
first used immunofluorescence and confocal microscopy to examine if ADM-
induced ubiquitination of CLR affect the trafficking of CLR•RAMP2 to endosomes 
and lysosomes compared to CLRΔ9KR•RAMP2. I show that ADM induced 
trafficking of CLR and RAMP2 to EEA1- and LAMP1-positive vesicles, presumably 
early endosomes and lysosomes respectively. This observation is supported by 
the study of Kuwasako et al. (Kuwasako et al., 2000), where CLR•RAMP2 co-
localised with lysotracker (a marker for acidic vesicles) following stimulation with 
ADM. Interestingly, I show that CLRΔ9KR•RAMP2 also traffic to early endosomes 
and to lysosomes upon ADM stimulation, suggesting that constitutively 
ubiquitination of CLR is not involved in the internalisation of the receptor as 
opposed to PAR1 (Wolfe et al., 2007). This result was not surprising as ADM 




further enhances ubiquitination of CLR, whereas thrombin induces deubiquitination 
leading to the internalisation of PAR1. However, the fact that CLRΔ9KR•RAMP2 
traffic to lysosomes upon ADM stimulation was surprising but not uncommon. 
Indeed, the δOR is ubiquitinated after stimulation with the synthetic opioid peptide 
DADLE. The study by Tanowitz et al. showed that a lysine-less mutant still traffics 
to lysosomes to be degraded (Tanowitz and Von Zastrow, 2002), as oppose to β2-
AR, where a lysine deficient receptor blocks its traffic to lysosomes and therefore 
prevents its degradation (Shenoy et al., 2001). The fact that CLRΔ9KR•RAMP2 
traffics to lysosomes might suggests that ubiquitination will not prevent the 
degradation of CLR•RAMP2 as it has been shown for δOR. As CLR is 
ubiquitinated, I chose to use a cell-surface biotinylation assay to monitor the 
degradation of CLR by lysosomal and proteasomal proteases, as CHX can affect 
the pool of free ubiquitin within the cell (Hanna et al., 2003). As suggested, I show 
that stimulation with ADM for 16 h did not show any differences in the degradation 
between CLR•RAMP2 or CLRΔ9KR•RAMP2, suggesting that ubiquitination was 
not involved in the degradation of CLR•RAMP2. It is interesting to note that in the 
first experiment looking at the degradation of CLR•RAMP2 with CHX, transient 
ADM stimulation promoted almost complete degradation of CLR. Whereas, biotin 
assays showed that transient ADM stimulation promotes only 20-30% of 
degradation. This difference can be explained by the fact that either CHX affects 
the degradation of CLR•RAMP2 or that the biotin assay is not as sensitive as the 
CHX degradation assay. Indeed, a recent study reported that CHX on its own 
induces internalisation and traffic to early endosomes of ErbB1 in HeLa cells 
(human cervical cancer cell line) (Oksvold et al., 2012). It is then possible than 
CHX also promotes internalisation of CLR•RAMP2 and further enhances its 
degradation. So, in order to confirm that transient ADM stimulation induces 
degradation of CLR•RAMP2, I decided to look at the internalisation of the receptor 
by a flow cytometry method. I showed that after transient ADM stimulation only 30-
40% of the cell-surface receptors were internalised for both CLR•RAMP2 and 
CLRΔ9KR•RAMP2. These results show that the amount of receptor internalised 
coincide with the amount of receptors degraded after transient ADM stimulation. 
Therefore, all receptors internalised are degraded. Additionally, I showed that 
HEK-CLR•RAMP2 expressed about 20% more receptor at the cell-surface 
compared to HEK-CLRΔ9KR•RAMP2. Altogether, I showed that all the ADM-
induced CLR•RAMP2 and CLRΔ9KR•RAMP2 receptors internalised are degraded 
and therefore that ubiquitin is not involved in the degradation of those receptors. 
 I also was interested to determine whether ubiquitination of CLR would modify 
ADM-induced signalling. Indeed, a study on the insulin-like growth factor 1 
receptor (IGF1R) suggests that the role of ubiquitination of the receptor is 
important in mediating IGF1R signalling (Sehat et al., 2007). In contrast to IGF1R, 
where ERK activation was abolished when ubiquitination of IGF1R was prevented, 
I showed that CLRΔ9KR•RAMP2 had no effect on the duration or intensity of 




ADM-induced ERK activation. However, even though it is not significant, I showed 
that the basal level of ERK activation in CLRΔ9KR•RAMP2 is lower compared to 
CLR•RAMP2. This could be explained by the fact that CLRΔ9KR•RAMP2 are less 
expressed at the cell-surface compared to CLR•RAMP2. Altogether, these results 
suggest that ubiquitination is not involved in ADM-induced ERK activation. 
However, it does not mean that ubiquitination is not involved in any CLR•RAMP2-
mediated signalling. 
 The study carried out by Hislop et al. suggested that in fact ubiquitination of 
δOR was involved in the rate of degradation. They showed that after 3-5 h of 
stimulation with DADLE, lysine-less mutant receptor show a significant higher 
ability to bind radioactive δOR antagonist diprenorphine, suggesting that down-
regulation of the lysine-less mutant receptor was slower than for the WT receptor 
(Hislop et al., 2009). I then decided to look at earlier time point of the degradation 
of CLR•RAMP2 and CLRΔ9KR•RAMP2. When both receptors were continuously 
stimulated for 8 h, no difference on the degradation was observed between the 
two receptors. However, when both receptors were continuously stimulated for 4 
h, CLR•RAMP2 show a significant higher degradation amount than 
CLRΔ9KR•RAMP2. These results are similar of those obtained with δOR (Hislop et 
al., 2009) and suggest that CLR•RAMP2 undergo degradation more rapidly than 
CLRΔ9KR•RAMP2. Therefore, ubiquitination is involved in the rate of degradation 
of CLR•RAMP2, by accelerating the process. 
 I showed that CLR•RAMP2 traffics to lysosomes and it is known that lysosomal 
proteases degrade CLR when expressed with RAMP1 (Cottrell et al., 2007). 
Subsequently, I was expected that lysosomal enzymes would similarly degrade 
CLR•RAMP2. Indeed, I observed that the same protease inhibitor cocktail, which 
prevented degradation of CLR•RAMP1, was also able to partially prevent 
degradation of CLR•RAMP2. However, I was expecting to see the degradation of 
CLR•RAMP2 completely prevented, as it has been shown for CLR•RAMP1 
(Cottrell et al., 2007). This result suggests that CLR•RAMP2 and CLR•RAMP1 are 
degraded by different lysosomal proteases. Another explanation is that 
CLR•RAMP2 degradation does not only take place in the lysosome. Indeed, when 
I inhibited the proteolytic activity of the proteasome, I also observed a reduction in 
ADM-induced degradation in both CLR•RAMP2 and CLRΔ9KR•RAMP2, even 
though the effects of MG-132 were more pronounced for CLR•RAMP2, suggesting 
a role of ubiquitination in the degradation of CLR•RAMP2. Although unexpected, 
the role of the proteasome in CLR•RAMP2 degradation is not without precedent. 
Indeed agonist-induced δOR degradation was prevented by different proteasome 
inhibitors, but not by lysosomal protease inhibitors (Chaturvedi et al., 2001). 
Similar results were also observed for the PTH receptor (Alonso et al., 2011) and 
the histamine H1 receptor (Hishinuma et al., 2010). The differences in the 
proteolytic degradation of CLR•RAMP1 and CLR•RAMP2 may be explained by the 




differences in their ubiquitination state during their trafficking through the endocytic 
network or perhaps, a non-specific or non-direct effect of proteasomal inhibition 
with MG-132. Indeed, it has been shown that the internalisation of ErbB1 
(Melikova et al., 2006) and β2-AR (Shenoy et al., 2001) was blocked by MG-132. 
Although the latter does not apply to the agonist-induced trafficking of the δOR 
(Tanowitz and Von Zastrow, 2002) neither to CLR•RAMP2, as I showed that the 
internalisation of CLR•RAMP2 was not prevented by MG-132. Moreover, to 
confirm the implication of the proteasomal activity in ADM-induced degradation of 
CLR•RAMP2, I used another proteasomal inhibitor. Conversely to MG-132, the 
use of epoxomicin, which is believed to be more specific than MG-132 (Meng et 
al., 1999), did not prevent the degradation of CLR•RAMP2. These results strongly 
suggest that the effects observed with MG-132 are due to side effects. However, 
further experiments would be necessary to assess this hypothesis. 
 In order to confirm the post-endocytic sorting of CLR•RAMP2 observed in HEK 
cells, I aimed to repeat key experiments in HMEC-1, a more physiological model 
that endogenously express CLR•RAMP2. However, endogenous levels of 
CLR•RAMP2 are low, which makes biochemical assays difficult to analyse. Thus, I 
transfected HMEC-1 in order to overexpress CLR•RAMP2. Many studies with 
similar transfection procedures have shown that the transfection of HMEC-1 was 
not an issue (Faure et al., 2000; Zhu et al., 2003). Conversely, I found that HMEC-
1 cells were sensitive to the transfection regent promoting the death of these cells. 
This result can be the consequence of a too large volume of transfection reagent. I 
then optimised the assay by changing the concentration of DNA, transfection 
reagent and number of cells. Although I succeeded to lower the toxicity of the 
assay, the rate of transfection remained poor. However, I managed to investigate 
the traffic of CLR•RAMP2 in HMEC-1. I show that CLR•RAMP2 traffic to 
endosomes and to lysosomes upon ADM stimulation, as observed in HEK cells. 
These primary data are really promising, suggesting that the study led in HEK cells 
are not due to artefacts. 
  




5.11 Summary and Conclusion 
 Compared to CLR•RAMP1 and CLR•RAMP3, little is known about the post-
endocytic sorting of CRL•RAMP2. Using HEK cells, stably expressing 
CLR•RAMP2, I investigated the regulation of the mechanisms of the ADM 
receptor. I first showed that, as oppose to CLR•RAMP1, transient stimulation of 
ADM causes degradation of CLR•RAMP2, which suggests that ADM receptors do 
not recycle to the cell-surface. As ubiquitin has been shown to be involved in the 
degradation of many GPCRs (reviewed in (Hanyaloglu and von Zastrow, 2008; 
Marchese et al., 2008)), I examined if CLR•RAMP2 was ubiquitinated upon ADM 
stimulation. I showed that CLR is constitutively ubiquitinated, which was further 
enhanced upon ADM stimulation. However, I did not observe any ubiquitination of 
RAMP2. 
 In order to elucidate the role of ADM-mediated ubiquitination of CLR, I made a 
lysine-less mutant of CLR, named CLRΔ9KR. I showed that ubiquitination of CLR 
did not affect the ADM-induced traffic to lysosome or the ERK signalling mediated 
by CLR•RAMP2. Although continuous stimulation of ADM induced degradation of 
both CLR•RAMP2 and CLRΔ9KR•RAMP2, I showed that ubiquitination of CLR 
was involved in the rate of degradation of the receptor. Indeed, I showed that at 4 
h stimulation CLR WT was largely degraded, whereas CLRΔ9KR•RAMP2 was 
untouched. 
 I also used protease inhibitors of the lysosome and of the proteasome in order 
to investigate the proteolytic site of CLR•RAMP2. Surprisingly, I found that 
lysosomal proteases inhibitors did not fully prevent ADM-induced degradation of 
CLR•RAMP2. More surprisingly, was that MG-132, a proteasome inhibitor, 
significantly prevented the degradation of CLR•RAMP2. However, this effect is 
believed to be due to off target effects rather than proteasome-dependent 
degradation. Altogether, these results show that CLR•RAMP2 does not recycle 
back to the cell-surface after transient stimulation and therefore is degraded. 
Furthermore, ADM induces ubiquitination of CLR only, which is involved in the 













Chapter 6. General Discussion 
 
  




6.1 Current Overview 
 This thesis aimed to better understand the molecular mechanisms of CGRP-
induced ERK activation of CLR•RAMP1 and ADM-mediated post-endocytic sorting 
of CLR•RAMP2 using HEK cells as a model system. 
 CGRP is a neuropeptide implicated in the regulation of many biological 
functions, but it is mostly known for its vasodilator actions on the cardiovascular 
system. The mechanisms of action of CGRP are known to involve 
NO/endothelium-dependent mechanisms or cyclic adenosine monophosphate 
(cAMP)-mediated/endothelium-independent pathways (reviewed in (Brain and 
Grant, 2004)). Moreover, it is well documented that CGRP can promote activation 
of ERK in many cell types. However, the biological functions of CGRP-induced 
ERK activation remain poorly defined. Recently, CGRP-induced ERK activation 
has been linked with the induction of iNOS in trigeminal ganglion glial cells (Vause 
and Durham, 2009). iNOS has been shown to be upregulated in different 
pathologies including migraine, atherosclerosis and sepsis (Ginnan et al., 2008; 
Hauser et al., 2005; Olesen and Jansen-Olesen, 2000). The induction of iNOS is 
known to produce large amounts of NO (Nathan and Xie, 1994) and is potentially 
responsible for the hypotension observed in sepsis and migraine (Gupta, 2005; 
Neuhauser and Lempert, 2004; Wijdicks and Stevens, 1992). CGRP is similarly 
upregulated and secreted in migraine and sepsis (Goadsby et al., 1990; Zhou et 
al., 2001). In the cardiovascular system, CGRP has been shown to promote 
upregulation of iNOS and NO release in SMC pretreated with interleukin-1β 
(Schini-Kerth et al., 1994). As both CGRP and NO are important signalling 
molecules in the cardiovascular system, I aimed as a first step, to determine the 
exact mechanisms through which CGRP activates ERK1-2. Understanding these 
mechanisms would allow us to determine whether ERK activation is involved in 
CGRP-induced iNOS upregulation in SMC.  
 ADM and its receptors have been shown to be expressed in several tissues and 
organs, including the heart, blood vessels, kidneys, lungs, gastrointestinal tract, 
endocrine glands and brain (reviewed in (Hinson et al., 2000)). This wide 
distribution suggests many biological functions for ADM. In the cardiovascular 
system, ADM, similarly to CGRP, promotes vasodilation of blood vessels, 
(reviewed in (Hinson et al., 2000)), but also plays an important role in the 
regulation of the endothelial barrier. ADM has been shown to protect and maintain 
the endothelial barrier during sepsis (reviewed in (Temmesfeld-Wollbruck et al., 
2007)). However, these mechanisms by which ADM protect and maintain the 
endothelial barrier remain poorly understood. Surprisingly, little is known about the 
post-endocytic sorting of ADM receptor, CLR•RAMP2. It has been shown that both 
CLR•RAMP1 and CLR•RAMP3 can recycle after transient stimulation (Bomberger 
et al., 2005; Cottrell et al., 2007). Moreover, it has been shown that ECE-1 




regulates the recycling of CLR•RAMP1 by cleaving CGRP in endosomes (Padilla 
et al., 2007). As ADM is also cleaved by ECE-1, only at endosomal pH 
(unpublished data, G.S. Cottrell), I hypothesised that ECE-1 would similarly 
regulate CLR•RAMP2. To test this hypothesis I first examined the mechanisms of 
the post-endocytic sorting of CLR•RAMP2 using HEK cells as a model. I was 
especially interested to see whether CLR•RAMP2 recycles or is degraded 
following ADM stimulation. This study in HEK cells is a first step in the 
investigation of the molecular mechanisms controlling CLR•RAMP2 trafficking. Key 
experiments would need to be carried out in a more physiological model, such as 
HMEC-1 cells, to confirm my observations in HEK cells. It is important to study the 
post-endocytic sorting of CLR•RAMP2, as a better understanding of how receptors 
are trafficked may lead to the development of new therapies to treat disease. 
 
6.2 CGRP-Induced ERK Activation and Future 
Direction 
 HEK cells are easy to manipulate and commonly used to study GPCRs-
mediated ERK activation (e.g. (Cottrell et al., 2009; Della Rocca et al., 1997; 
Luttrell et al., 2001)). Moreover, they have already been used to study CGRP-
induced ERK activation, showing that CGRP induces ERK phosphorylation in a 
concentration-dependent manner (Parameswaran et al., 2000). As expected, 
CGRP induces ERK activation in HEK-CLR•RAMP1 cells and I showed that 
CGRP-induced ERK activation is mainly activated through two major pathways: 
the Gαs-mediated cAMP/PKA pathway and transactivation of ErbB1. 
 The cAMP/PKA pathway is commonly involved in GPCR-induced ERK 
activation (reviewed in (Goldsmith and Dhanasekaran, 2007; Rozengurt, 2007)). 
CLR•RAMP1 is known to couple a Gαs subunit in HEK cells and SK-N-MC cells 
(human neuroblastoma cell line that endogenously expresses CGRP receptor) 
(Aiyar et al., 1999; Van Valen et al., 1990), which leads to accumulation of cAMP. 
Indeed, I used H-89, a PKA inhibitor (Chijiwa et al., 1990) and showed that CGRP-
induced ERK activation was reduced by about 50% (Fig. 6.1). This result confirms 
that CGRP promotes ERK activation through the cAMP/PKA pathway, possibly 
mediated by Gαs subunit. This result is consistent with similar observations in HEK 
cells, where CGRP-induced ERK activation was also blocked by H-89 
(Parameswaran et al., 2000). Even though H-89 is commonly used to assess the 
role of PKA in different cellular systems (Chao and Hamilton, 2009; Lee and 
Linstedt, 2000; Murphy et al., 2010), H-89 has been found to inhibit kinases other 
than PKA (reviewed in (Lochner and Moolman, 2006)). Indeed, H-89 inhibits the 
p70 ribosomal protein S6 kinase 1, which is involved in protein synthesis and cell 
proliferation, and the mitogen- and stress-activated protein kinase-1 that mediates 




activation of the cAMP response element-binding protein and activating 
transcription factor-1 (Davies et al., 2000). Therefore, I used two different 
concentrations of H-89 and obtained similar results. The lower concentration (10 
µM) of H-89 gives a more specific inhibition of PKA. Thus, I can say with more 
certainty that CGRP activates ERK through PKA. However, it would be necessary 
to use other PKA inhibitors to verify that the same effect is observed on CGRP-
induced ERK activation.  
 I show for the first time that CGRP induces transactivation of ErbB1 by using a 
specific ErbB1 inhibitor AG1478 (Osherov and Levitzki, 1994), which lead to about 
40% inhibition of the total ERK activation (Fig. 6.1). This result is not uncommon, 
as many GPCRs have been shown to induce transactivation of ErbB1 (Daub et al., 
1996; Eisinger and Ammer, 2008; Maudsley et al., 2000; Zajac et al., 2011). 
However, it is interesting to note that only a few Gαs-mediated GPCRs have been 
described to promote ErbB1 transactivation, which are the EP2 receptor, the GnRH 
receptor and the MC2 receptor (Carbajal et al., 2011; Sales et al., 2004). ErbB1 
transactivation has been reported to play an important role in cancer-related 
disorders (reviewed in (Fischer et al., 2003)), notably by promoting angiogenesis 
(de Jong et al., 1998; Schreiber et al., 1986). CGRP is also known to enhance 
tumour-associated angiogenesis (reviewed in (Majima et al., 2011)). However, the 
molecular mechanisms governing CGRP-mediated angiogenesis remain unknown. 
Future studies could be directed to investigate whether CGRP-induced ErbB1 
transactivation plays a role in CGRP-mediated angiogenesis. This could lead to 
the identification of new drug targets and possibly to alternative therapies in 
cancer. 
 The tyrosine kinase Src is known to play an important role in GPCR-mediated 
ERK activation (reviewed in (McGarrigle and Huang, 2007)). Moreover, many 
studies reported that Src was involved in ErbB1 transactivation (Buteau et al., 
2003; Daub et al., 1997; Eguchi et al., 1998), as well as in the cAMP/PKA 
pathway-mediated ERK activation (Obara et al., 2004; Schmitt and Stork, 2002). 
Interestingly, I showed by using PP2, a Src inhibitor, that CGRP-induced ERK 
activation was reduced (Fig. 6.1). Thus, Src is required for CGRP-induced ERK 
activation. However, further experiments are required to determine whether Src is 
involved in cAMP/PKA pathway, in ErbB1 transactivation pathway or both 
pathways.  
 The metalloprotease ECE-1 regulates the recycling and the endosomal ERK 
signalling of NK1R (Cottrell et al., 2009; Roosterman et al., 2007). Surprisingly, 
even though ECE-1 also regulates the trafficking of CLR•RAMP1 (Padilla et al., 
2007), inhibition of ECE-1 or preventing endosomal acidification, (both of which 
prevent CGRP degradation in endosomes) did not affect the magnitude or duration 
of CGRP-induced ERK signalling. One reason why perhaps ECE-1 does not 
regulate CGRP-induced ERK activation is that β-arrestin does not play a role in 




CGRP-induced ERK activation. For example, the NK1R-mediated endosomal ERK 
signalling have been showed to be dependent on β-arrestin (Cottrell et al., 2009). 
Indeed, β-arrestins, other than mediating GPCR desensitisation and 
internalisation, also facilitate mitogenic signalling due to their ability to act as a 
scaffold for signalling proteins (reviewed in (Luttrell and Gesty-Palmer, 2010)). 
Therefore, it is possible that ECE-1 does not regulate CGRP-induced ERK 
signalling because CGRP does not induce ERK activation through β-arrestin. To 
confirm this hypothesis, I used β-arrestin mutant to study CGRP-induced ERK 
activation. As expected, when I transfected HEK-CLR•RAMP1 with a dominant-
negative β-arrestin1 P91G P121E mutant that cannot bind Src, the magnitude or 
duration of CGRP-induced ERK signalling was not affected. This result suggests 
that CGRP-ERK activation is not dependent on β-arrestin1, which confirms the 
results seen with ECE-1. However, CLR is a class B GPCR (that bind both β-
arrestins) (Hilairet et al., 2001), it would then be interested to use a β-arrestin2 
mutant to confirm these observations, such as the β-arrestin2 V54D, that act as a 
dominant negative (Ferguson et al., 1996). Altogether, these data suggest that 
CGRP does not activate ERK via a β-arrestin-dependent mechanism, nor does it 
use the endosome as a signalling platform to activate ERK.  
 GPCRs can also induce ERK activation through the PLC/PKC/Ca2+ pathway 
(reviewed in (Belcheva and Coscia, 2002; Goldsmith and Dhanasekaran, 2007; 
Rozengurt, 2007)) either through the coupling with a Gαq subunit or through 
βγ subunits-dependent mechanism of the G protein. By using different inhibitors at 
different level of the signalling cascade, I show that CGRP-induced ERK activation 
is unlikely signalling through PLC/PKC/Ca2+ in HEK cells. It is a surprising result as 
CGRP has been shown to induce Ca2+ mobilisation through Gαq/11-mediated 
activation of PLC-β1 in OHS-4 cells (human bone cell line) (Drissi et al., 1998). 
Moreover, CGRP has also been shown to induce Ca2+ mobilisation and cAMP 
production in HEK cells (Aiyar et al., 1999), suggesting that CLR•RAMP1 signals 
through both Gαs and Gαq. Therefore, it would be interesting to confirm that CGRP 
induces Ca2+ mobilisation in HEK-CLR•RAMP1 and whether its mediated through 
the PLC/PKC/Ca2+ pathway. If CGRP do induce Ca2+ mobilisation in HEK-
CLR•RAMP1, then it is possible that Ca2+ mobilisation is not involved in CGRP-
induced ERK activation. Obviously, further experiments are required to confirm 
this hypothesis. 
 Altogether those results give a better understanding of the CGRP-induced ERK 
signalling in HEK cells (Fig. 6.1). The step forward to this study is to repeat the 
key experiments in a more physiological model such as the primary rat TA-SMC, 
in order to determine whether CGRP induces ERK activation that would lead to 
iNOS upregulation in these cells. With this aim to investigate the CGPR-induced 
ERK activation pathways in SMC, I managed to isolate and culture primary TA-
SMC from rat thoracic artery. These cells express CLR•RAMP1 and I showed that 




CGRP induces iNOS upregulation, as previously shown by an earlier study 
(Schini-Kerth et al., 1994). Although, they pretreated TA-SMC with IL-1β before 
stimulating them with CGRP. Despite the fact that CGRP induces iNOS 
upregulation, it is unknown whether iNOS promotes NO production. Therefore, the 
quantification of NO production is necessary to further assess the role of CGRP in 
iNOS expression/NO production. Primary data using the MEK inhibitor U0126 
show that CGRP-induced iNOS expression is partially blocked. This promising 
result suggests that CGRP regulate the iNOS expression in SMC in an ERK-
dependent manner. However, I was not able to take the study further as the 
primary TA-SMC seemed to lose the expression of CLR•RAMP1 and therefore 
were not responding to CGRP. Indeed, other studies reported similar loss of 
expression in SMC of other membrane proteins such as the α7 integrin (Yao et al., 
1997) and the muscarinic acetylcholine receptor M2 (Hsieh and Farley, 2002) due 
to differentiation of these cells. Therefore, one way to overcome this issue would 
be to use exogenously expressed CLR and RAMP1 in TA-SMC, for example by 
using the lentivirus or adenovirus system. It would allow the ERK activation 
pathways in CGRP-induced iNOS upregulation to be investigated. Particularly, to 
determine whether CGRP induces iNOS through the cAMP/PKA pathway or 
through transactivation of ErbB1, by using pharmalogical inhibitors. The 
upregulation of iNOS is likely to require gene transcription, which can be promoted 
by transcription factor that can be activated by the translocation of pERK1-2 into 
the nucleus. Therefore, it is possible that only the cAMP/PKA pathway might be 
involved in the upregulation of iNOS as a study showed that the transactivation of 
ErbB1 does not lead to the translocation of pERK1-2 into the nucleus (Tilley et al., 
2009). To further investigate CGRP-induced iNOS upregulation, it could be 
interesting to use knockdown, mutant or overexpression studies targeting key 
element of the ERK pathway. Determining the CGRP-induced iNOS upregulation 
mechanisms would help to better understand the relationship between CGRP and 
NO. These two components play an important role in the regulation of the blood 
pressure and understanding their regulation could potentially lead to the discovery 
of new drug target or alternative therapies in cardiovascular disease related. 
 
  







Figure 6.1 General model of CGRP-induced iNOS upregulation. (1) CGRP induces 
iNOS upregulation in primary rat TA-SMC. However, it is unknown whether CGRP-
induced iNOS upregulation promotes NO formation. Therefore, the quantification of NO 
remains to be determine in CGRP-stimulated TA-SMC. (2) TA-SMC treated with the MEK 
inhibitor U0126, have shown that CGRP-induced iNOS upregulation is reduced, 
suggesting that upregulation of iNOS is ERK-dependent. As shown in HEK cells, 
CLR•RAMP1 promotes ERK signalling mainly through (3) the activation of the cAMP/PKA 
pathway or (4) the transactivation of ErbB1. The CGRP-induced ERK activation that 
promotes iNOS upregulation remains to be determined. Moreover, Src also has been 
shown to be involved in the CGRP-induced ERK activation. However, it is unknown 
whether Src is involved in the cAMP/PKA pathways or the ErbB1 transactivation.  




6.3 The Post-Endocytic Sorting of CLR•RAMP2 
and Future Direction 
 The receptor CLR•RAMP2 was stably transfected into HEK cells, in order to 
study its post-endocytic sorting. HEK cells are a common model used to study the 
molecular mechanisms regulating GPCRs (e.g (Luttrell et al., 2001; Roosterman et 
al., 2007)). Moreover, HEK cells have already been used for studying the traffic of 
CLR•RAMP2, where ADM stimulation induces internalisation of the receptor 
(Kuwasako et al., 2000). I also show by immunofluorescence and confocal 
microscopy that exposure to ADM induces a rapid internalisation of CLR•RAMP2 
in HEK-cells. Moreover, I showed that ADM induces ERK1-2 activation in HEK-
CLR•RAMP2, in accordance with other studies in HMEC-1 (human microvascular 
endothelial cell line) and HUVEC (human umbilical vein endothelial cells) (Kim et 
al., 2003; Schwarz et al., 2006). All together, these results suggest that 
CLR•RAMP2 is fully functional when expressed in HEK cells. Therefore, HEK-
CLR•RAMP2 cells are a suitable model to study the post-endocytic sorting of 
CLR•RAMP2. 
 It is known that both CLR•RAMP1 and CLR•RAMP3 can recycle after transient 
stimulation (Bomberger et al., 2005; Cottrell et al., 2007). However, little is known 
about CRL•RAMP2 regulation. A study looking at the traffic of CRL•RAMP2 in 
HEK cells suggested that this receptor was degraded following transient 
stimulation with ADM (Kuwasako et al., 2000). By using CHX to inhibit newly 
synthesised proteins, I showed and confirmed that transient stimulation of ADM 
induces degradation of CRL•RAMP2 (Fig. 6.2). Therefore, as oppose to 
CLR•RAMP1 and CLR•RAMP3, CRL•RAMP2 does not recycle back to the cell-
surface. It would be also interesting to see whether other agonists of CLR•RAMP2, 
such as ADM2 (Roh et al., 2004), also induce degradation of the receptor.  
 As ubiquitin has been involved in the degradation of many GPCRs (reviewed by 
(Hanyaloglu and von Zastrow, 2008; Marchese et al., 2008)), I investigated 
whether ADM promotes ubiquitination of CRL•RAMP2. However, it is known that 
continued stimulation with CGRP induces traffic and degradation to lysosomes of 
CLR•RAMP1, in an ubiquitin-independent mechanism (Cottrell et al., 2007). I then 
expected that CLR•RAMP2 would also be degraded in an ubiquitin-independent 
mechanism. Surprisingly, I show for the first time that CLR, but not RAMP2, is 
ubiquitinated in unstimulated cells, suggesting that CLR is constitutively 
ubiquitinated, which is further enhanced by ADM stimulation (Fig. 6.2). It is 
interesting to see that CLR is ubiquitinated upon ADM stimulation but not upon 
CGRP stimulation. Moreover, as I saw that CLR is constitutively ubiquitinated 
when associated with RAMP2, this suggests that association with RAMP1 or 
RAMP2 modify CLR ability to bind ubiquitin. These results could be explain by the 
fact that the C-terminal tail of RAMP1 physically covers all the intracellular facing 




lysine residues of CLR and therefore block ubiquitination of the receptor. However, 
it is unlikely as RAMP1 and RAMP2 have short C-terminal tails (McLatchie et al., 
1998), unless all the lysine residues of CLR form a “pocket” close to RAMP1. 
Thus, it would be interesting to investigate the difference of ubiquitination 
observed in CLR while associated with RAMP1 or RAMP2. For example, by 
“switching” the C-terminal tail of both RAMP1 and RAMP2, it would be interesting 
to see whether CGRP is able to induce ubiquitination of CLR or if ADM is still able 
to promote CLR ubiquitination. Other than the mechanisms of how ubiquitination 
occurs for CLR, I was first interested to understand what is the role of CLR 
ubiquitination in the regulation of CRL•RAMP2. Ubiquitination has been shown to 
be involved in different processes of the post-endocytic sorting of GPCRs, such as 
promoting or blocking internalisation (Hicke and Riezman, 1996; Wolfe et al., 
2007), targeting to degradation (Shenoy et al., 2001) or increasing the rate of 
degradation (Hislop et al., 2009). I then undertook the construction of a CLR 
mutant named CLRΔ9KR, where all intracellular facing lysine residues were 
replaced by arginine residues. This method that prevents covalent binding of 
ubiquitin to the receptor, has already been used in other studies to help 
understand the role of ubiquitination in GPCRs regulation (Shenoy et al., 2001; 
Tanowitz and Von Zastrow, 2002; Wolfe et al., 2007). Once CLRΔ9KR•RAMP2 
was stably express in HEK cells, I show that the receptor trafficked to early 
endosomes and lysosomes, as shown for CLR•RAMP2, suggesting that ubiquitin 
was not involved in neither the internalisation of the receptor nor its traffic to 
lysosomes. The fact that CLRΔ9KR•RAMP2 traffics to lysosomes suggests that 
the receptor is degraded, as it has been shown for the δOR lysine-less mutant 
(Tanowitz and Von Zastrow, 2002), as opposed to the lysine deficient β2-AR 
receptor that was sequestered in endosomes and therefore not degraded (Shenoy 
et al., 2001). Indeed, as suggested I showed that stimulation with ADM for 16 h did 
not show any differences in the degradation of CLR•RAMP2 or CLRΔ9KR•RAMP2. 
The study carried out by Hislop et al., showed that ubiquitin is involved in the rate 
of δOR degradation (Hislop et al., 2009), therefore I also looked at ADM-induced 
degradation of CLR•RAMP2 and CLRΔ9KR•RAMP2 at earlier time points. I 
showed, when both receptors were continuously stimulated for 4 h, CLR•RAMP2 
is significantly degraded, whereas CLRΔ9KR•RAMP2 is untouched, suggesting 
that CLR•RAMP2 undergo degradation more rapidly than CLRΔ9KR•RAMP2 (Fig. 
6.2). These results are similar of those obtained with δOR, where after 3-5 h of 
stimulation with DADLE, the lysine-less mutant show a significant higher ability to 
bind radioactive δOR antagonist diprenorphine, suggesting that the down-
regulation of the lysine-less mutant was slower than for the WT receptor (Hislop et 
al., 2009). Altogether, these results suggest that the ubiquitination of CLR is 
involved in the rate of degradation of CLR•RAMP2. 




 In order to investigate the proteolytic site of CLR•RAMP2, I used inhibitors of 
lysosomal and proteasomal proteases (Fig. 6.2). Surprisingly, a lysosomal 
protease inhibitor cocktail that inhibits cysteine and aspartate proteases, which 
have been shown to completely block CGRP-induced CLR•RAMP1 degradation 
(Cottrell et al., 2007), only partially prevented ADM-induced CLR•RAMP2 
degradation. This result suggests that CLR•RAMP2 could be degraded by other 
proteases such as serine, threonine or glutamic proteases. To investigate this 
eventuality, inhibitors targeting these proteases could be used to see whether 
ADM-induced CLR•RAMP2 degradation is prevented or not. Another, explanation 
is that CLR•RAMP2 is not degraded by the lysosome, which seems unlikely as I 
showed that CLR•RAMP2 traffic to lysosome. However, many studies have shown 
that δOR degradation is prevented by the proteasome inhibitor MG-132 
(Chaturvedi et al., 2001; Tanowitz and Von Zastrow, 2002), suggesting that this 
receptor down-regulation is mediated by the proteasome. Interestingly, I also 
showed that CLR•RAMP2 degradation was significantly prevented by MG-132. 
This result could explain why the lysosome inhibitors did not fully blocked the 
degradation of CLR•RAMP2. However, in the aim to confirm these results I also 
used another proteasome inhibitor, epoxomicin, which did not prevent 
CLR•RAMP2 degradation, suggesting that the effects seen with MG-132 are due 
to off-target effects. Indeed, MG-132 has been found to inhibit certain cathepsins 
(e.g. B, L and K) found in lysosomes (Goulet et al., 2004; Guery et al., 2011; 
Longva et al., 2002). It is then possible than MG-132 prevents CLR•RAMP2 
degradation through the inhibition of lysosomal proteases. Thus, using different 
cathepsins inhibitors would help to determine the site of down-regulation of ADM-
induced CLR•RAMP2.  
 As already mentioned, HEK cells do not endogenously express CLR•RAMP2, 
therefore repeating key experiments in a more physiological relevant model, such 
as HMEC-1, is necessary. Primary data showed that HMEC-1 cells endogenously 
express CLR•RAMP2. However, endogenous levels of CLR•RAMP2 are low, 
which makes biochemical analysis impossible. Therefore, I decided to overexpress 
CLR•RAMP2 and CLRΔ9KR•RAMP2 in HMEC-1 cells. I used a cationic lipid-
based transfection reagent to overexpress the receptor in HMEC-1 that has 
already been described to work in other studies (Faure et al., 2000; Zhu et al., 
2003). However, I found that HMEC-1 cells were sensitive to the transfection 
regent and therefore promoted cell death. By modifying the protocol, I managed to 
lower the cell toxicity of the assay, however, the level of transfection was also 
negatively affected. Nevertheless, I showed that ADM promotes the trafficking of 
CLR•RAMP2 and CLRΔ9KR•RAMP2 to lysosomes in transfected HMEC-1 cells. 
These primary data are really promising, suggesting that observations made in 
HEK cells would also occur in endothelial cells. The next step would be to find 
alternative ways to overexpress CLR•RAMP2 and CLRΔ9KR•RAMP2 in HMEC-1, 
such as using a lentivirus or adenovirus system. Once HMEC-1 stably express 




CLR•RAMP2 and CLRΔ9KR•RAMP2, it would be necessary to confirm that 
transient stimulation of ADM induces degradation of CLR•RAMP2 and that ADM 
promotes ubiquitination of CLR. This would allow us to confirm the results 
observed in HEK cells and would contribute to better characterise the post-
endocytic regulation of CLR•RAMP2. Further ahead, as I show that the traffic or 
degradation is not driven by ubiquitin, it would be interesting to determine which 
system is responsible of CLR•RAMP2 traffic to lysosome. For example, the 
ESCRT machinery has been shown to regulate the traffic of many GPCRs, 
including CLR•RAMP1 (Gullapalli et al., 2006; Hasdemir et al., 2007; Marchese et 
al., 2003). Therefore, by using knockdown studies targeting components of the 
ESCRT machinery, the regulation of CLR•RAMP2 trafficking could be determined. 
Altogether, understanding the post-endocytic sorting of CLR•RAMP2 could lead to 
the discovery of new drug target and alternative therapies involved in 
cardiovascular disease related. 
 
  





Figure 6.2 General model of CLR•RAMP2 post-endocytic sorting. (1) Transient ADM 
stimulation induces internalisation and trafficking to endosomes and lysosomes of 
CLR•RAMP2 to be degraded. CLR has been shown to be constitutively ubiquitinated, 
which is further enhanced by ADM stimulation. (2) ADM-induced ubiquitination of CLR 
observed occurs relatively late compared to other GPCRs. Therefore, CLR ubiquitination 
is thought to take place in endosomes, but further experiments are necessary to confirm 
this hypothesis. ADM-induced CLR ubiquitination has been shown to be involved in the 
rate of degradation of CLR•RAMP2, by accelerating the process. (3) The cocktail of 
lysosomal proteases inhibitors used in this study was not able to completely prevent the 
degradation of CLR•RAMP2. Moreover, a proteasome inhibitor also showed to partially 
prevent the degradation of CLR•RAMP2. These results suggest that CLR•RAMP2 is 
degraded by both lysosome and proteasome. Further experiments remain to determine 
whether other lysosomal proteases are involved in the degradation of CLR•RAMP2 or if 
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Product Supplier Cat. number 
Ammonium persulphate (APS): (NH4)2S2O8  Sigma-Aldrich A3678 
Bromophenol blue sodium salt: C19H10Br4O5S Sigma-Aldrich B5525 
Butan-2-ol: CH3(CH2)3OH BDH 100616J 
Calcium chloride (1 M): CaCl2 Sigma-Aldrich 21114 
Chloroform: CHCl3 Sigma-Aldrich C2432 
Dimethyl sulphoxide (DMSO): (CH3)2SO Sigma-Aldrich D2650 
Diethyl pyrocarbonate (DEPC): O(COOC2H5)2 Sigma-Aldrich D5758 
Ethanol: C2H6O (Molecular Biology Grade) Sigma-Aldrich E7023 
Ethanol: C2H6O Sigma-Aldrich 32221 
Ethylenediaminetetraacetic acid (EDTA): 
C10H14N2Na2O8 
Sigma-Aldrich E5134 
Ethylene glycotetraacetic acid (EGTA): 
C14H24N2O10 
Sigma-Aldrich E4378 
Glacial acetic acid: C2H4O2 BDH 27013 
Glycerol: C3H8O3 Sigma-Aldrich G6279 
Glycine: NH2CH2COOH Sigma-Aldrich G7403 
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4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic 
acid (HEPES): C8H18N2O4S 
Sigma-Aldrich H3375 
Hydrochloric acid: HCl Fisher Scientific J/4310/15 
Magnesium chloride: MgCl2 Fisher Scientific 
M/0550/5
3 
Manganese chloride: MnCl2 Sigma-Aldrich M3634 
2-mercaptoethanol: C2H6SO Sigma-Aldrich M6250 
Methanol: CH3OH Sigma-Aldrich 34860 
Nonidet P-40 (NP-40): C18H30O3 BDH 560092L 
Paraformaldehyde (PFA): OH(CH2O)nH (n=8-100) Sigma-Aldrich P6148 




disodium salt (Orange G): C16H10N2Na2O7S2 
Sigma-Aldrich O3756 
Potassium dihydrogen orthophosphate: KH2PO4 BDH 436053H 
Potassium chloride: KCl Sigma-Aldrich P9333 
2-propanol: C3H8O Sigma-Aldrich I9516 
Saponin from Quillaja Bark Sigma-Aldrich S4521 
Sodium Chloride: NaCl Sigma-Aldrich 433209 
Sodium dodecyl sulphate (SDS): NaC12H25SO4 Sigma-Aldrich L6026 
Sodium fluoride: NaF BDH 102464T 
Sodium hydroxide: NaOH Fisher Scientific J/7800/15 
Sodium orthovanadate: Na3VO4 Sigma-Aldrich S6508 
Sodium phosphate dibasic: HNa2O4P Sigma-Aldrich S3264 
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Triton™-X-100: C14H22O(C2H4O)n (n=9-10) Sigma-Aldrich X100 
Trizma® base (Tris/HCl): NH2C(CH2OH)3•HCl Sigma-Aldrich T6066 
Tween® 20: C58H114O26 Sigma-Aldrich P7949 
Xylene cyanol FF: C25H27N2NaO6S2 Sigma-Aldrich X4126 








Antibiotics Supplier Cat. number 
Ampicillin Sigma-Aldrich A9518 
Lysogeny Broth (LB) Broth, tablets Sigma-Aldrich L7275 
Tryptone (EZMix™): Pancreatic digest of casein Sigma-Aldrich T2559 
Yeast extract (EZMix™) Sigma-Aldrich Y1626 
Table I.3 List of bacteria consumable. Ampicillin was stored at 4°C. All the other 
consumables were stored at RT. 
  
Stock of peptides Diluent Stock Supplier Cat. number 
rat ADM DDW* 1 mM Bachem H-2934 
rat CGRP DDW 1 mM Bachem H-2265 
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Cell Culture Consumables 
Media Supplier Cat. number 
Dulbecco’s Modified Eagles medium (DMEM): L-
glutamine, high glucose, sodium pyruvate, phenol red Invitrogen 
41966-
029 
DMEM: no L-glutamine, high glucose, no sodium 
pyruvate, no phenol red Invitrogen 
31053-
028 
Ad. DMEM: no L-glutamine, non-essential amino acids 
(NEAA), high glucose, sodium pyruvate, phenol red Invitrogen 
12491-
023 
MCDB 131: no L-glutamine, low glucose, sodium 
pyruvate, phenol red Invitrogen 
10372-
019 
Opti-MEM® Reduced-Serum Medium: L-glutamine, 
phenol red Invitrogen 
31985-
062 
Serum and supplements Supplier Cat. number 




L-glutamine: 100x Invitrogen 25030-123 






Epidermal Growth Factor (EGF): from mouse, tested 
for cell culture VWR 734-1304 
Hydrocortisone (HCORT): suitable for cell culture Sigma-Aldrich H0888 
MEM NEAA: 100x Invitrogen 11140-035 
Antibiotics Supplier Cat. number 
Hygromycin B Invitrogen 10687-010 
Zeocin™  Invitrogen R250-01 
Penicillin-Streptomycin (P/S) Invitrogen 15070-063 
Amphotericin B preparation (Fungizone™) Sigma-Aldrich A 2942 
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Other consumables Supplier Cat. number 
Dulbecco's Phosphate-Buffered Saline (PBS): no 
calcium no magnesium Invitrogen 
14190-
169 
Dulbecco's PBS: calcium and magnesium (PBSCM) Invitrogen 14040-174 
0.05% Trypsin-EDTA: phenol red Invitrogen 25300-096 





Gelatin: from porcine skin Sigma-Aldrich G1890 
Cell Surface protein Isolation kit: includes EZ-Link 
Sulfo-NHS-SS-Biotin, NeutrAvidin Agarose Pierce 89881 
Lipofectamine® 2000 Transfection Reagent Invitrogen 11668-019 
Table I.4 List of Cell Culture Consumables. All consumables were stored according to 
the manufacturer’s guidelines. 
 
Protein Analysis Consumables 
Product Supplier Cat. number 
40 % (w:v) Acrylamide/Bis Solution, ratio 37.5:1 Bio-Rad 161-0149 
BCA Protein Assay Reagent (bicinchoninic acid) Pierce 23225 
Bovine Serum Albumin (BSA) Fisher 
Scientific 
BPE9702-
100 Enhanced chemiluminescence kit (ECL) Geneflow K1-0170 
Horse Serum Invitrogen 16050-122 
Milk powder Local store N/A 
Polyvinylidene fluoride (PVDF) membrane Millipore IPVH00010 
Protease inhibitor cocktail  Roche 1183617000
1 Extra thick blot paper Biorad 170-3965 
Table I.5 Consumable for Western Blotting. All consumables were stored according to 
the manufacturer’s guidelines. 
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Inhibitors 
Stock of inhibitors Diluent Stock Supplier Cat. number 
AG1478 DMSO 1 mM Calbiochem 658548 
Bafilomycin A1 DMSO 1 mM 
Acros 
Organic 328120001 
Cycloheximide (CHX) Ethanol 140 mM Sigma-Aldrich C7698 
E-64d DMSO 10 mM Enzo Life Science BML-PI107 
Epoxomicin DMSO 5 mM Enzo Life Science BML-PI127 
Gö6976 DMSO 10 mM Calbiochem 365250 
Gö6983 DMSO 10 mM Tocris 2285 
H-89 DMSO 50 mM Enzo Life Science BML-EI196 
MG-132  DMSO 20 mM Enzo Life Science BML-PI102 
Pepstatin A DMSO 10 mM Enzo Life Scicence 
ALX-260-
085 
PP2 DMSO 10 mM Enzo Life Science BML-EI297 
SM-19712 DDW 10 mM Sigma-Aldrich S3445 
U-0126  DMSO 10 mM Enzo Life Science BML-EI282 
U-73122 DMSO 100 mM Enzo Life Science BML-ST391 
Z-Phe-Ala-
diazomethylketone (Z-PAD) DMSO 200 mM Bachem N-1040 
Table I.6 List of inhibitors. All inhibitors were used at a single concentration 
(except for H-89, see 3.6) according to previously published findings. All inhibitors 
were stored at -80°C. 
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Appendix II: 
Preparation of Buffers and Other Solutions 
 
Biochemical Buffers 
Phosphate buffered saline (PBS) 
Component Quantity per liter Working solution 
NaCl 80 g 136.9 mM 
KCl 2 g 2.7 mM 
HNa2PO4 14.4 g 10.1 mM 
KH2PO4 2.4 g 1.8 mM 
Table II.1 Composition of 10x PBS. Components were dissolved in DDW. To make 1x 
solution, 10x PBS was diluted in DDW 
 
PBS-Tween® 20 (PBS-T) 
 PBS-T was composed of 1x PBS supplemented with Tween® 20 (0.1 % (v:v)). 
Stored at RT. 
 
Blocking Buffer for Western Blotting 
 Blocking Buffer was composed of 1x PBS-T, BSA (2% (w:v)) and/or Milk 
powder (5% (w:v)). Blocking buffer was made fresh before each WB. 
 
Blocking Solution for Immunocytochemistry 
 Blocking solution was composed of 1x PBS containing normal horse serum (2% 
(v:v)) and saponin (0.1% (w:v)). The solution was stored at -20°C. 
 
Fixation solution: 4% PFA 
 For solution (100mL) of PFA (4% (w:v)), DDW (~70 mL) was heated (~60°C) 
and PFA (4 g) and 10x PBS (10 mL) were added. NaOH (10 M) was then added 
(2-3 drops) and swirl until the PFA has dissolved. The solution was allowed to cool 
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at RT and the pH was adjusted to 7.4. Then the volume was adjusted to 100 mL. 
The solution was then filtered through 0.2 µm filter, aliquoted (10 mL) in centrifuge 
tube and stored at -20°C. 
 
Lysis Buffer 
 Solution of Na3VO4 (100 mM) was prepared separately in DDW, aliquoted in 
microcentrifuge tube (1 mL) and stored at -20°C. Before use, aliquot were heated 
(100°C). 
Component Quantity/Volume per 500 mL Working solution 
Tris/HCl 3.02 g 50 mM 
NaF 0.21 g 10 mM 
Na3VO4 (100 mM) 500 µL 0.1 mM 
Triton-X-100 500 µL 0.1% (v:v) 
Protease inhibitors* 1 tablet/10 mL - 
Table II.2 Composition of Lysis Buffer. Components were dissolved in DDW. The pH 
was adjusted to 7.4. *Protease inhibitors (Roche, 11836170001) were used according to 
the manufacturer’s guidelines. 
 
Radio-Immunoprecipitation Assay (RIPA) Buffer 
Component Quantity/Volume per 500 mL Working solution 
Tris/HCl 3.02 g 50mM 
NaF 0.21 g 10 mM 
NaCl 4.38 g 150 mM 
Na4P2O7 2.23 g 10 mM 
EGTA 0.19 g 1 mM 
Na3VO4 (100 mM) 500 µL 0.1 mM 
NP-40 2.5 mL 0.5% (v:v) 
Table II.3 Composition of RIPA Buffer. Components were dissolved in DDW. The pH 
was adjusted to 7.4. 
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SDS-Loading Buffer 
Component 5x buffer 
Tris/HCl 250 mM 
Bromophenol blue 0.001% (w/v) 
SDS 10% (w/v) 
Glycerol 50% (v:v) 
Table II.4 Composition of SDS-Loading Buffer. Components were dissolved in DDW. 
The pH was adjusted to 6.8. The solution was aliquoted (875 µL) in microcentrifuge tubes 
and stored at -20°C. Before use, 2-mercaptoethanol (125 µL) was added to the 
aliquot (final working solution 12.5 % (v:v)) and kept at -20°c after use. 
 
Running Buffer 
Component Quantity per liter Working solution 
Tris/HCl 30.3 g 25 mM 
Glycine 188 g 192 mM 
Table II.5 Composition of 10x Running Buffer. Components were dissolved in DDW. 
The pH was adjusted to 8.3. To make 1x solution, 10x running buffer was diluted in DDW, 




Component Quantity per liter Working solution 
Tris/HCl 116 g 25 mM 
Glycine 58 g 192 mM 
SDS 7.4 g 1.3 mM 
Table II.6 Composition of 20x Transfer Buffer. Components were dissolved in DDW. 
The pH was adjusted to 8.3. To make 1x solution, 20x transfer buffer was diluted in DDW, 
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Stripping Buffer 
Component Quantity per liter Working solution 
Tris/HCl 7.6 g 62.7 mM 
SDS 20.0 g 2% (w:v) 
Table II.7 Composition of 1x Stripping Buffer. Components were dissolved in DDW. 
The pH was adjusted to 6.8. Just before use, 2-mercaptoethanol (140µL) was added in 
stripping buffer (20 mL) to make a final working solution at 0.7% (v:v) of 2-
mercaptoethanol. 
 
Bacterial Buffer and Culture Broth 
Super Optimal Broth (SOB) Medium 
 Solution of KCl (250 mM) and MgCl2 (2 M) were prepared separately in DDW 
and autoclaved (105 kPa, 30 min, 121°C). 
Component Quantity/Volume per liter Working solution 
Tryptone 20 g 2% (w:v) 
Yeast extract 5 g 0.5% (w:v) 
NaCl 0.5 g 8.56 mM 
KCl (250 mM) 10 mL 2.5 mM 
Table II.8 Composition of SOB medium. The components were dissolved in DDW. The 
pH was adjusted to 7 and autoclaved (105 kPa, 30 min, 121°C). Just before use, MgCl2 (5 
mL) was added to the solution for a final concentration of 10 mM 
 
LB Broth 
 LB was supplied as tablets. One tablet was diluted in 50 mL of DDW according 
to the manufacturer’s guideline. LB broth was then autoclaved (105 kPa, 30 min, 
121°C). LB broth was store at room temperature (RT). 
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Preparation of LB-agar 
 Bacteria were grown on a solid surface referred to as LB-agar plate: 1.5 % (w:v) 
of agar (BDH, 33004) was added to LB broth, autoclaved (105 kPa, 30 min, 
121°C) and left to cool (~50-55°C) before adding appropriate antibiotics. LB-Agar 
(20 mL) was added to a 100 mm dish and left set at room temperature (RT). 
Plates were then dried upside down in an incubator (30 min, 37°C) and then 
stored at 4°C. 
 
Transformation Buffer (TB) 
Component Quantity/Volume per liter Working solution 
PIPES 3.02 g 10 mM 
KCl 11.18 g 150 mM 
CaCl2 (1 M) 10 mL 10 mM 
Table II.9 Composition of TB buffer. The components were dissolved in DDW. The pH 
was adjusted to 6.7. Then MnCl2 (35 mM) was added and the buffer was sterilised by 
filtration through 0.45 µm filter. Buffer was stored at 4°C. 
 
Molecular Biology Buffers 
DEPC-H2O 
 DEPC (0.01% (w:v)) was dissolved in DDW, incubated on the bench (overnight, 
RT) and then autoclaved (105 kPa, 30 min, 121°C). DEPC-H2O was store at RT. 
 
Tris-Acetate EDTA (TAE) Buffer 
 Solution of EDTA (0.5 M) was prepared separately. EDTA will not go completely 
into solution until the pH is around 8. Once completely dissolve the pH was 
adjusted to 8. 
Component Quantity/Volume per liter Working solution 
Tris/HCl 242 g 
40 mM Glacial acetic acid 57.1 mL 
EDTA (0.5 M, pH 8) 100 mL 1 mM 
Table II.10 Preparation of 50x TAE buffer. The components were dissolved in DDW. To 
make 1x solution, 50x TAE was diluted in DDW. 
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DNA Loading Buffer 
Component 6x buffer 
Bromophenol blue 0.25% (w:v) 
Xylene cyanol FF 0.25% (w/v) 
Orange G 0.25% (w/v) 
Glycerol 30% (v:v) 
Table II.11 DNA Loading Buffer preparation. The components were dissolved in DDW. 
The buffer was stored at 4°C. 
 
 
 
 
